Melanocortin 1 receptor ligands and methods of use by David L. Morse et al.
(12) United States Patent 
Gillies et al. 
USOO9441 013B2 
US 9.441,013 B2 
Sep. 13, 2016 
(10) Patent No.: 
(45) Date of Patent: 
(54) MELANOCORTIN 1 RECEPTOR LIGANDS 
AND METHODS OF USE 
(75) Inventors: Robert J. Gillies, Tampa, FL (US); 
David L. Morse, Tampa, FL (US); 
Natalie M. Barkey, Tampa, FL (US); 
Kevin N. Sill, Tampa, FL (US); Josef 
Vagner, Tucson, AZ (US); Narges K. 
Tafreshi, Tampa, FL (US); Jonathan L. 
Sessler, Austin, TX (US); Christian 
Preihs, Austin, TX (US); Victor J. 
Hruby, Tucson, AZ (US) 
(73) Assignees: H. LEE MOFFITT CANCER 
CENTER AND RESEARCH 
INSTITUTE, INC., Tampa, FL (US); 
INTEZYNE TECHNOLOGIES INC, 
Tampa, FL (US); ARIZONA BOARD 
OF REGENTS ON BEHALF OF 
THE UNIVERSITY OF ARIZONA, 
Tucson, AZ (US); BOARD OF 
REGENTS, UNIVERSITY OF 
TEXAS SYSTEM, Austin, TX (US) 
(*) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 0 days. 
(21) Appl. No.: 14/117,949 
(22) PCT Filed: May 17, 2012 
(86). PCT No.: 
S 371 (c)(1), 
(2), (4) Date: 
PCT/US2O12/038425 
Nov. 15, 2013 
(87) PCT Pub. No.: WO2012/158960 
PCT Pub. Date: Nov. 22, 2012 
(65) Prior Publication Data 
US 2014/O112873 A1 Apr. 24, 2014 
Related U.S. Application Data 
(60) Provisional application No. 61/487.239, filed on May 
17, 2011, provisional application No. 61/487.245, 
filed on May 17, 2011, provisional application No. 
61/531,357, filed on Sep. 6, 2011, provisional 
application No. 61/618,144, filed on Mar. 30, 2012. 
(51) Int. Cl. 
A6 IK 38/00 (2006.01) 
C07K 4/00 (2006.01) 
C07K 7/08 (2006.01) 
A6 IK 47/48 (2006.01) 
A6 IK 49/14 (2006.01) 
A6 IK 49/18 (2006.01) 
C07K 5/II 7 (2006.01) 
C07K 7/06 (2006.01) 
C07K I4/72 (2006.01) 
A6 IK 49/10 (2006.01) 
(52) U.S. Cl. 
CPC ............... C07K 7/08 (2013.01); A61K 47/488 
(2013.01); A61K 47/48246 (2013.01); A61 K 
49/101 (2013.01); A61K 49/14 (2013.01); 
A6IK 49/1809 (2013.01); C07K 5/1024 
(2013.01); C07K 7/06 (2013.01); C07K 14/723 
(2013.01) 
(58) Field of Classification Search 
None 
See application file for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
5,714,576 A 2/1998 Hruby et al. 
5,830,994 A 11/1998 D'Hinterland et al. 
6,228,840 B1 5, 2001 Wei et al. 
6,350,430 B1 2/2002 Dooley et al. 
7,045,503 B1 5, 2006 McBride et al. 
7, 160,873 B2 1/2007 Magda et al. 
7,582,610 B2 9, 2009 Haskell-Luevano 
2005/OO38230 A1* 
2005. O187164 A1 
2007/0270411 A1 11/2007 Szewczyk et al. 
2009, 0232838 A1 9/2009 Dong et al. 
2009,0297444 A1* 12/2009 Perricone ......... A61K 47,48246 
424,169 
2/2005 Sharma et al. ............... 530/350 
8, 2005 Pinel 
FOREIGN PATENT DOCUMENTS 
WO WO 2005-120588 12/2005 
WO WO 2011-063367 5, 2011 
OTHER PUBLICATIONS 
Barkey NM et al., “Development of melanoma-targeted polymer 
micelles by conjugation of a Melanocortin 1 Receptor (MC1R) 
specific ligand” Journal of Medicinal Chemistry, 2011, 
54(23):8078-8084. 
(Continued) 
Primary Examiner — Jeanette Lieb 
(74) Attorney, Agent, or Firm — Saliwanchik Lloyd & 
Eisenschenk 
(57) ABSTRACT 
The subject invention pertains to a modified MC1R peptide 
ligand comprising a peptide that is a melanocortin1 receptor 
(MC1R) ligand and a functionality or linker, such as a click 
functionality, for conjugation to a surface or agent. The 
modified MC1R peptide ligand can be coupled, e.g., via a 
click reaction with a complementary click functionality 
attached, to a moiety to form an MC1R-targeted agent. 
Drugs, contrast agents, polymers, particles, micelles, Sur 
faces of larger structures, or other moieties can be targeted 
to the MC1R. The subject invention also pertains to a MC1R 
peptide ligand-micelle complex comprising a peptide that is 
a melanocortin 1 receptor ligand connected via a click 
reaction product to a micelle. The micelle is stable in vivo 
and can target melanoma tumor cells by association of the 
peptide ligand with the MC1R or the tumor and selectively 
provide a detectable and/or therapeutic agent (Such as an 
imageable contrast agent and/or anti-cancer agent) selec 
tively to the tumor cell. 
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1. 
MELANOCORTIN 1 RECEPTOR LIGANDS 
AND METHODS OF USE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
The present application is the National Stage of Interna 
tional Application Number PCT/US2012/038425, filed May 
17, 2012, which claims the benefit of U.S. Provisional 
Application Ser. No. 61/487.239, filed May 17, 2011, U.S. 
Provisional Application Ser. No. 61/487.245, filed May 17, 
2011, U.S. Provisional Application Ser. No. 61/531,357, 
filed Sep. 6, 2011, and U.S. Provisional Application Ser. No. 
61/618,144, filed Mar. 30, 2012, which are hereby incorpo 
rated by reference herein in their entirety, including any 
figures, tables, nucleic acid sequences, amino acid 
sequences, and drawings. 
GOVERNMENT SUPPORT 
This invention was made with Government support under 
Grant No. CA097360 awarded by the National Institute of 
Health (NIH). The Government has certain rights in the 
invention. 
BACKGROUND OF THE INVENTION 
The incidence of malignant melanoma is rising faster than 
that of any other cancer in the United States; reportedly, 
melanoma diagnoses doubled from 1986 to 20011. Mela 
noma progression is associated with altered expression of 
cell surface proteins, including adhesion proteins and recep 
tors 2-7. It has been estimated that over 80% of malignant 
melanomas express high levels of the melanocyte stimulat 
ing hormone (CMSH) receptor, melanocortin 1 receptor 
(MC1R)8; thus, MC1R has been investigated as a target 
for selective imaging and therapeutic agents. MC1R belongs 
to a family of five G protein-coupled receptors (MC1R 
MC5R) known as the “melanocortins.” The melanocortins 
have been discovered in a wide range of tissues and organs 
throughout the body, ranging from the hair/skin (MC1R).9 
and kidneys (MC5R) 10 to the adrenal gland (MC2R) 11 
and hypothalamus (MC3R/MC4R)12, 13 and are known to 
play a role in skin pigmentation, hair coloration, obesity, 
metabolism, diabetes, sexual behavior, erectile dysfunction, 
stress response and mood. 9-16 Endogenously, the agonists 
for the melanocortins are the Cl-, 3-, y-melanocyte stimulat 
ing hormones (MSH) and adrenocorticotropic hormone 
(ACTH, MC2R specific), all of which contain the same 
central sequence of His-Phe-Arg-Trp (SEQ ID NO: 1) 17. 
This high degree of pharmacophore homology makes it 
difficult to design a selective ligand which is highly specific 
for receptor subtype. 
Due to its high expression on the Surface of melanomas, 
MC1R has been investigated as a target for selective imag 
ing and therapeutic agents, and a number of selective ligands 
have been developed 18-20. The most well known of these, 
|Nile'.D-Phe-C-MSH, has been investigated extensively 
by Chen who showed that mTc-CGCG labeled NDP-O- 
MSH bound to melanomas with very high avidity (6.5% 
ID/g)21. Unfortunately, NDP-O-MSH has also been shown 
to possess relatively strong nanomolar binding affinities with 
MC3R, MC4R and MC5R as well22-24. Such off-target 
binding is highly undesirable given the presence of these 
receptors in sensitive organs such as the kidney and brain. A 
co-injection of lysine has been reported to diminish off 













most agents will not be able to cross the blood-brain barrier; 
nonetheless, the need for the development of highly specific 
and selective ligands against MC1R is one of importance. 
The development of ligands that can be attached to 
micelles and/or liposomes and designed to selectively target 
cancer cells relative to healthy organs represents a major 
hurdle in current research. Many such attempts fail either 
from (1) a loss of affinity resulting from the attachment of 
Small peptides to large micelles or liposomes; (2) an inherent 
instability that results in collapse before entering the vicinity 
of the tumor, or (3) a nanoparticle size that is too large to 
escape the vasculature. In order to effectively design tar 
geted particles, each of these issues must be addressed. 
BRIEF SUMMARY OF THE INVENTION 
It has been estimated that over 80% of malignant mela 
nomas express high levels of the melanocyte stimulating 
hormone (CMSH) receptor, melanocortin 1 receptor 
(MC1R). Although there have been ligands designed to 
attach to micelles and selectivity target cancer cells relative 
to healthy organs, many fail either from (1) a loss of affinity 
resulting from the attachment of Small peptides to large 
micelles (2) an inherent instability of the system in vivo; or 
(3) a nanoparticle size that is too large. According to 
embodiments of the invention, a series of hMC1R ligands 
known to be selective against hMC1R are modified for 
attachment to a polymer, gel, or Surface of a particle, 
micelle, or other structure. The most selective ligand was 
appended to a triblock polymer micelle via click chemistry 
to a 100 nm polymer micelle comprises a targeted micelle 
with a nanomolar binding affinity to hMC1R. 
One aspect of the invention concerns a modified melano 
cortin 1 receptor (MC1R) peptide ligand, comprising an 
MC1R peptide ligand coupled to a click functionality at the 
C-terminus or N-terminus of the MC1R peptide ligand. In 
Some embodiments, the click functionality is an alkyne. The 
modified MC1R peptide ligand may comprise, for example, 
the amino acid motif His-Phe-Arg-Trp (HFRW) (SEQ ID 
NO: 1) or His-DPhe-Arg-Trp (HfRW) (SEQ ID NO:2). In 
some embodiments, MC1R peptide ligand is selected from: 




(SEQ ID NO: 




(SEQ ID NO: 
H-Lys (hex.- 5-ynoyl) Tyr-Val-Nile-Gly-His-DNal (2') - 
Arg-DPhe-Asp-Arg-Phe-Gly-NH2. 
5) 
Throughout the various aspects of the invention described 
herein, in addition to click reactions, it should be understood 
that other methods for conjugating the MC1R peptide ligand 
to micelles or to other structures may be utilized. The 
attachment of peptide moieties to hydrophilic polymers are 
known in the art, as multiple bio-conjugation approaches 
exist. As described herein, a preferred approach utilizes the 
copper catalyzed click chemistry reaction between an alkyne 
and an azide to form a 1.2.3-triazole linkage. In some 
embodiments, a metal-free click reaction can be utilized to 
form a triazole linkage between the azide and alkyne moi 
eties (Jewett J C and C R Bertozzi, "Cu-free click cycload 
dition reactions in chemical biology, Chem Soc Rev., 2010 
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April: 39(4): 1272-1279, which is incorporated herein by 
reference in its entirety). Other bio-conjugation approaches 
include, but are not limited to, the reaction between an amine 
and aldehyde to form an imine linkage; the oxidation of two 
thiol moieties to form a disulfide; the thiolene click reaction 
between an alkene and a thiol to form a thioether (Killops K 
L et al., “Robust, Efficient, and Orthogonal Synthesis of 
Dendrimers via Thiol-ene “Click Chemistry”, JACS, 2008, 
which is incorporated herein by reference in its entirety); 
reaction between an amine an an ester to form an amide; the 
Michael addition conjugation between an amine and a 
maleimide to form a secondary amine linkage; and the 
reaction between an amine and an activated ester to form an 
amide. 
Another aspect of the invention is a method of preparing 
a MC1R peptide ligand of the invention, comprising: pro 
viding an MC1R peptide ligand; and covalently bonding a 
moiety comprising a click functionality to the C-terminus or 
N-terminus of the MC1R peptide ligand, wherein a MC1R 
peptide ligand comprising a click functionality is formed. 
In some embodiments, the C-terminus or N-terminus of 
the MC1R peptide ligand comprises a lysine (Lys) residue or 
other nitrogen-bearing, thiol-bearing, or —OH bearing resi 
due, and wherein the moiety comprising the click function 
ality is covalently bound to the residue. In some embodi 
ments, the residue at the C-terminus or N-terminus 
comprises the Lys residue. Preferably, the moiety having the 
click functionality comprises a terminal alkynyl acid of 5 to 
12 carbons. 
Another aspect of the invention concerns a melanocortin 
1-targeted agent comprising: a MC1R peptide ligand; and a 
moiety (a "payload”), wherein the MC1R peptide ligand and 
the moiety are covalently linked by a click reaction product 
(a reaction product of a first click functionality and a 
complementary second click functionality). The moiety is 
one to be directed to MC1R expressing cells. Such as a drug, 
contrast agent, polymer, gel, particle, Surface, or any com 
bination thereof. 
Another aspect of the invention concerns a method of 
delivering a moiety to cells expressing the melanocortin 1 
receptor (MC1R), comprising administering an MC1R-tar 
geted agent of the invention to the cells in vitro or in vivo. 
In in vivo embodiments, MC1R-targeted agent may be 
administered to a human or non-human animal Subject 
systemically, or locally at the site of the cells. In some 
embodiments, the MC1R-targeted agent is administered to 
the Subject intravascularly (e.g., intravenously or intra 
arterially). In some embodiments, the moiety (“payload”) 
carried by the MC1R-targeted agent is an anti-cancer agent 
(such as a chemotherapeutic agent). Preferably, the anti 
cancer agent is one having efficacy against MC1R-express 
ing cells (melanoma cells). In some embodiments, the 
moiety carried by the MC1R-targeted agent is a contrast 
agent, such as imaging contrast agents. Examples of imaging 
contrast agents include, but are not limited to, near infrared 
fluorescent dyes (e.g., ICG derivatives); gold for CT con 
trast; Gd, Tc99m or 'In chelate for MRI or SPECT 
imaging; Yttrium for radiotherapy, 18-F, 11-C, 18-O, Gal 
lium 64, Copper-64 for PET imaging. Examples of anti 
cancer agents include, but are not limited to, alkylating 
chemotherapy agents such as melphalan or ifosfamide; and 
other systemic melanoma chemotherapies Such as Dacarba 
Zine, paclitaxel, and Vincristine. 
In some embodiments, the Subject is one diagnosed with 
melanoma. In some embodiments, the Subject is one diag 
nosed with melanoma, and the moiety of the MC1R-targeted 














treatment of melanoma (e.g., an agent that kills melanoma 
cells or inhibits the growth of melanoma cells). In some 
embodiments, the Subject has not been diagnosed with 
melanoma. 
In some embodiments, the moiety carried by the MC1R 
targeted agent comprises an imaging contrast agent, and the 
delivery method further comprises imaging the Subject using 
an imaging modality (e.g., with an imaging device) appro 
priate for the administered contrast agent, thereby determin 
ing the localization of the contrast agent within the Subject 
(for example, to determine the location of MC1R expressing 
cells). 
Another aspect of the invention concerns a pharmaceuti 
cal composition comprising an MC1R targeted agent of the 
invention, and a pharmaceutically acceptable carrier. 
Another aspect of the invention concerns a modified 
melanocortin 1 receptor (MC1R) peptide ligand-micelle 
complex, comprising: an MC1R peptide ligand; and a 
micelle comprising an inner core, outer core and hydrophilic 
shell, wherein the MC1R peptide ligand is linked to the shell 
of the micelle by a click reaction product. In some embodi 
ments, the inner core of the micelle comprises a hydrophobic 
polypeptide, the outer core comprises a crosslinked peptide 
comprising a multiplicity of crosslinked amino acid residues 
and the hydrophilic shell comprises a water soluble polymer, 
and the inner core is covalently attached to the outer core 
and the outer core is covalently attached to the hydrophilic 
shell. In some embodiments, the water soluble polymer 
comprises polyethylene glycol. In some embodiments, the 
click reaction product comprises a 1,2,3-triazole from the 
addition of an azide and an alkyne. In some embodiments, 
the click reaction product is coupled to the C-terminus of the 
MC1R ligand. In some embodiments, the click reaction 
product is coupled to the N-terminus of the MC1R ligand. In 
some embodiments, the MC1R peptide ligand and a first 
click functionality of the click reaction product are selected 
from: 




(SEQ ID NO: 




(SEQ ID NO: 
H-Lys (hex.- 5-ynoyl) Tyr-Val-Nile-Gly-His-DNal (2') - 
Arg-DPhe-Asp-Arg-Phe-Gly-NH2. 
5) 
In some embodiments, the MC1R peptide ligand comprises 
the amino acid motif His-Phe-Arg-Trp (HFRW) (SEQ ID 
NO: 1) or His-DPhe-Arg-Trp (HfRW) (SEQ ID NO:2). 
In some embodiments, the MC1R peptide ligand-micelle 
complex further comprises an agent residing in the inner 
core of the micelle. The agent may be an anti-cancer agent, 
contrast agent, or some other agent to be administered. 
Another aspect of the invention concerns a pharmaceuti 
cal composition comprising an MC1R peptide ligand-mi 
celle complex, and a pharmaceutically acceptable carrier. 
Another aspect of the invention concerns a method of 
imaging a melanoma tumor of a Subject, comprising: admin 
istering the MC1R peptide ligand-micelle complex of the 
invention to the Subject, wherein a contrast agent is present 
within the inner core of the micelle, and wherein the MC1R 
peptide ligand-micelle complex concentrates in the tumor; 
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and observing a signal from the contrast agent by an imaging 
device. In some embodiments, method of imaging com 
prises: 
providing a MC1R peptide ligand-micelle complex of the 
invention; 
incorporating a contrast agent into the inner core of the 
MC1R peptide ligand micelle complex; 
administering the MC1R peptide ligand-micelle complex 
with the contrast agent to a human or non-human 
animal subject, wherein the MC1R peptide ligand 
micelle complex concentrates in the tumor, and 
observing a signal from the contrast agent by an imaging 
device. 
In some embodiments, the contrast agent comprises a near 
infrared (NIR) fluorescent dye, such as an ICG derivative. In 
Some embodiments, the contrast agent comprises a CT 
contrast agent, Such as gold. In some embodiments, the 
contrast agent is a MRI or SPECT contrast agent, such as 
Gd, Tc99m, or an 'In chelate. In some embodiments, the 
contrast agent comprises a PET imaging agent, Such as 18-F, 
11-C, 18-O, or Gallium 64. 
Another aspect of the invention concerns a method of 
treating melanoma tumor cells in a Subject, comprising: 
administering the MC1R peptide ligand-micelle complex of 
the invention to the Subject, wherein an anti-cancer agent is 
present within the inner core of the micelle, and wherein the 
MC1R peptide ligand-micelle complex releases the anti 
cancer agent at the site of the tumor. Preferably, the anti 
cancer agent is one that demonstrates efficacy in the treat 
ment of melanoma (for example, kills melanoma cells or 
inhibits the growth of melanoma cells). In some embodi 
ments, the method comprises: 
providing a MC1R peptide ligand-micelle complex of the 
invention; 
incorporating an anti-cancer agent into the inner core of 
the MC1R peptide ligand-micelle complex; and 
administering the MC1R peptide ligand-micelle complex 
with the anti-cancer agent to the Subject, wherein the 
MC1R peptide ligand-micelle complex releases the 
anti-cancer agent at the site of the tumor. 
In some embodiments, the anti-cancer agent is a radio 
therapy agent, such as Yttrium. In some embodiments, the 
anti-cancer agent comprises an alkylating chemotherapy 
agent, such as melphalan or Ifosfamide. In some embodi 
ments, the agent comprises a systemic melanoma chemo 
therapy agent, such as dacarbazine, paclitaxel, and/or Vin 
cristine. 
Another aspect of the invention concerns a method of 
preparing a MC1R peptide ligand-micelle complex, com 
prising: 
providing multiplicity of triblock polymer chains com 
prising a hydrophobic polypeptide block attached to a 
central crosslinkable peptide block comprising a mul 
tiplicity of crosslinkable amino acid residues attached 
to a water soluble polymer block, wherein a portion of 
the triblock polymer chains further comprise a first 
click functionality covalently attached to the water 
soluble polymer block distal to the central crosslinkable 
peptide block and wherein the triblock polymer chains 
self assemble into a micelle; 
providing a MC1R peptide ligand comprising a comple 
mentary second click functionality covalently attached 
to a MCIR targeting peptide; and 
combining the triblock polymer chains with the MC1R 
peptide ligand, wherein the first click functionality and 
the complementary second click functionality react to 













block polymer to the MC1R peptide ligand to form a 
MC1R peptide ligand-micelle complex. 
In some embodiments, the MC1R peptide ligand is 4-phe 
nylbutyryl-His-DPhe-Arg-Trp-Gly-Lys(hex-5-ynoyl)-NH 
(SEQ ID NO:3); H-Lys(hex-5-ynoyl)-Tyr-Val-Nle-Gly-His 
DNal(2)-Arg-DTrp-Asp-Arg-Phe-Gly-NH. (SEQ ID 
NO:4); or H-Lys(hex-5-ynoyl)Tyr-Val-Nle-Gly-His-DNal 
(2)-Arg-DPhe-Asp-Arg-Phe-Gly-NH. (SEQ ID NO:5). 
In some embodiments, the method for preparing a MC1R 
peptide ligand-micelle complex further comprises crosslink 
ing the multiplicity of crosslinkable amino acid residues. In 
Some embodiments, the method further comprises the incor 
poration of an agent. In some embodiments, the agent 
comprises a contrast agent, anti-cancer agent, or both. In 
Some embodiments, the anti-cancer agent is a chemothera 
peutic agent. Such as a taxane. 
Fluorescent and MRI targeted molecular imaging probes 
have been designed that bind strongly and specifically to the 
melanocortin1 receptor (MC1R) that is found expressed on 
the surface of over 80% of melanoma cells. In some embodi 
ments, the binding portion of the probes is the MC1R ligand 
with the structure 4-phenylbutyryl-His-DPhe-Arg-Trp-Gly 
Lys (hex-5-ynoyl)-NH. (SEQID NO:3) that shows high (0.2 
nM) binding affinity for MC1R. Functionalization of the 
ligand at the C-terminus with an alkyne for use in Cu 
catalyzed click chemistry was used to attach a fluorescent 
dye or a micelle. Fluorescent targeted molecular imaging 
probes were developed by binding the MC1R ligand to a 
near infrared fluorescent dye, and cellular uptake of the 
probe by receptor-mediated endocytosis was shown in engi 
neered A375/MC1R cells in vitro as well as in vivo by 
intravital fluorescence imaging with higher uptake values in 
tumors with high expression of MC1R compared to low 
(P<0.05). MRI targeted molecular imaging probes were 
developed by binding the MC1R ligand to a micelle con 
taining a gadolinium texaphyrin (Gd-TX) chelate. These 
Gd-Tx micelles, stabilized by crosslinking with Fe(III), are 
able to actively target MC1R expressing Xenograft tumors in 
vitro and in vivo Suggesting that appropriately designed 
micelles may eventually be able to deliver therapeutic 
payloads. The incidence of malignant melanoma is rising 
faster than that of any other cancer in the United States, with 
diagnoses having doubled from 1986 to 2001. Nodal metas 
tases are frequently the initial manifestation of metastatic 
spread in patients with melanoma and accurate determina 
tion of nodal status is important for treatment planning. 
Currently, sentinal lymph node biopsies are performed to 
determine if the cancer has metastasized; however, one 
study showed only 24.3% (288/1184) of melanoma patients 
who had a sentinal lymph node biopsy had metastases. The 
diagnostic probes of the invention can be used to determine 
if a biopsy is avoidable. For example, the probes can be 
administered to subjects with melanoma before and/or after 
treatment and the detectable signal from the probe is 
observed to check nodal status and ascertain whether the 
cancer has metastasized. If a positive signal is detected, 
further diagnostic methods may be utilized, such as sentinel 
nodal biopsy, and/or therapy may be undertaken. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1: A synthetic route that was used for compound 4. 
in which a) (i) Fmoc-AA-OH (3 eq), HOCt or HOBt (3 eq), 
and DIC (3 eq) in DMF/DCM (10 mL/1 g of resin) for amino 
acid couplings; b) Piperidine/DMF (1:10, 2+20 minutes); 
(ii) 4-phenylbutyric acid (6 eq), and DIC (3 eq) in DMF/ 
DCM; b) (i) Pd(0)-tetrakistriphenylphosphine (0.01 eq), 
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N,N'-dimethylbarbituric acid (5 eq) in degassed DCM (2x30 
minutes) (ii) 5-hexynoic acid (5 eq) and DIC (3 eq) in 
DMF/DCM c)(i) TFA-scavengers cocktail (91% trifluoro 
acetic acid, 3% water, 3% thioanisole, 3% ethanedithiol); (ii) 
ether extraction; (iii) HLPC purification. 
FIG. 2: A reaction scheme for preparation of the MC1R 
peptide ligand micelle complex according to an embodiment 
of the invention (SEQ ID NO:15). 
FIGS. 3A-B: Representative competitive binding assays 
for targeted and untargeted micelles on HCT116/MC1R 
cells. 
FIGS. 4A-C: Representative competitive binding assays 
for (FIG. 4A) 4-targeted polymer; (FIG. 4B) untargeted 
micelles; and (FIG. 4C) 4-targeted micelles against 
HCT116/hMC1R cells. X-axis concentrations for (FIG. 4A) 
and (FIG. 4C) were normalized to the targeting group. 
FIGS. 5A-B: Plot of absorbance of a Gd-Tx agent in a 
(FIG. 5A) 4-targeted (ML21-1 targeted) crosslinked (XL) 
micelle and a (FIG. 5B) 4-targeted (ML21-1 targeted) 
uncrosslinked (UXL) micelle for in vitro binding of the 
4-targeted micelles at nanomolar concentrations. 
FIG. 6: Grid of in vitro MR T1 weighted signals from 
Gd-Tx containing 4-targeted (T) and 4-free (UT) micelles 
that are crosslinked (XL) or crosslink free (UXL) for various 
loadings of Gd-Tx in the micelles and two different con 
centrations of the micelles. 
FIG. 7: Grid of in vitro MR T1 weighted signals from 
Gd-Tx containing 4-targeted (T) and 4-free (UT) micelles 
that are crosslinked (XL) or crosslink free (UXL), where the 
columns are of the same order as FIG. 6, for various loadings 
of Gd-TX in the micelles showing an optimal signal at 
loadings of Gd-TX at a concentration of about 1.3% Gd-TX 
in the micelle. 
FIG. 8: Tabulated averaged data of quantified MRT1 
weighted signals from the data displayed in FIG. 7. 
FIG. 9: In vivo MRT1 weighted images of mice that were 
injected with micelles to produce a 12 mg/mL Gd-Tx 
concentration with targeted or untagged micelles that are 
crosslinked or uncrosslinked. 
FIG. 10: A closer view of the in vivo MRT1 weighted 
images of Mice of FIG. 9 for micelles with the 4-targeted 
crosslinked micelles, where the tumor images are indicated. 
FIG. 11: A reaction scheme for preparation of the MC1R 
peptide ligand micelle complex according to an embodiment 
of the invention (a gadolinium-texaphyrin (Gd-TX) micelle 
formulation) (SEQ ID NOS:16-17). 
FIGS. 12-15: Results of europium-time resolved fluores 
cence (Eu-TRF) binding assays. 
FIG. 16: Micelle characterization data from twelve 
samples. 
FIG. 17: In vitro SCOUT phantoms of Gd-Tx micelle 
with a multiple TR SEMS. The TR calculation sequence 
consisted of TR values of 20, 10.99, 6.03, 3.31, 1.82, 1.00, 
0.55, 0.30, 0.17, 0.09 and 0.05 s: TE=8.62 ms; data 
matrix=128x128, 4 averages, 2 dummy scans, FOV-80 
mmx40 mm or 40 mmx90 mm and the slice thickness=1-2 
mm. T1 values were calculated using the Vnmri Software 
(Agilent Life Sciences Technologies, Santa Clara, Calif.), 
and values were verified using MATLAB (Mathworks, 
Natick, Mass.). 
FIGS. 18-21. In vivo MRI results. 
FIG. 22: Coronal-90, T1-weighted contrast-enhanced 
SEM images through the center slice of subcutaneous 
MC1R-expressing tumors. Arrows indicated the location of 
the tumors. Data matrix=128x128; FOV of 40 mm (read)x 
90 mm (phase); 15 one-mm thick slices were taken with a 













8 averages for total scan time of about 3 minutes per SEMS 
image. Images were processed using MATLAB (Math 
works, Matick, Mass.). 
FIG. 23: A synthetic route for Cy5 and IR800CW ligands 
(Scheme S1). a. Fmoc/t3u synthesis continued as follows: i) 
Fmoc-aa-OH (3 eq), HOBt (3 eq), DIEA (6 eq), and HBTU 
(3 eq) in DMF for amino acid couplings; ii) Piperidine/DMF 
(1:4) for Fmoc deprotection; b. Aloe deprotection: i) Pd(0) 
TPP (0.2 eq), dimethylbarbituric acid (5.0 eq) in DCM (0.5 
M) for 30 min' ii) Trt-OH (3 eq), DIEA (6 eq), and HBTU 
(3 eq) in DMF; c. TFA-scavengers cocktail (91% trifluoro 
acetic acid, 3% water, 3% triisopropylsilane, and 1.2-ethyl 
enedithiol (3%) for 4 hrs; d. IR800CW maleimide or Cy5 
maleimide (1 eq) in DMF. 
FIGS. 24A-C: DNA microarray expression profile of 
MC1R in melanoma, other skin cancers and normal tissues 
(FIG. 24A). Data are represented as meant-SD. Note the 
logo scale. DNA microarray of primary human melanocytes 
(white), melanoma cell lines with the NRAS mutation (gray) 
and melanoma cell lines with the BRAF mutation (black) 
(FIG. 24B). Representative IHC staining of MC1R in nor 
mal skin with a pathology score of 3 and different types of 
melanoma with pathology score of equal to or greater than 
4 (FIG. 24C). 
FIGS. 25A-C: ICC of MC1R expression on the surface of 
A375 parental and engineered cells (FIG. 25A). Confocal 
micrographs of cells incubated with the nuclear marker 
DAPI (blue), the plasma- and plasma-membrane marker, 
WGA (green) and MC1R antibody-Alexa 555 (red). To 
inhibit cellular uptake, cells were incubated with antibodies 
and dyes at 4° C. for 10 min. The merged image shows 
colocalization of MC1R (red) with membrane marker 
(green) indicating accumulation of the receptor on the 
cell-surface (yellow). Representative saturation binding 
assays for A375/hMC1R cells (FIG. 25B). A representative 
competition binding plot of MC1RL-800 imaging probe to 
A375/hMC1R cells (FIG. 25C). 
FIGS. 26A-B: Uptake studies of MC1R targeted imaging 
probes in vitro and in vivo. FIG. 26A shows uptake of the 
MC1RL-800 probe on A375/MC1R cells. The probe is 
detected on the cell membrane as early as 15 seconds after 
incubation and internalized into the cells by 5 min after 
incubation. No binding or uptake of the probe was observed 
when high concentrations of NDP-O-MSH was used as a 
blocking agent before adding the probe to the cells. FIG. 
26B shows in vivo uptake studies of the MC1R-635 probe 
using the dorsal skin-fold window chamber Xenograft tumor 
for intravital confocal imaging. The fluorescent signal from 
the probe was detected on the cell surface (yellow arrow) by 
5 min after i.v. injection of the probe, and was detected 
inside the cells 24 h after injection. 
FIGS. 27A-1, 27 A-2, and 27B: In vivo and ex vivo 
targeting of MC1RL-800. FIG. 27A-1 shows a representa 
tive image of normalized fluorescence intensity maps of a 
mouse bearing Xenograft tumors, 2 hours post intravenous 
injection of the probe (left mouse): A375 cells that consti 
tutively express low levels of MC1R were used to form the 
low-expressing tumor (left flank) and A375/MC1R cells 
were used to form the high expressing tumor (right flank). A 
blocking experiment was performed using co-injection of 
0.25 ug unlabeled NDP-O-MSH and 5 nmol/kg of the 
MC1RL-800 probe to determine target specificity (right 
mouse). Inset (FIG. 27 A-2) is showing quantification of 
MC1RL-800 normalized fluorescent count of low and high 
expressing tumors in control and blocking animals. Data 
represent meants.d. NC: Normalized Count (FIG. 27B) are 
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ex vivo images of low- and high-expressing tumors with 
corresponding IHC staining of MC1R. 
FIGS. 28A, 28B-1, and 28B-2: FIG. 28A shows ex vivo 
bio-distribution of MC1RL-800 in the tumors, kidneys and 
liver at different time-points post-injection. No signal was 
detected in the heart, lung, brain and other organs (not 
shown). The values were normalized as percentage of the 
highest signal. FIGS. 28B-1 and 28B-2 show mathematical 
modeling of ex vivo and in vivo bio-distribution of the 
probe, respectively. Sim: simulation, T. Tumor, K: kidneys. 
FIGS. 29 A-1, 29A-2, and 29B: Reduction of MC1RL-800 
kidney uptake. FIGS. 29 A-1 and 29A-2 show pharmacoki 
netics of different concentrations of injected probe in MC1R 
low expressing and high expressing tumors and kidneys. 
Note that the lower concentration (1 nmol/kg) has the lowest 
kidney accumulation. Insets show representative images of 
normalized fluorescence intensity maps of a mouse bearing 
Xenograft tumors, 2 hours post intravenous injection of the 
probe for each concentration. FIG. 29B shows co-injection 
of 1 nmol/kg of MC4R/5R compound and 5 nmol/kg of 
MC1RL-800 (right image) to reduce kidney uptake of the 
probe. Inset shows representative images of mice bearing 
Xenograft tumors, 30 min post intravenous injection of the 
probe (control, left image) and probe plus MC4R/5R com 
pound (co-injection, right image). Data represent meants.d. 
NC: Normalized Counts. 
FIGS. 30A-D: Pharmacokinetics of different MC1RL-800 
probe concentrations injected into mice bearing low- and 
high-MC1R expressing tumors and kidneys (1 nMol/Kg, 5 
nMol/Kg, 10 nMol/Kg, and 30 nMol/Kg, respectively). Note 
that the peak signal in the tumors and kidneys occurs 2-hours 
post-injection and the lowest probe concentration injected 
had the lowest kidney accumulation. Data represent 
meants.d. 
FIGS. 31A, 31 B-1, and 31B-2: FIG. 31A shows verifica 
tion of rat microVessel patency using Multiphoton Laser 
Scanning Microscope. Mice were intravenously injected 
with Blue Dextran to verify GFP rat microvessel (green) 
patency. Note the flowing of the Dextran in green microve 
ssels. FIGS. 31 B-1 and 31B-2 show in vivo uptake studies 
of the MC1RL-800 probe using the dorsal skin-fold window 
chamber Xenograft tumor for intravital confocal imaging. 
The probe (red) has been taken into the tumor surrounded by 
GFP microvessels (green) at 24 hr after injection. 
FIGS. 32A-C: MC1RL-800 concentration and location 
combined with the 3D probe profile in the tumors using 
Optix-MX3 imaging system in vivo and ex vivo. FIG. 32A 
shows 3D topography of a representative mouse bearing 
A375 xenograft tumor (left leg) and A375/MC1R tumor 
(right leg) 2 hours post intravenous injection of the probe 
and ex vivo image of the same tumor. FIG. 32B shows 
A357/MC1R slices from top to bottom through the tumor 
Volume. The distance from the Surface of the scanning stage 
underneath the mouse is indicated in mm underneath each 
slice. FIG. 32C shows an enlarged image of the currently 
selected slice (green squared labeled image, 13.48 in the ex 
vivo panel of FIG.32B). The color bar in FIG.32C indicates 
the corresponding concentration of probe. Note that the ex 
vivo image and IHC staining of the center slice from the 
same tumor is shown in FIG. 27B. 
FIG. 33: Dorsal skin-fold window-chamber xenograft 
tumor model in SCID mouse. Intravital confocal imaging of 
MC1R-800CW probe tumor cell uptake in vivo using the 
dorsal skin-fold window chamber xenograft tumor model is 













FIG. 34: Formulation of Gd-TX micelles. Detailed infor 
mation of the Gd-Tx crystal structure can be found in the 
Supporting Information. 
FIG.35: Effect of% ligand 2 coverage on micelle binding 
avidity. 
FIG. 36: Multiple TR SEMS (spin echo) images were 
acquired to calculate the T1 values of a Gd-Tx micelle MR 
phantom prepared with Samples containing Gd-TX at 0.01 
mg/mL with varying weight loading percentages and micelle 
concentrations. T1 values from each row are presented as an 
average for simplicity. A table of the T1 values for each well 
is available in the Supplemental Information. 
FIG. 37A-B: Coronal-90 T1 weighted spin echo multi 
slice (SEMS) images of mice treated with different Gd-Tx 
micelle formulations. A) Representative images from each 
group of mice treated with 0.5% Gd-Tx micelles at selected 
time points. White arrows denote location of tumors. B) 
Pre-injection and 24 h post-injection image of the 5% T-XL 
formulation loaded with 5% Gd-Tx (w/w). 
FIG. 38A-D: Buildup and clearance data of Gd-Tx con 
trast enhancement in (a-b) tumor, (c) liver and (d) kidney. 
p-values are in comparison to T-XL group. All groups 
contained 3 mice except where noted. "One mouse expired 
between 24 h and 48 h time point. One mouse expired upon 
injection of micelle agent. 
FIG. 39: Synthesis of Gd-Texaphyrin (Gd-Tx) 6. 
FIG. 40A-C: Low resolution ESI-MS spectrum for 6. 
FIG. 41: High resolution ESI-MS spectrum for 6. 
FIG. 42A-D: HPLC spectrum for 6. 
FIG. 43A-B: Xenograft tumor Expression of MC1R. 
In-vivo characterization of MC1R surface expression for 
HCT116/MC1R cells. (a-b) IHC staining of representative 
left (a) and right (b) tumors from a SCID mouse. Both were 
scored as 3 for MC1R by a Board Certified Pathologist. 
FIG. 44: Multiple TR SEMS (spin echo) images were 
acquired to calculate the T1 values of a Gd-Tx micelle MR 
phantom prepared with Samples containing Gd-TX at 0.01 
mg/mL with varying weight loading percentages and micelle 
concentrations. Individual T1 values are located under each 
well. 
FIG. 45: View of the Gd-Tx complex 6 after showing a 
partial atom labeling scheme. Displacement ellipsoids are 
scaled to the 50% probability level. The hydrogen atoms 
were omitted for clarity. 
FIG. 46: Side view of the Gd complex 6 showing a partial 
atom labeling scheme. Displacement ellipsoids are scaled to 
the 50% probability level. The hydrogenatoms were omitted 
for clarity. 
DETAILED DISCLOSURE OF THE INVENTION 
According to an embodiment of the invention, MC1R 
ligands are selected from those disclosed in the literature 
22, 27, 28 for their selectivity to MC1R over other G 
protein-coupled receptors and modified for attachment to a 
Surface, for example the Surface of a polymer-based micelle. 
For example, one ligand that displays a high affinity for 
MC1R, with little-to-no interaction with MC4R and MC5R, 
is functionalization and attached to a 100 nm micelle where 
attachment does not significantly alter its binding affinity to 
MC1R. In one embodiment of the invention the attachment 
of the ligand comprises a functionality that can react with a 
complementary functionality on a polymer, Such as a poly 
mer-based micelle, via click chemistry. Some ligands with 
MC1R binding affinity are given in Table 1, below. 
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TABL E 1. 




(SEQ ID NO : 6) 
2 AC-Homophenylalanine-His-DPhe-Arg-Trp-NH2 
(SEO ID NO: 7) 
3 4-hydroxycinnamoyl-His-DPhe-Arg-Trp-NH 





substituted with an Ac-homophenylalaninyl (HPE) moiety 
of compound 2, wherein the amino group is an alternative 
attachment point to the C-terminal attachment via a lysine 
S-amino as in compound 4. Compounds 4, 6, and 8, are 
ligands comprising a click functionality, an alkyne, for 
attachment to a moiety comprising a complementary func 
tionality. 
In general, unless otherwise specified, the abbreviations 
used for the designation of amino acids and the protective 
groups used therefore are based on recommendations of the 
IUPAC-IUB Commission of Biochemical Nomenclature 
(Biochemistry, 11:1726-1732 (1972)). The nomenclature 
used to define compounds of the invention is that specified 
by IUPAC, published in European Journal of Biochemistry, 
138:9-37 (1984). With regard to certain amino acids dis 
closed herein, their structures and abbreviations are apparent 




H-Tyr-Val-Nle-Gly-His-DPhe-Arg-DNal(2)-Asp-Arg-Phe-Gly-NH2 (SEQID NO: 11) 
Lys (hex-5-ynoyl)-NH2 






H H H 
N N N 
HN N N 
i H H 
O 1N O O 
TABLE 1 - continued 
Structures of ligands screened for MC1R selectiv 
ity. 
Compound Structure 
5 H-Tyr-Val-Nile-Gly-His-DNal (2') -Arg-DTrp 
Asp-Arg-Phe-Gly-NH2 
(SEO ID NO: 9) 
6 H-Lys (hex-5-ynoyl) -Tyr-Val-Nile-Gly-His 
DNal. (2) -Arg-DTrp-Asp-Arg-Phe-Gly-NH2 
(SEQ ID NO : 4) 
7 H-Tyr-Val-Nile-Gly-His-DNal (2') - 
Arg-DPhe-Asp-Arg-Phe-Gly-NH2 
(SEQ ID NO: 1.O) 
8 H-Lys (hex-5-ynoyl) Tyr-Val-Nile-Gly-His 
DNal (2') -Arg-DPhe-Asp-Arg-Phe-Gly-NH2 
(SEO ID NO; 5) 
MC1R-selective ligands evaluated include: one based on 
LK-184 (compound 1); 20, 29 compound 2, an N-terminal 
amino analog compound to facilitate attachment to nano 
particles structures; compound 3 where the flexible —(CH) 
— of compound 1 is replace with a more rigid double bond 
(—CH=CH-) and with a 4-hydroxy function incorporated 
with the phenyl ring as an alternative N-terminal attachment 
point; and peptides known from a prior study (compounds 5 







The letter “D’ preceding any three-letter abbreviation for 
an amino acid, e.g. as in “D-Nal' or “D-Phe, denotes the 
D-form of the amino acid. The letter “L” preceding an amino 
acid three-letter abbreviation denotes the natural L-form of 
the amino acid. For purposes of this disclosure, unless 
otherwise indicated, absence of a “D' or “L” designation 
indicates that the abbreviation refers to both the D- and 
L-forms. Where the common single-letter abbreviation is 
used, capitalization refers to the L-form and small letter 
designation refers to the D-form, unless otherwise indicated. 
For each amino acid, an additional conservative Substitution 
includes the “homolog” of that amino acid, where the 
“homolog” is an amino acid with a methylene group (CH2) 
inserted into the side chain at the beta position of that side 
chain. Examples of Such homologs include, without limita 
tion, homophenylalanine, homoarginine, homoserine, and 
the like. As used herein, the term "peptide,” is defined as an 
amino acid sequence from three amino acids to about 700 
amino acids in length. 
As used herein, “MC1R ligand’ and “ligand refer to a 
compound with affinity for melanocortin receptors, particu 
larly melanocortin 1 receptors, that can result in measurable 
biological activity in cells, tissues, or organisms that contain 
the MC receptor or blocks stimulation by a known MC 
agonist. Assays that demonstrate melanocortin receptor ago 
nistic or antagonist activity of compounds are well known in 
the art. 
Related peptides includes allelic variants; fragments; 
derivatives; Substitution, deletion, and insertion variants; 
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fusion polypeptides; and orthologs; and each amino acid of 
each Such related peptide may be either natural or unnatural 
of the "D' or “L” configuration which corresponds to the 
stereochemical designation “S” and “R.' respectively, as 
defined in the RS system of Cahn et al., (Pure Applied 
Chemistry, 45:11-30 (1974), and references cited therein). 
Such related peptides may be mature peptides, i.e., lacking 
a signal peptide. 
Embodiments of the invention are directed to a MC1R 
ligand comprising a reactive functionality towards a comple 
mentary functionality on a moiety Such as a Small molecule, 
a polymer or a functionalized surface, for example a func 
tionality on the polymer shell of an in vivo stable micelle 
wherein the MC1R comprises a functionality that allows 
attachment via a Huisgen 1,3-dipolar cycloaddition, Diels 
Alder reaction, or any other reaction that has the features of 
"click' chemistry to a complementary functionality on the 
moiety. Click chemistry involves a reaction that displays 
selectivity and high conversion, generally although not 
necessarily, without driving the reaction by removal of a side 
product. In addition to use with a polymer shell of a micelle, 
the MC1R-ligand can be attached as end groups or side 
groups of a water Soluble or water Suspendable homopoly 
mer or copolymer. The homopolymer or copolymer can be 
linear, branched, hyperbranched, dendritic, or a network. 
The copolymer can be a random copolymer, block copoly 
mer, or graft copolymer. Surfaces can be that of a particle, 
including polymeric, ceramic, glass, or metal where the 
Surface is flat or irregular including within the pores of a 
Solid porous material. The dimensions of particles can be in 
the nanometer, micrometer or of larger dimensions. 
Some embodiments of the invention provide a stabilized, 
targeted micelle system capable of delivering systemic diag 
nostic agents and/or therapeutic agents (“theragnostics’) 
specifically to a tumor site. Gadolinium-texaphyrin (Gd-Tx) 
has been investigated as a radiation sensitizing agent, and is 
used for exemplification herein. In some embodiments, the 
therapeutic agent is a chemotherapeutic agent, Such as a 
taxane. 
The MC1R-ligand can be coupled via a linking group to 
a small molecule, polymer or functionalized surface that 
includes a contrast agent (e.g., imaging contrast agent) or a 
therapeutic agent by a stable or biodegradable linker. The 
contrast agents can include: near infrared (NIR) fluorescent 
dyes, such as ICG derivatives; CT contrast agents, such as 
gold; MRI or SPECT contrast agents, such as Gd, Tc99m, 
and 'In chelates; radiotherapy agents, such as Yttrium; 
PET imaging agents comprising, for example, 18-F, 11-C, 
18-O, or Gallium 64; alkylating chemotherapy agents, such 
as melphalan or ifosfamide; and compounds for systemic 
melanoma chemotherapies, such as dacarbazine, paclitaxel, 
and Vincristine. 
In some embodiments of the invention, the MC1R-ligand 
is attached to a stable micelle (an MC1R peptide ligand 
micelle complex) comprising a diblock, triblock or tetra 
block copolymer that self organizes into: an inner core 
comprising a hydrophobic block that provides an environ 
ment where a drug or other agent can reside within the 
micelle; an outer core comprising a intermediate unit or 
block comprising at least one group that crosslinks, hence 
stabilizing the micelle; and a hydrophilic shell comprising a 
water soluble polymer with a functionality distal to the core 
wherein the functionality is used to attach the targeting 
MC1R-ligand. Micelles of this type are disclosed in Breit 
enkamp, et al., U.S. Pat. No. 7,638,558, and incorporated 
herein by reference. The crosslink of the outer shell can be 













bonds or a physical crosslink that involve associated func 
tional groups or ions, which bind by ligation of ions, dipolar 
interactions, or any other intermolecular forces. The cross 
link can be a disulfide, ester, hydrazone, Schiff base, zinc 
complexation, Iron (III) complexation, or other crosslinking 
that can be reversible. In embodiments of the invention, the 
crosslink is stable in vivo at a normal pH exhibited in most 
normal cells but uncrosslinks at the lower pH of a malignant 
cell that is targeted, permitting delivery of a payload to a 
desired anatomical site, such as a tumor site, through a 
pH-triggered mechanism. Barkey N M et al., “Development 
of Melanoma Targeted Polymer Micelles by Conjugation of 
a Melanocortin 1 Receptor (MC1R) Specific Ligand.’ J. 
Med. Chem., October 2011, 54:8078-8084, which describes 
the formation of embodiments of MC1R peptide ligand 
micelle complexes of the invention, is incorporated herein 
by reference in its entirety (see, for example, compound #4 
in Table 1 of Barkey N M et al.). 
Water soluble, hydrophilic, polymers that can be used 
include polyethyleneoxide (also referred to as polyethylene 
glycol or PEG), poly(N-vinyl-2-pyrolidone), poly(N-isopro 
pylacrylamide), poly(hydroxyethyl acrylate), poly(hydroxy 
lethyl methacrylate), poly(N-(2-hydroxypropoyl)methacry 
lamide) (HMPA), or any derivatives thereof. Such water 
soluble polymers are prepared in a manner Such that the 
distal end to the core has a reactive functionalized that is 
complementary to a reactive functionality on the targeting 
MC1R-ligand. In an embodiment of the invention, the 
reactive functionality on the hydrophilic polymer can be a 
triazine and the complementary functionality on the MC1R 
ligand can be a terminal alkyne. In another embodiment of 
the invention the reactive functionality on the hydrophilic 
polymer can be a terminal alkyne and the complementary 
functionality on the MC1R-ligand can be a triazine. 
In an embodiment of the invention, the micelle has an 
inner core that comprises a poly(amino acid) block where a 
Sufficient proportion of the amino acid repeating units have 
a hydrophobic side group to render the block hydrophobic. 
The amino acids can be natural or unnatural. The amino 
acids can include phenylalanine, alanine benzyl glutamate, 
alkyl glutamate, benzyl aspartate, alkyl aspartate, leucine, 
tyrosine, serine, threonine, glutamic acid, aspartic acid, or a 
combination thereof. 
In some embodiments of the invention, the micelle has an 
outer core comprising a reaction functionality that can be 
combined with a like reaction functionality to form a cross 
link. For example, a pair of thiol functionality can be 
combined to form a disulfide. The combined functionality 
can be with the inclusion of a disubstituted coupling reagent. 
For example, a carboxylic acid functionality can be com 
bined with a divalent or polyvalent salt to form an ionic 
crosslink, or condensed with a diol, diamine, or other 
symmetrically or asymmetrically disubstituted reagent to 
form a covalent crosslink. 
Some embodiments of the invention are directed to a 
method for the preparation of the MC1R-ligands comprising 
a functional group that can undergo a click reaction, as 
shown in FIG. 1. The method involves preparation of a 
peptide sequence comprising a 4-propynyl amide at either 
the C terminal or, alternately, the N terminal end of the 
peptide. The peptide can be prepared using a Rink Amide 
Tentagel resin (0.23 mmol/g) using a Fmoc/tEu synthetic 
strategy and standard activations. The protected peptide is 
selectively deprotected with cleavage of the Aloc group, and 
Subsequently condensed with a click reagent containing 
compound, for example a 5-hexynoic acid, to form the 
5-hexynyl amide group, as the site for Surface attachment of 
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the MC1R-ligand. The remainder of the protection groups 
and the cleavage from the resin can be carried out by 
addition of a TFA Scavenger cocktail. 
Some embodiments of the invention are directed to the 
functionalization of a surface with a MC1R-ligand compris 
ing a functional group for a click reaction and a surface 
comprising the complementary functionality. In an embodi 
ment of the invention, an MC1R-ligand comprises an alkyne 
functionality at an amino acid residue at the C terminal end, 
or alternately at the N terminal end, is added to an azide 
functionalized surface of an in vivo stable micelle. In cases 
in which the surface is the surface of a micelle, a MC1R 
peptide ligand micelle complex can be formed as shown in 
FIG 2. 
Some embodiments of the invention are directed to the 
delivery of drugs, contrast agents, or other agents attached to 
the MC1R-ligand or contained within a particle or micelle 
that is attached to the MC1R-ligand, to a patient. The micelle 
can be an in vivo stable micelle that can de-crosslink at a low 
pH. The terms “subject”, “individual’, or “patient’ as used 
herein refer to any human or non-human animal, including 
mammals, to whom treatment with a composition according 
to the present invention is provided. Mammalian species that 
benefit from the disclosed methods of treatment include, and 
are not limited to, apes, chimpanzees, orangutans, humans, 
monkeys; domesticated animals (e.g., pets) such as dogs, 
cats, guinea pigs, hamsters, rabbits, rats, mice, and ferrets; 
and domesticated farm animals such as cows, horses, Swine, 
and sheep. 
The methods of the present invention can be advanta 
geously combined with at least one additional diagnostic 
and/or treatment method, including but not limited to, che 
motherapy, radiation therapy, Surgery, immunotherapy or 
any other therapy known to those of skill in the art for the 
treatment and management of a cancer. 
While MC1R peptide ligands of the invention can be 
administered to cells in vitro and in vivo as isolated agents, 
it is preferred to administer these MC1R peptide ligands as 
part of a pharmaceutical composition. The Subject invention 
thus further provides compositions comprising a peptide of 
the invention in association with at least one pharmaceuti 
cally acceptable carrier. The pharmaceutical composition 
can be adapted for various routes of administration, such as 
enteral, parenteral, intravenous, intramuscular, topical, Sub 
cutaneous, intratumoral, and so forth. Administration can be 
continuous or at distinct intervals, as can be determined by 
a person of ordinary skill in the art. 
The MC1R peptide ligands of the invention can be 
formulated according to known methods for preparing phar 
maceutically useful compositions. Formulations are 
described in a number of sources which are well known and 
readily available to those skilled in the art. For example, 
Remington's Pharmaceutical Science (Martin, E. W., 1995, 
Easton Pa., Mack Publishing Company, 19" ed.) describes 
formulations which can be used in connection with the 
subject invention. Formulations suitable for administration 
include, for example, aqueous sterile injection Solutions, 
which may contain antioxidants, buffers, bacteriostats, and 
solutes that render the formulation isotonic with the blood of 
the intended recipient; and aqueous and nonaqueous sterile 
Suspensions which may include Suspending agents and 
thickening agents. The formulations may be presented in 
unit-dose or multi-dose containers, for example sealed 
ampoules and vials, and may be stored in a freeze dried 
(lyophilized) condition requiring only the condition of the 
sterile liquid carrier, for example, water for injections, prior 














may be prepared from Sterile powder, granules, tablets, etc. 
It should be understood that in addition to the ingredients 
particularly mentioned above, the compositions of the Sub 
ject invention can include other agents conventional in the 
art having regard to the type of formulation in question. 
Examples of pharmaceutically acceptable salts are 
organic acid addition salts formed with acids that form a 
physiological acceptable anion, for example, tosylate, meth 
anesulfonate, acetate, citrate, malonate, tartarate. Succinate, 
benzoate, ascorbate, alpha-ketoglutarate, and alpha-glycero 
phosphate. Suitable inorganic salts may also be formed, 
including hydrochloride, Sulfate, nitrate, bicarbonate, and 
carbonate salts. 
Pharmaceutically acceptable salts of compounds may be 
obtained using standard procedures well known in the art, 
for example, by reacting a Sufficiently basic compound Such 
as an amine with a suitable acid affording a physiologically 
acceptable anion. Alkali metal (for example, sodium, potas 
sium or lithium) or alkaline earth metal (for example cal 
cium) salts of carboxylic acids can also be made. 
The active agent (MC1R peptide ligands/complexes) may 
also be administered intravenously or intraperitoneally by 
infusion or injection. Solutions of the active agent can be 
prepared in water, optionally mixed with a nontoxic Surfac 
tant. Dispersions can also be prepared in glycerol, liquid 
polyethylene glycols, triacetin, and mixtures thereof and in 
oils. Under ordinary conditions of storage and use, these 
preparations can contain a preservative to prevent the 
growth of microorganisms. 
The pharmaceutical dosage forms suitable for injection or 
infusion can include sterile aqueous solutions or dispersions 
or sterile powders comprising the compounds of the inven 
tion which are adapted for the extemporaneous preparation 
of sterile injectable or infusible solutions or dispersions, 
optionally encapsulated in liposomes. The ultimate dosage 
form should be sterile, fluid and stable under the conditions 
of manufacture and storage. The liquid carrier or vehicle can 
be a solvent or liquid dispersion medium comprising, for 
example, water, ethanol, a polyol (for example, glycerol, 
propylene glycol, liquid polyethylene glycols, and the like), 
vegetable oils, nontoxic glyceryl esters, and Suitable mix 
tures thereof. The proper fluidity can be maintained, for 
example, by the formation of liposomes, by the maintenance 
of the required particle size in the case of dispersions or by 
the use of surfactants. Optionally, the prevention of the 
action of microorganisms can be brought about by various 
antibacterial and antifungal agents, for example, parabens, 
chlorobutanol, phenol, Sorbic acid, thimerosal, and the like. 
In many cases, it will be preferable to include isotonic 
agents, for example, Sugars, buffers or sodium chloride. 
Prolonged absorption of the injectable compositions can be 
brought about by the inclusion of agents that delay absorp 
tion, for example, aluminum monostearate and gelatin. 
MC1R peptide ligands/complexes of the invention may 
be administered locally at the desired anatomical site. Such 
as a tumor site, or remote from the desired State, or sys 
temically. Sterile injectable solutions are prepared by incor 
porating the MC1R peptide ligands of the invention in the 
required amount in the appropriate solvent with various 
other ingredients enumerated above, as required, followed 
by filter sterilization. In the case of sterile powders for the 
preparation of sterile injectable solutions, the preferred 
methods of preparation are vacuum drying and the freeze 
drying techniques, which yield a powder of the active 
ingredient plus any additional desired ingredient present in 
the previously sterile-filtered solutions. 
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For topical administration, the agents may be applied in 
pure-form, i.e., when they are liquids. However, it will 
generally be desirable to administer them topically to the 
skin as compositions, in combination with a dermatologi 
cally acceptable carrier, which may be a solid or a liquid. 
The agents of the Subject invention can be applied topi 
cally to a Subject’s skin to reduce the size (and may include 
complete removal) of malignant or benign growths. The 
MC1R peptide ligands of the invention can be applied 
directly to the growth. For example, the MC1R peptide 
ligand may be applied to the growth in a formulation Such 
as an ointment, cream, lotion, Solution, tincture, or the like. 
Drug delivery systems for delivery of pharmacological 
Substances to dermal lesions can also be used, such as that 
described in U.S. Pat. No. 5,167,649 (Zook). 
Useful solid carriers include finely divided solids such as 
talc, clay, microcrystalline cellulose, silica, alumina and the 
like. Useful liquid carriers include water, alcohols or glycols 
or water-alcohol/glycol blends, in which the peptide can be 
dissolved or dispersed at effective levels, optionally with the 
aid of non-toxic Surfactants. Adjuvants such as fragrances 
and additional antimicrobial agents can be added to optimize 
the properties for a given use. The resultant liquid compo 
sitions can be applied from absorbent pads, used to impreg 
nate bandages and other dressings, or sprayed onto the 
affected area using pump-type or aerosol sprayers, for 
example. 
Thickeners such as synthetic polymers, fatty acids, fatty 
acid salts and esters, fatty alcohols, modified celluloses or 
modified mineral materials can also be employed with liquid 
carriers to form spreadable pastes, gels, ointments, Soaps, 
and the like, for application directly to the skin of the user. 
Examples of useful dermatological compositions which can 
be used to deliver the peptides to the skin are disclosed in 
Jacquet et al. (U.S. Pat. No. 4,608.392), Geria (U.S. Pat. No. 
4,992.478), Smith et al. (U.S. Pat. No. 4,559,157) and 
Woltzman (U.S. Pat. No. 4,820,508). 
Useful dosages of the pharmaceutical compositions of the 
present invention can be determined by comparing their in 
vitro activity, and in vivo activity in animal models. Meth 
ods for the extrapolation of effective dosages in mice, and 
other animals, to humans are known in the art; for example, 
see U.S. Pat. No. 4,938,949. 
Patients in need of treatment and/or diagnosis using the 
compositions and methods of the present invention can be 
identified using standard techniques known to those in the 
medical or veterinary professions, as appropriate. 
As used herein, the terms "cancer and “malignancy” are 
used inclusively. As used herein, the terms “cancer and 
“malignancy” refer to or describe the physiological condi 
tion in mammals that is typically characterized by unregu 
lated cell growth. The cancer may be drug-resistant or 
drug-sensitive. Examples of cancer include but are not 
limited to, carcinoma, lymphoma, blastoma, Sarcoma, and 
leukemia. More particular examples of such cancers include 
melanoma breast cancer, prostate cancer, colon cancer, 
squamous cell cancer, Small-cell lung cancer, non-Small cell 
lung cancer, gastrointestinal cancer, pancreatic cancer, cer 
Vical cancer, ovarian cancer, peritoneal cancer, liver cancer, 
e.g., hepatic carcinoma, bladder cancer, colorectal cancer, 
endometrial carcinoma, kidney cancer, and thyroid cancer. 
The cancer may be primary or metastatic. In some embodi 
ments, the cancer is metastatic melanoma. 
Other non-limiting examples of cancers are basal cell 
carcinoma, biliary tract cancer, bone cancer; brain and CNS 
cancer, choriocarcinoma; connective tissue cancer, esopha 













cancer, intra-epithelial neoplasm; larynx cancer, lymphoma 
including Hodgkin’s and Non-Hodgkin’s lymphoma; 
myeloma; neuroblastoma; oral cavity cancer (e.g., lip, 
tongue, mouth, and pharynx); retinoblastoma, rhabdomyo 
sarcoma; rectal cancer, cancer of the respiratory system; 
sarcoma; skin cancer, stomach cancer, testicular cancer, 
uterine cancer, cancer of the urinary system, as well as other 
carcinomas and sarcomas. Examples of cancer are listed in 
Table 15 below. 
As used herein, the terms “administering or “administer 
is defined as the introduction of a substance (MC1R peptide 
ligand or complex) into cells in vitro or into the body of an 
individual in vivo and includes oral, nasal, ocular, rectal, 
vaginal and parenteral routes. The MC1R peptide ligand or 
complex may be administered individually or in combina 
tion with other agents via any route of administration, 
including but not limited to Subcutaneous (SQ), intramus 
cular (IM), intravenous (IV), intraperitoneal (IP), intrader 
mal (ID), via the nasal, ocular or oral mucosa (IN), or orally. 
For example, the MC1R peptide ligand or complex can be 
administered by direct injection into a tumor or at a site 
remote from the tumor. 
The MC1R peptide ligand or complex can be adminis 
tered to treat a disorder. Such as cancer. As used herein, the 
terms “treat' or “treatment” refer to both therapeutic treat 
ment and prophylactic or preventative measures, wherein 
the object is to prevent or slow down (lessen) an undesired 
physiological change or disorder, Such as the development 
or spread of cancer or other proliferation disorder. For 
purposes of this invention, beneficial or desired clinical 
results include, but are not limited to, alleviation of symp 
toms, diminishment of extent of disease, stabilized (i.e., not 
worsening) state of disease, delay or slowing of disease 
progression, amelioration or palliation of the disease state, 
and remission (whether partial or total), whether detectable 
or undetectable. For example, treatment with a peptide of the 
invention may include reduction of undesirable cell prolif 
eration, and/or induction of apoptosis and cytotoxicity. 
“Treatment can also mean prolonging Survival as compared 
to expected survival if not receiving treatment. Those in 
need of treatment include those already with the condition or 
disorder as well as those prone to have the condition or 
disorder or those in which the condition or disorder is to be 
prevented or onset delayed. Optionally, the patient may be 
identified (e.g., diagnosed) as one Suffering from the disease 
or condition (e.g., cancer) prior to administration of the 
peptide of the invention. 
As used herein, the term “(therapeutically) effective 
amount” refers to an amount of the MC1R peptide ligand or 
complex of the invention or other agent (e.g., a drug) 
effective to treat a disease or disorder in a mammal. In the 
case of cancer or other proliferation disorder, the therapeu 
tically effective amount of the agent may reduce (i.e., slow 
to some extent and preferably stop) unwanted cellular pro 
liferation; reduce the number of cancer cells; reduce the 
tumor size: inhibit (i.e., slow to some extent and preferably 
stop) cancer cell infiltration into peripheral organs; inhibit 
(i.e., slow to Some extent and preferably stop) tumor metas 
tasis; inhibit, to some extent, tumor growth; and/or relieve, 
to Some extent, one or more of the symptoms associated with 
the cancer. To the extent the administered MC1R peptide 
ligand or complex prevents growth of and/or kills existing 
cancer cells, it may be cytostatic and/or cytotoxic. For 
cancer therapy, efficacy can, for example, be measured by 
assessing the time to disease progression (TTP) and/or 
determining the response rate (RR). 
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As used herein, the term “growth inhibitory amount of 
the MC1R peptide ligand or complex of the invention refers 
to an amount which inhibits growth or proliferation of a 
target cell. Such as a tumor cell, either in vitro or in vivo, 
irrespective of the mechanism by which cell growth is 
inhibited (e.g., by cytostatic properties, cytotoxic properties, 
etc.). In a preferred embodiment, the growth inhibitory 
amount inhibits (i.e., slows to Some extent and preferably 
stops) proliferation or growth of the target cell in vivo or in 
cell culture by greater than about 20%, preferably greater 
than about 50%, most preferably greater than about 75% 
(e.g., from about 75% to about 100%). 
The terms “cell and “cells' are used interchangeably 
herein and are intended to include either a single cell or a 
plurality of cells, in vitro or in vivo, unless otherwise 
specified. 
In some embodiments, an agent is coupled to the MC1R 
peptide ligand or incorporated within the micelle of the 
complex. In some embodiments, the agent is an anti-cancer 
agent, Such as a chemotherapeutic agent, biologic, etc. 
having anti-cancer activity. 
As used herein, the term “anti-cancer agent” refers to a 
Substance or treatment (e.g., radiation therapy) that inhibits 
the function of cancer cells, inhibits their formation, and/or 
causes their destruction in vitro or in vivo. Examples 
include, but are not limited to, cytotoxic agents (e.g., 5-fluo 
rouracil, TAXOL), chemotherapeutic agents, and anti-Sig 
naling agents (e.g., the PI3K inhibitor LY). In addition to 
being coupled to the MC1R peptide ligand or incorporated 
within the micelle, additional anti-cancer agents may be 
administered before, during, after administration of the 
MC1R peptide ligand or complex. Anti-cancer agents 
include but are not limited to the chemotherapeutic agents 
listed Table 14. 
As used herein, the term “cytotoxic agent” refers to a 
substance that inhibits or prevents the function of cells 
and/or causes destruction of cells in vitro and/or in vivo. The 
term is intended to include radioactive isotopes (e.g., At', 
Ill, Il 25, Yo, Reis, Reis, Smit53, Bill2, P32, and radio 
active isotopes of Lu), chemotherapeutic agents, toxins such 
as Small molecule toxins or enzymatically active toxins of 
bacterial, fungal, plant or animal origin, and antibodies, 
including fragments and/or variants thereof. 
As used herein, the term “chemotherapeutic agent is a 
chemical compound useful in the treatment of cancer, Such 
as, for example, taxanes, e.g., paclitaxel (TAXOL, BRIS 
TOL-MYERS SQUIBB Oncology, Princeton, N.J.) and dox 
etaxel (TAXOTERE, Rhone-Poulenc Rorer, Antony, 
France), chlorambucil, Vincristine, vinblastine, anti-estro 
gens including for example tamoxifen, raloxifene, aro 
matase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, tri 
oxifene, keoxifene, LY 1 17018, onapristone, and toremifene 
(FARESTON, GTX, Memphis, Tenn.), and anti-androgens 
Such as flutamide, nilutamide, bicalutamide, leuprolide, and 
goserelin, etc. Examples of chemotherapeutic agents that 
may be used in conjunction with the compounds of the 
invention are listed in Table 14. In some embodiments, the 
chemotherapeutic agent is one or more anthracyclines. 
Anthracyclines are a family of chemotherapy drugs that are 
also antibiotics. The anthracyclines act to prevent cell divi 
sion by disrupting the structure of the DNA and terminate its 
function by: (1) intercalating into the base pairs in the DNA 
minor grooves; and (2) causing free radical damage of the 
ribose in the DNA. The anthracyclines are frequently used in 
leukemia therapy. Examples of anthracyclines include 












CIN, RUBEX), epirubicin (ELLENCE, PHARMORUBI 
20 
CIN), and idarubicin (IDAMYCIN). 



















































































































































Prolifeprospan 20 with Carmustine implant 























































































granulocyte - colony stimulating factor 












Hydrocortisone sodium phosphate 
Hydrocortisone sodium succinate 
Hydrocortone phosphate 
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TABLE 14-continued 





























































interferon Alfa-2b (PEG conjugate) 
interleukin-2 
interleukin-11 































Examples of Cancer Types 
Acute Lymphoblastic Leukemia, Adult 
Acute Lymphoblastic Leukemia, 
Childhood 
Acute Myeloid Leukemia, Adult 
Acute Myeloid Leukemia, Childhood 
Adrenocortical Carcinoma 




Astrocytoma, Childhood Cerebellar 
Astrocytoma, Childhood Cerebral 
Basal Cell Carcinoma 
Bile Duct Cancer, Extrahepatic 
Bladder Cancer 
Bladder Cancer, Childhood 
Bone Cancer, Osteosarcoma Malignant 
Fibrous Histiocytoma 
Brain Stem Glioma, Childhood 
Brain Tumor, Adult 
Brain Tumor, Brain Stem Glioma, 
Childhood 
Hairy Cell Leukemia 
Head and Neck Cancer 
Hepatocellular (Liver) Cancer, Adult (Primary) 
Hepatocellular (Liver) Cancer, Childhood 
(Primary) 
Hodgkin's Lymphoma, Adult 
Hodgkin's Lymphoma, Childhood 
Hodgkin's Lymphoma. During Pregnancy 
Hypopharyngeal Cancer 
Hypothalamic and Visual Pathway Glioma, 
Childhood 
intraocular Melanoma 
slet Cell Carcinoma (Endocrine Pancreas) 
Kaposi's Sarcoma 
Kidney (Renal Cell) Cancer 
Kidney Cancer, Childhood 
Laryngeal Cancer 
Laryngeal Cancer, Childhood 
Leukemia, Acute Lymphoblastic, Adult 
Leukemia, Acute Lymphoblastic, Childhood 
Leukemia, Acute Myeloid, Adult 
Leukemia, Acute Myeloid, Childhood 
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TABLE 15-continued 
Examples of Cancer Types 
Brain Tumor, Cerebellar Astrocytoma, 
Childhood 
Brain Tumor, Cerebral 
Astrocytoma Malignant Glioma, 
Childhood 
Brain Tumor, Ependymoma, Childhood 
Brain Tumor, Medulloblastoma, 
Childhood 
Brain Tumor, Supratentorial Primitive 
Neuroectodermal Tumors, Childhood 
Brain Tumor, Visual Pathway and 
Hypothalamic Glioma, Childhood 
Brain Tumor, Childhood 
Breast Cancer 
Breast Cancer, Childhood 
Breast Cancer, Male 
Bronchial Adenomas Carcinoids, 
Childhood 
Burkitt's Lymphoma 
Carcinoid Tumor, Childhood 
Carcinoid Tumor, Gastrointestinal 
Carcinoma of Unknown Primary 
Central Nervous System Lymphoma, 
Primary 
Cerebellar Astrocytoma, Childhood 




Chronic Lymphocytic Leukemia 
Chronic Myelogenous Leukemia 
Chronic Myeloproliferative Disorders 
Colon Cancer 
Colorectal Cancer, Childhood 
Cutaneous T-Cell Lymphoma, see 





Esophageal Cancer, Childhood 
Ewing's Family of Tumors 
Extracranial Germ. Cell Tumor, 
Childhood 
Extragonadal Germ. Cell Tumor 
Extrahepatic Bile Duct Cancer 
Eye Cancer, Intraocular Melanoma 
Eye Cancer, Retinoblastoma 
Gallbladder Cancer 
Gastric (Stomach) Cancer 
Gastric (Stomach) Cancer, Childhood 
Gastrointestinal Carcinoid Tumor 
Germ. Cell Tumor, Extracranial, 
Childhood 
Germ Cell Tumor, Extragonadal 
Germ. Cell Tumor, Ovarian 
Gestational Trophoblastic Tumor 
Glioma, Adult 
Glioma, Childhood Brain Stem 
Glioma, Childhood Cerebral 
Astrocytoma 
Glioma, Childhood Visual Pathway and 
Hypothalamic 
Skin Cancer (Melanoma) 
Skin Carcinoma, Merkel Cell 
Small Cell Lung Cancer 
Small Intestine Cancer 
Soft Tissue Sarcoma, Adult 
Soft Tissue Sarcoma, Childhood 
Squamous Cell Carcinoma, see Skin 
Cancer (non-Melanoma) 
Squamous Neck Cancer with Occult 
Primary, Metastatic 
Stomach (Gastric) Cancer 
Stomach (Gastric) Cancer, Childhood 
Supratentorial Primitive 
Neuroectodermal Tumors, Childhood 
T-Cell Lymphoma, Cutaneous, see 
Leukemia, Chronic Lymphocytic 
Leukemia, Chronic Myelogenous 
Leukemia, Hairy Cell 
Lip and Oral Cavity Cancer 
Liver Cancer, Adult (Primary) 
Liver Cancer, Childhood (Primary) 
Lung Cancer, Non-Small Cell 
Lung Cancer, Small Cell 
Lymphoma, AIDS-Related 
Lymphoma, Burkitt's 
Lymphoma, Cutaneous T-Cell, see Mycosis 
Fungoides and Sezary Syndrome 
Lymphoma, Hodgkins, Adult 
Lymphoma, Hodgkins, Childhood 
Lymphoma, Hodgkin's During Pregnancy 
Lymphoma, Non-Hodgkins, Adult 
Lymphoma, Non-Hodgkins, Childhood 
Lymphoma, Non-Hodgkin's During Pregnancy 
Lymphoma, Primary Central Nervous System 
Macroglobulinemia, Waldenstrom's 




Melanoma, Intraocular (Eye) 
Merkel Cell Carcinoma 
Mesothelioma, Adult Malignant 
Mesothelioma, Childhood 
Metastatic Squamous Neck Cancer with Occult 
Primary 
Multiple Endocrine Neoplasia Syndrome, 
Childhood 




Myelogenous Leukemia, Chronic 
Myeloid Leukemia, Adult Acute 
Myeloid Leukemia, Childhood Acute 
Myeloma, Multiple 
Myeloproliferative Disorders, Chronic 
Nasal Cavity and Paranasal Sinus Cancer 
Nasopharyngeal Cancer 
Nasopharyngeal Cancer, Childhood 
Neuroblastoma 
Non-Hodgkin's Lymphoma, Adult 
Non-Hodgkin's Lymphoma, Childhood 
Non-Hodgkin's Lymphoma. During Pregnancy 
Non-Small Cell Lung Cancer 
Oral Cancer, Childhood 
Oral Cavity Cancer, Lip and 
Oropharyngeal Cancer 
Osteosarcoma Malignant Fibrous Histiocytoma 
of Bone 
Ovarian Cancer, Childhood 
Ovarian Epithelial Cancer 
Ovarian Germ Cell Tumor 
Ovarian Low Malignant Potential Tumor 
Pancreatic Cancer 
Pancreatic Cancer, Childhood 
Pancreatic Cancer, Islet Cell 




Pineoblastoma and Supratentorial Primitive 
Neuroectodermal Tumors, Childhood 
Pituitary Tumor 
Plasma Cell Neoplasm/Multiple Myeloma 
Pleuropulmonary Blastoma 
Pregnancy and Breast Cancer 
Pregnancy and Hodgkin's Lymphoma 
Pregnancy and Non-Hodgkin's Lymphoma 
Primary Central Nervous System Lymphoma 
Prostate Cancer 
Rectal Cancer 
Renal Cell (Kidney) Cancer 
Renal Cell (Kidney) Cancer, Childhood 
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TABLE 15-continued 
Examples of Cancer Types 




Thymoma and Thymic Carcinoma 
Thyroid Cancer 
Thyroid Cancer, Childhood 
Transitional Cell Cancer of the Renal 
Pelvis and Ureter 
Trophoblastic Tumor, Gestational 




Salivary Gland Cancer 
Salivary Gland Cancer, Childhoo 
Sarcoma, Kaposi's 
Sarcoma, Soft Tissue, Adult 
Sarcoma, Soft Tissue, Childhood 
Sarcoma, Uterine 
Adult Sezary Syndrome 
Unknown Primary Site, Cancer of, Skin Cancer (non-Melanoma) 
Childhood Skin Cancer, Childhood 
Unusual Cancers of Childhood 
Ureter and Renal Pelvis, Transitional Cell 
Cancer 
Urethral Cancer 
Uterine Cancer, Endometrial 
Uterine Sarcoma 
Vaginal Cancer 





As used herein, the term “tumor refers to all neoplastic 
cell growth and proliferation, whether malignant or benign, 
and all pre-cancerous and cancerous cells and tissues. For 
example, a particular cancer may be characterized by a Solid 
tumor mass or a non-solid tumor. A primary tumor mass 
refers to a growth of cancer cells in a tissue resulting from 
the transformation of a normal cell of that tissue. In most 
cases, the primary tumor mass is identified by the presence 
of a cyst, which can be found through visual or palpation 
methods, or by irregularity in shape, texture, or weight of the 
tissue. However, some primary tumors are not palpable and 
can be detected only through medical imaging techniques 
Such as X-rays (e.g., mammography), or by needle aspira 
tions. The use of these latter techniques is more common in 
early detection. Molecular and phenotypic analysis of cancer 
cells within a tissue will usually confirm if the cancer is 
endogenous to the tissue or if the lesion is due to metastasis 
from another site. Depending upon the type of agent (pay 
load) utilized, the compositions of the invention may be 
capable of inducing apoptosis in tumor cells and reducing 
tumor cell growth. The compositions of the invention can be 
administered locally at the site of a tumor (e.g., by direct 
injection) or remotely. Depending upon the payload, the 
compositions of the invention can induce cell death in 
circulating tumor cells (CTC) in a Subject, e.g., by admin 
istering the compositions intravenously. Furthermore, 
depending upon payload, the compositions of the invention 
can prevent or reduce onset of metastasis to other tissues. 
Furthermore, in cases in which the payload is a detectable 
moiety, Such as a contrast agent, the compositions of the 
invention can be used to detect metastasis to other tissues 
and potentially avoid the need for nodal biopsy. 
As used herein, the term "payload” refers to agents and 
moieties linked to the MC1R peptide ligand or residing 
within the inner core of the MC1R peptide ligand-micelle 
complex. The payload may be any desired agent or moiety 
that is capable of being directly or indirectly linked to the 
MC1R peptide ligand or incorporated within the micelle. 
Examples of payloads include, but are not limited to, mol 
ecules such as contrast agents (e.g., detectable Substances 
d 










Renal Pelvis and Ureter, Transitional Cell 
Such as dyes), biologically active agents, such as biologics, 
anti-cancer agents such as chemotherapeutic agents (see, for 
example, Table 14), or other drugs. The terms “payload’. 
“agent, and “moiety” are used interchangeably herein. 
As used in this specification, the singular forms “a”, “an', 
and “the include plural reference unless the context clearly 
dictates otherwise. Thus, for example, a reference to “a cell 
includes one or more cells. A reference to “a peptide' 
includes one or more Such peptide, and so forth. 
The practice of the present invention can employ, unless 
otherwise indicated, conventional techniques of molecular 
biology, microbiology, recombinant DNA technology, elec 
trophysiology, and pharmacology that are within the skill of 
the art. Such techniques are explained fully in the literature 
(see, e.g., Sambrook, Fritsch & Maniatis, Molecular Clon 
ing: A Laboratory Manual, Second Edition (1989); DNA 
Cloning, Vols. I and II (D. N. Glover Ed. 1985); Perbal, B., 
A Practical Guide to Molecular Cloning (1984); the series, 
Methods In Enzymology (S. Colowick and N. Kaplan Eds. 
Academic Press, Inc.); Transcription and Translation 
(Hames et al. Eds. 1984); Gene Transfer Vectors For Mam 
malian Cells (J. H. Miller et al. Eds. (1987) Cold Spring 
Harbor Laboratory, Cold Spring Harbor, N.Y.); Scopes, 
Protein Purification Principles and Practice (2nd ed., 
Springer-Verlag); and PCR: A Practical Approach (McPher 
son et al. Eds. (1991) IRL Press)), each of which are 
incorporated herein by reference in their entirety. 
Exemplified Embodiments: 
Embodiment 1: A modified melanocortin1 receptor (MC1R) 
peptide ligand, comprising an MC1R peptide ligand 
coupled to a functionality. 
Embodiment 2: The modified MC1R peptide ligand of 
embodiment 1, wherein the functionality is an alkyne, 
azide, amine, aldehyde, thiol, alkene, ester, or maleimide. 
Embodiment 3: The modified MC1R peptide ligand of 
embodiment 1, wherein the functionality is coupled to the 
C-terminus of said MC1R ligand. 
Embodiment 4: The modified MC1R peptide ligand of 
embodiment 1, wherein the functionality is coupled to the 
N-terminus of said MC1R ligand. 
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Embodiment 5: The modified MC1R peptide ligand of 
embodiment 1, wherein the MC1R peptide ligand is 
selected from: 
(SEQ ID NO: 
4 -phenylbutyryl-His-DPhe-Arg-Trp-Gly-Lys (hex-5- 
ynoyl) -NH2; 
3) 
(SEQ ID NO: 




(SEQ ID NO: 
H-Lys (hex.- 5-ynoyl) Tyr-Val-Nile-Gly-His-DNal (2') - 
Arg-DPhe-Asp-Arg-Phe-Gly-NH2. 
5) 
Embodiment 6: The modified MC1R peptide ligand of 
embodiment 1, wherein the MC1R peptide ligand com 
prises the amino acid motif His-Phe-Arg-Trp (HFRW) 
(SEQ ID NO:1). 
Embodiment 7: The modified MC1R peptide ligand of 
embodiment 1, wherein the MC1R peptide ligand com 
prises the amino acid motif His-DPhe-Arg-Trp (HfRW) 
(SEQ ID NO:2). 
Embodiment 8: A method of preparing a MC1R peptide 
ligand according to embodiment 1, comprising: 
providing an MC1R peptide ligand; and 
covalently bonding a moiety comprising a functionality to 
the C-terminus or N-terminus of the MC1R peptide 
ligand, wherein a MC1R peptide ligand comprising a 
functionality is formed. 
Embodiment 9: The method of embodiment 8, wherein the 
MC1R peptide ligand comprises a Lys residue or other 
nitrogen-bearing, thiol-bearing, or —OH bearing residue 
at the C-terminus or N-terminus, and wherein the moiety 
comprising the functionality is covalently bound to the 
residue. 
Embodiment 10: The method of embodiment 9, wherein the 
residue at the C-terminus or N-terminus comprises the 
Lys residue. 
Embodiment 11: The method of embodiment 8, wherein the 
moiety comprises a terminal alkynyl acid of 5 to 12 
carbons. 
Embodiment 12: A melanocortin 1 receptor (MC1R)-tar 
geted agent comprising: 
a MC1R peptide ligand; and 
a moiety, wherein the MC1R peptide ligand and the 
moiety are covalently linked by a reaction product of a 
first functionality coupled to the peptide ligand and a 
complementary second functionality coupled to the 
moiety. 
Embodiment 13: The melanocortin 1-targeted agent of 
embodiment 12, wherein the moiety comprises an anti 
cancer agent, drug (e.g., chemotherapeutic agent, immu 
notherapeutic agent, etc.), contrast agent, polymer, gel, 
particle, Surface, or any combination of one or more of the 
foregoing. 
Embodiment 14: The melanocortin 1-targeted agent of 
embodiment 13, wherein the moiety comprises a contrast 
agent comprising a fluorescent dye. 
Embodiment 15: The melanocortin 1-targeted agent of 
embodiment 14, wherein the fluorescent dye comprises 
RDye800CW. 
Embodiment 16: The melanocortin 1-targeted agent of any 
one of embodiment 13-15, wherein the contrast agent is 














Embodiment 17: The melanocortin 1-targeted agent of 
embodiment 13 or 14, wherein the contrast agent is 
covalently linked to the C terminus of the MC1R peptide 
ligand. 
Embodiment 18: The melanocortin 1-targeted agent of 
embodiment 12, wherein the first functionality comprises 
an alkyne, azide, amine, aldehyde, thiol, alkene, ester, or 
maleimide and the reaction product is a 1.2.3-triazole, 
imine, disulfide, thioether, primary amide, or secondary 
amide. 
Embodiment 19: A method of delivering a moiety to cells 
expressing the melanocortin 1 receptor (MC1R), com 
prising administering an MC1R-targeted agent of 
embodiment 12 or 13 to the cells in vitro or in vivo. 
Embodiment 20: The method of embodiment 19, wherein 
the MC1R-targeted agent is administered to the cells in 
V1VO. 
Embodiment 21: The method of embodiment 20, wherein 
the MC1R-targeted agent is administered systemically to 
a human or non-human animal Subject. 
Embodiment 22: The method of embodiment 21, wherein 
the MC1R-targeted agent is administered to the subject 
intravascularly (e.g., intravenously). 
Embodiment 23: The method of embodiment 20, wherein 
the MC1R-targeted agent is administered locally to the 
cells. 
Embodiment 24: The method of embodiment 19, wherein 
the MC1R-targeted agent is administered to a human or 
non-human animal Subject, and wherein the moiety com 
prises a contrast agent. 
Embodiment 25: The method of embodiment 20, further 
comprising imaging the subject using an imaging modal 
1ty. 
Embodiment 26: The method of embodiment 19, wherein 
the MC1R-targeted agent is administered locally or sys 
temically to a human or non-human animal Subject having 
melanoma, and wherein the moiety comprises an anti 
cancer agent. 
Embodiment 27: The method of embodiment 26, wherein 
the anti-cancer agent kills or inhibits the growth of 
melanoma cells. 
Embodiment 28: A pharmaceutical composition comprising 
the MC1-R targeted agent of embodiment 12 or 13, and a 
pharmaceutically acceptable carrier. 
Embodiment 29: A method of treating melanoma in a human 
or non-human animal Subject, comprising administering 
an MC1R-targeted agent of embodiment 12 or 13 to the 
Subject, wherein the moiety comprises an anti-cancer 
agent. 
Embodiment 30: The method of embodiment 29, wherein 
the anti-cancer agent kills or inhibits the growth of 
melanoma cells. 
Embodiment 31: A modified melanocortin 1 receptor 
(MC1R) peptide ligand-micelle complex, comprising: 
an MC1R peptide ligand; and 
a micelle comprising an inner core, outer core and hydro 
philic shell, wherein the MC1R peptide ligand is linked 
to the shell of the micelle by a linker. 
Embodiment 32: The MC1R peptide ligand-micelle com 
plex of embodiment 31, further comprising an agent 
residing in the inner core of the micelle. 
Embodiment 33: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the linker com 
prises a 1.2.3-triazole, imine, disulfide, thioether, primary 
amide, or secondary amide. 
Embodiment 34: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the inner core of 
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the micelle comprises a hydrophobic polypeptide, the 
outer core comprises a crosslinked peptide comprising a 
multiplicity of crosslinked amino acid residues and the 
hydrophilic shell comprises a water soluble polymer, and 
wherein the inner core is covalently attached to the outer 
core and the outer core is covalently attached to the 
hydrophilic shell. 
Embodiment 35: The MC1R peptide ligand-micelle com 
plex of embodiment 34, wherein the water soluble poly 
mer comprises polyethylene glycol. 
Embodiment 36: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the linker is a 
1,2,3-triazole from the addition of an azide and an alkyne. 
Embodiment 37: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the linker is 
coupled to the C-terminus of said MC1R ligand. 
Embodiment 38: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the linker is 
coupled to the N-terminus of said MC1R ligand. 
Embodiment 39: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the linker com 
prises a reaction product, and wherein the MC1R peptide 
ligand is selected from: 
(SEQ ID NO: 
4 -phenylbutyryl-His-DPhe-Arg-Trp-Gly-Lys (hex-5- 
ynoyl) -NH2; 
3) 
(SEQ ID NO: 




(SEQ ID NO: 
H-Lys (hex.- 5-ynoyl) Tyr-Val-Nile-Gly-His-DNal (2') - 
Arg-DPhe-Asp-Arg-Phe-Gly-NH2. 
5) 
Embodiment 40: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the MC1R peptide 
ligand comprises the amino acid motif His-Phe-Arg-Trp 
(HFRW) (SEQ ID NO:1). 
Embodiment 41: The MC1R peptide ligand-micelle com 
plex of embodiment 31 or 32, wherein the MC1R peptide 
ligand comprises the amino acid motif His-DPhe-Arg-Trp 
(HfRW) (SEQ ID NO:2). 
Embodiment 42: The MC1R peptide ligand-micelle com 
plex of embodiment 32, wherein the agent comprises an 
anti-cancer drug. 
Embodiment 43: The MC1R peptide ligand-micelle com 
plex of embodiment 32, wherein the agent comprises a 
contrast agent. 
Embodiment 44: A method of imaging a melanoma tumor of 
a Subject, comprising: 
administering the MC1R peptide ligand-micelle complex 
of embodiment 31 or 32 to the subject, wherein a 
contrast agent is present within the inner core of the 
micelle, and wherein the MC1R peptide ligand-micelle 
complex concentrates in the tumor; and 
observing a signal from the contrast agent, e.g., using an 
imaging device also referred to herein as an imaging 
modality). 
Embodiment 45: A method of imaging a melanoma tumor, 
comprising: 
providing a MC1R peptide ligand-micelle complex of 
embodiment 31 or 32; 
incorporating a contrast agent into the inner core of said 
MC1R peptide ligand micelle complex; 
administering the MC1R peptide ligand-micelle complex 














animal subject, wherein the MC1R peptide ligand 
micelle complex concentrates in the tumor, and 
observing a signal from the contrast agent, e.g., using an 
imaging device (also referred to herein as an imaging 
modality). 
Embodiment 46: The method of embodiment 45, wherein 
the contrast agent is a near infrared (NIR) fluorescent dye. 
Embodiment 47: The method of embodiment 46, wherein 
the NIR fluorescent dye comprises a ICG derivative. 
Embodiment 48: The method of embodiment 45, wherein 
the contrast agent is a CT contrast agent. 
Embodiment 49: The method of embodiment 48, wherein 
the CT contrast agent comprises gold. 
Embodiment 50: The method of embodiment 45, wherein 
the contrast agent is a MRI or SPECT contrast agent. 
Embodiment 51: The method of embodiment 50, wherein 
the MRI or SPECT contrast agent comprises Gd, Tc99m, 
or an 'In chelate. 
Embodiment 52: The method of embodiment 45, wherein 
the contrast agent is a PET imaging agent. 
Embodiment 53: The method of embodiment 52, wherein 
the PET imaging agent comprises 18-F, 11-C, 18-O, or 
Gallium 64. 
Embodiment 54: A method of treating melanoma tumor cells 
in a subject, comprising: 
administering the MC1R peptide ligand-micelle complex 
of embodiment 31 or 32, to the subject, wherein an 
anti-cancer agent is present within the inner core of the 
micelle, and wherein the MC1R peptide ligand-micelle 
complex releases the anti-cancer agent at the site of the 
tumor. 
Embodiment 55: A method of treating melanoma tumor cells 
in a subject, comprising: 
providing a MC1R peptide ligand-micelle complex of 
embodiment 31 or 32; 
incorporating an anti-cancer agent into the inner core of 
said MC1R peptide ligand-micelle complex; 
administering the MC1R peptide ligand-micelle complex 
with the anti-cancer agent to the Subject, wherein the 
MC1R peptide ligand-micelle complex releases the 
anti-cancer agent at the site of the tumor. 
Embodiment 56: The method of embodiment 55, wherein 
the anti-cancer agent is a radiotherapy agent. 
Embodiment 57: The method of embodiment 56, wherein 
the radiotherapy agent comprises Yttrium. 
Embodiment 58: The method of embodiment 55, wherein 
the anti-cancer agent comprises an alkylating chemo 
therapy agent. 
Embodiment 59: The method of embodiment 58, wherein 
the alkylating chemotherapy agent comprises melphalan 
or ifosfamide. 
Embodiment 60: The method of embodiment 55, wherein 
the anti-cancer agent is a systemic melanoma chemo 
therapy agent. 
Embodiment 61: The method of embodiment 60, wherein 
the systemic melanoma chemotherapy agent comprises 
dacarbazine, paclitaxel, and/or Vincristine. 
Embodiment 62: A method of preparing a MC1R peptide 
ligand-micelle complex, comprising: 
providing a MC1R peptide ligand comprising a first 
functionality covalently attached to a MC1R targeting 
peptide; 
providing a multiplicity of triblock polymer chains com 
prising a hydrophobic polypeptide block attached to a 
central crosslinkable peptide block comprising a mul 
tiplicity of crosslinkable amino acid residues attached 
to a water soluble polymer block, wherein a portion of 
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the triblock polymer chains further comprise a second 
functionality covalently attached to the water soluble 
polymer block distal to the central crosslinkable pep 
tide block, wherein the second functionality is comple 
mentary to the first functionality and wherein the 
triblock polymer chains self-assemble into a micelle; 
and 
combining the triblock polymer chains with the MC1R 
peptide ligand, wherein the first functionality and the 
complementary second click functionality react to form 
a reaction product that covalently joins the triblock 
polymer to the MC1R peptide ligand to form a MC1R 
peptide ligand-micelle complex. 
Embodiment 63: The method of embodiment 62, wherein 
the MC1R peptide ligand is 4-phenylbutyryl-His-DPhe 
Arg-Trp-Gly-Lys(hex-5-ynoyl)-NH. (SEQ ID NO:3); 
H-Lys(hex-5-ynoyl)-Tyr-Val-Nle-Gly-His-DNal(2)-Arg 
DTrp-Asp-Arg-Phe-Gly-NH. (SEQ ID NO:4); or H-Lys 
(hex-5-ynoyl)Tyr-Val-Nle-Gly-His-DNal(2)-Arg-DPhe 
Asp-Arg-Phe-Gly-NH. (SEQ ID NO:5). 
Embodiment 64: The method of embodiment 62 or 63, 
further comprising crosslinking the multiplicity of cross 
linkable amino acid residues. 
Embodiment 65: The method of embodiment 62 or 63, 
further comprising the incorporation of an agent. 
Embodiment 66: The method of embodiment 65, wherein 
the agent comprises a contrast agent, anti-cancer agent, or 
both. 
Embodiment 67: A pharmaceutical composition comprising 
the MC1R peptide ligand-micelle complex of embodi 
ment 31 or 32; and a pharmaceutically acceptable carrier. 
Embodiment 68: The MC1R peptide ligand, method, com 
position, or MC1R peptide ligand-micelle complex of any 
one of embodiments 1-67, wherein the agent is a biologi 
cally active agent or contrast agent. 
Embodiment 69: The MC1R peptide ligand, method, com 
position, or MC1R peptide ligand-micelle complex of 
embodiment 68, wherein the biologically active agent is 
a drug or biologic. 
Embodiment 70: The MC1R peptide ligand, method, com 
position, or MC1R peptide ligand-micelle complex of 
embodiment 68, wherein the biologically active agent is 
an anti-cancer agent. 
Embodiment 71: The MC1R peptide ligand, method, com 
position, or MC1R peptide ligand-micelle complex of 
embodiment 70, wherein the anti-cancer agent is an 
immunotherapeutic agent, a chemotherapeutic agent 
listed in Table 14, or another chemotherapeutic agent. 
It should be understood that the examples and embodi 
ments described herein are for illustrative purposes only and 
that various modifications or changes in light thereof will be 
Suggested to persons skilled in the art and are to be included 
within the spirit and purview of this application and the 
Scope of the appended claims. In addition, any elements or 
limitations of any invention or embodiment thereof dis 
closed herein can be combined with any and/or all other 
elements or limitations (individually or in any combination) 
or any other invention or embodiment thereof disclosed 
herein, and all Such combinations are contemplated with the 
scope of the invention without limitation thereto. 
All patents, patent applications, provisional applications, 
and publications referred to or cited herein, Supra or infra, 
are incorporated by reference in their entirety, including all 
figures and tables, to the extent they are not inconsistent with 
the explicit teachings of this specification. 
Following are examples which illustrate procedures for 













construed as limiting. All percentages are by weight and all 
Solvent mixture proportions are by Volume unless otherwise 
noted. 
Materials and Methods for Example 1 
Abbreviations used for amino acids and designation of 
peptides follow the rules of the IUPAC-IUB Commission of 
Biochemical Nomenclature in J. Biol. Chem. 1972, 247:977 
983. The following additional abbreviations are used: Aloe, 
allyloxycarbonyl; Boc, tert-butyloxycarbonyl; Bu, tert-bu 
tyl; DMSO, dimethylsulfoxide: DVB, divinylbenzene: 
Fmoc, (9H-fluoren-9-ylmethoxy)carbonyl: HBTU, 2-(1H 
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluoro 
phosphate: HOBt, N-hydroxybenzotriazole: HOCt, 
6-chloro-1H-hydroxybenzotriazole; NMI, N-methylimida 
Zole; Pbf 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sul 
fonyl: PS, polystyrene; RP-HPLC, reverse-phase high per 
formance liquid chromatography: TFA, trifluoroacetic acid; 
and Trt, triphenylmethyl (trity1). 
Materials. N-C-Fmoc-protected amino acids, HBTU, 
HCTU, HOCt and HOBt were purchased from Anaspec (San 
Jose, Calif.) or from Novabiochem (San Diego, Calif.). Rink 
amide Tentagel S and R resins were acquired from Rapp 
Polymere (Tubingen, Germany). Rink amide 1%-DVB PS 
resin was acquired from Novabiochem (San Diego, Calif.). 
For the N-C-Fmoc-protected amino acids, the following side 
chain protecting groups were used: Arg(N-Pbf); Asp(O- 
tBu); His(N"-Trt); Trp(N-Boc); Tyr(Bu), and Lys(N- 
Aloc). IRDye 800CW maleimide was acquired from Li-Cor 
(Lincoln, Nebr.). Reagent grade solvents, reagents, and 
acetonitrile (ACN) for HPLC were acquired from VWR 
(West Chester, Pa.) or Aldrich-Sigma (Milwaukee, Wis.), 
and were used without further purification unless otherwise 
noted. N-terminal heterocyclic acids, NMI, and scavengers 
were obtained from Sigma-Aldrich or TCI. The solid-phase 
synthesis was performed in fritted Syringes using a Domino 
manual synthesizer obtained from Torvid (Niles, Mich.). 
The C-18 Sep-PakTM Vac RC cartridges for solid phase 
extraction were purchased from Waters (Milford, Mass.). 
Ligand Synthesis. Ligands 1-8 were prepared as previ 
ously published by Solid-phase synthesis as Summarized in 
Scheme 1 on Rink Amide Tentagel resin (0.23 mmol/g) 
using a Fnoc/Bu synthetic strategy and standard activa 
tions.30, 31. After final deprotection of the Fmoc group, the 
resin was coupled with HOBt ester of 4-phenylbutyric acid 
(compounds 1, 4), acetylated with acetic anhydride/pyridine 
(compound 2) or left unreacted as a free amino group 
(compounds 5-8). The 4-hydroxycinnamoyl-His-DPhe-Arg 
Trp-NH (SEQ ID NO:8) NH-resin was treated with 50% 
piperidine in DMF to remove 4-hydroxycinnamoyl oligom 
ers. The ligands were cleaved off the resins with TFA 
scavenger cocktail (91% TFA, 3% water, 3% thioanisole, 
3% ethanedithiol), extracted with cold diethylether, then 
dissolved in 1.0 m aqueous acetic acid. The crude ligands 
were purified by SEC and HPLC. The pure compounds were 
dissolved in DI water or DMSO at approximately 1.0 mM 
concentrations and concentration was determined by Trp 
HPLC measurement32, 33. 
Ligand Purification and Characterization. Peptides were 
purified using solid-phase extraction. Briefly, C-18 Sep 
PakTM cartridges (100 mg or 500 mg) were used and 
pre-conditioned initially with acetonitrile, methanol, and 
water. After loading the compound, the column was washed 
with DI water, and then gradually with 5, 10, 20, 30, 50 and 
70% of aqueous ACN. Fractions containing product were 
collected, concentrated to remove organic solvent and 
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lyophilized. Product purity was verified by analytical RP 
HPLC using a Waters Alliance 2695 Separation Model with 
a Waters 2487 dual wavelength detector (220 and 280 nm) 
on a reverse phase column (Waters XBridge C18, 3.0x75 
mm, 3.5 mm). Peptides were eluted with a linear gradient of 
aqueous ACN/0.1% TFA at a flow rate of 0.3 mL/min. 
Purification of ligands was achieved on a Waters 600 HPLC 
using a reverse phase column (Waters XBridge C18, 19.0x 
250 mm, 10 mm). Peptides were eluted with a linear gradient 
of ACN/O.1% TFA at a flow rate of 5.0-10.0 mL/min. 
Separation was monitored at 230 and 280 nm. Size exclusion 
chromatography was performed on a borosilicate glass col 
umn (2.6x250 mm, Sigma, St. Louis, Mo.) filled with 
medium sized Sephadex G-25 or G-10. The compounds 
were eluted with an isocratic flow of 1.0 M aqueous acetic 
acid. Mass spectra and HPLC characterization is given in 
Table 2, below. 
QC and Purification: The purity of products was checked 
by analytical PR-HPLC using a Waters Alliance 2695 Sepa 
ration Model with a Waters 2487 dual wavelength detector 
(220 and 280 nm) on a reverse phase column (Waters 
XBridge C18, 3.0x75 mm, 3.5 um). Peptides were eluted 
with a linear gradient of aqueous ACN/0.1% TFA at a flow 
rate of 0.3 mL/min. Purification of ligands was achieved on 
a Waters 600 HPLC using a reverse phase column (Waters 
XBridge C18, 19.0x250 mm, 10um). Peptides were eluted 
with a linear gradient of ACN/0.1% TFA at a flow rate of 
5.0-10.0 mL/min. Separation was monitored at 230 and 280 
nm. Size exclusion chromatography was performed on a 
borosilicate glass column (2.6x250 mm, Sigma, St. Louis, 
Mo.) filled with medium sized Sephadex G-25 or G-10. The 
compounds were eluted with an isocratic flow of 1.0 M 
aqueous acetic acid. 
Solid-Phase Extraction (SPE): C-18 Sep-PakTM cartridges 
(100 mg or 500 mg) were used and pre-conditioned initially 
with 5 column volumes (5 times the volume of packed 
column bed) each of acetonitrile, methanol, and water. After 
loading the compound, the column was washed with DI 
water, and then gradually with 5, 10, 20, 30, 50, and 70% of 
aqueous ACN. Fraction containing product were collected, 
concentrated to remove organic solvent, and lyophilized. 
Quantitative HPLC: The peptide concentrations were 
determined by monitoring absorbance of peptides against 
0.5 mM solution of Tryptophan in DMSO at 280 nm. The 
peptides were initially dissolved in DMSO at approximately 
1-5 mM concentration. Co-injections of peptide and Trp 
were made on analytical HPLC with a number of different 
Volumes and peptide concentration calculated from area 
under the peaks using the formula given here: 
Peptide C Abs. of Comp. X 
eptide one. = As of 
0.5 Vol. of Trp 
X&280 (Trp-Tyr-- CyS + Cy5 + ...) X Vol. of Comp. 
&280 (Trp) 
es of compounds were determined by Summation of tryp 
tophans (es 5500), tyrosine (eso-1490), thiol (eso-63), 
and Cy5 dye (es 5800), and normalized to extinction 
coefficient of one tryptophan. Other amino acids in these 
peptides do not absorb significantly at this wavelength. For 
Cy5 dye, eso was determined in a similar manner by 














Cy5-malenimide ester in DMSO at 280 nm wavelength. 
Mass spectra and HPLC characterization data are provided 
in Table 2, below. 
Mass Spectrometry: Mass spectra of positive ions were 
recorded either with a single stage reflectron MALDI-TOF 
mass spectrometer (Bruker Rexlex III, Bruker Daltonics, 
Billerica, Mass., C-cyanocinnamic acid as a matrix) in 
reflectron mode or with a low resolution ESI mass spec 
trometer (Finnigan, Thermoguest LCQ ion trap instrument, 
Lake Forrest, Calif.) and/or using high resolution Fourier 
transform mass spectrometer (FT-ICRMS, Bruker Apex Qh, 
Bremen, Germany) equipped with an ESI source. For inter 
nal calibration, an appropriate mixture of standard peptides 
was used with an average resolution of ca. 10,000 on the 
Reflex III and 60,000 on the FT-ICR instrument. 
TABLE 2 
High resolution mass Spectral data and HPLC 
Compound R. (k') Calc. (MH) Exp. MH' 
1 4.14 790.4147 790.5 
2 3.89 746.4362 746.5 
3 2.54 790.3.783 790.4 
4 4.32 1069.5730 1069.5726 
5 3.61 16O18124 16O1.8 
6 3.90 1823.9493 1824.0 
7 3.41 1562.801S 1562.5 
8 3.79 1784.9384 1784.3 
Peptide was eluted with a linear ACN 0.1% CFCO2Haqueous gradient (10% to 90% in 
30 min) at a flow rate of 0.3 mL/min); Waters XBridge C-18 column (3.0 x 150 mm, 3.5 
um); HPLC k = (peptide retention time - solvent retention time), solvent retention time. 
All the obtained purified peptides showed s-95% purity, 
(b) The major molecular peak corresponds to M+3Na', formula C10H127O4S5N18Na3. 
Cell Culture. HCT116 cells overexpressing hMC1R and 
HEK293 cells overexpressing hMC4R23 or hMC5R were 
used in all studies. The parental human colorectal carcinoma 
cell line, HCT116 (American Type Culture Collection, CCL 
247) was also used. Cells were maintained under standard 
conditions (37° C. and 5% CO) and were grown in Dul 
becco's modified Eagle medium (DMEM) supplemented 
with 10% FBS and 5% penicillin/streptomycin. For 
HCT116/hMC1R cells, geneticin (G418S, 0.4 mg/mL) was 
added to the media to ensure proper selection. 
Europium Binding Assays. Competitive binding assays 
were performed using HCT116/hMC1R cells and HEK293/ 
hMC4R or hMC5R as previously described, with slight 
modifications|23. HCT116/hMC1R cells were plated in 
black PerkinElmer 96-well plates and HEK293/hMC4R and 
HEK293/hMC5R cells were plated on SigmaScreen Poly 
D-Lysine Coated Plates (Sigma Aldrich), all at a density of 
10,000-30,000 cells/well. Poly-D-Lysine Coated Plates con 
tain a PDL polymer coating that creates a uniform positive 
charge at the Surface of the plastic, thereby facilitating cell 
attachment, growth and differentiation. Cells were grown in 
the 96-well plates for 2-3 days. On the day of the experi 
ment, the media was aspirated and 50 uL of non-labeled 
competing ligand was added to each well in a series of 
decreasing concentrations (ranging from ~1 M to 0.1 nM), 
followed by 50 uL of Eu-NDP-O-MSH at 10 nM. Both 
labeled and non-labeled ligands were diluted in binding 
media (DMEM, 1 mM 1,10-phenanthroline, 200 mg/L baci 
tracin, 0.5 mg/L leupeptin, 0.3% BSA). In the case of the 
triblock polymer micelle solutions, micelles were allowed to 
equilibrate in solution for a period of 30 min prior to cell 
addition. Cells were incubated with labeled and non-labeled 
ligands for 1 hour at 37° C. Following incubation, cells were 
washed three times with wash buffer (50 mM Tris-HCl, 
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0.2% BSA, 30 mM NaCl) and 50 uL of enhancement 
solution (PerkinElmer) was added to each well. Cells were 
incubated for an additional 30 min at 37°C. prior to reading. 
The plates were read on a PerkinElmer VICTORX42030 
36 
than that of 2. Ligands 5-8 demonstrated a high affinity for 
hMC1R as well; however, they were also shown to have an 
even stronger affinity for hMC4R and hMC5R. Ligand 3 
demonstrated no affinity to hMC1R. 
TABLE 3 
Affinity and Selectivity of ligands assayed in this publication. 
Ki (nM) 
Values determined 
Ligand MC1R MC4R, 
1 O.17 16O.OO 
2 1.77 988.20 
3 NBT NB 
4 O.24 NA 
5 1.98 0.75 
6 2.59 1.74 
7 5.64 0.77 
8 4.19 4.40 
4-targeted 25.65 NA 
polymer 
4-targeted 11.47 NA 
micelles 
NDP-a-MSH 18O 18.8O 
Values derived from literature 
27.OO 946.7S 159.76 O.O1 7.30 NA 1216.67 NA 
S8.19 SS8.31 32.88 NA NA NA NA NA 
NB NA NA NA NA NA NA NA 
NA NA NA NA NA NA NA NA 
O.76 O.38 0.38 0.30" 6.00- 3.50- 2O.OO 11.67 
1.48 O.67 O.S7 NA NA NA NA NA 
O.71 O.13 0.13 1.60- 20.00- 3.30- 12.SO 2.06 
3.90 1.OS O.93 NA NA NA NA NA 
NA NA NA NA NA NA NA NA 
NA NA NA NA NA NA NA NA 
9.90 10.44 S.SO 0.40 3.SO NA 8.75 NA 
All values represent Ki values except where denoted. 
NB = Non-binding: 
"NA = Not available; 
'Value denotes an EC50 (nM) value. 
multilabel reader using the standard Eu TRF measurement 
(340 nm excitation, 400s delay, and emission collection for 
400 s at 615 nm). Competition curves were analyzed with 
GraphPad Prism Software using the sigmoidal dose-response 
(variable slope) classical equation for nonlinear regression 
analysis. 
Synthesis of Targeted Triblock Polymers. Triblock poly 
mer with a terminal azide incorporated into the polyethylene 
glycol (PEG) block were obtained from Intezyne Technolo 
gies, LLC (Tampa, Fla.). The triblock polymer comprised a 
shell hydrophilic block of PEG, a outer core block of 
comprising Asp, and a core block comprising a hydrophobic 
block of Leu and Tyr. To a solution of 1:1 DMSO:H2O (10 
mL) was added 4 (16 mmol. 1.2 equiv), triblock polymer 
(13.3 mmol. 1 equiv), sodium ascorbate (334.15 mmol, 25 
equiv), (BimCA) catalyst34 (13.42 mmol. 1 equiv). The 
solution was heated to 50° C. and stirred for 2 days. The 
mixture was then cooled and placed in a 3500 MW dialysis 
bag and dialyzed against EDTA/H2O (x3) and H2O (x3). 
Following purification by dialysis, the solution was 
lyophilized. Successful click coupling was verified through 
visualization of the triazole-H in 1H NMR (8.02 ppm). 
Micelle Formulation. Triblock polymers were dissolved at 
20 mg/mL in 30% tert-butanol/water at room temperature, 
stirred for 4 hours and then lyophilized. For the targeted 
micelle system, 10% targeted polymer and 90% untargeted 
polymer were used in the formulation mixture. Micelle size 
was determined by dynamic light scattering (DLS) and 
Surface charge was determined by Zeta measurement. 
Competitive Binding Assays. Competitive binding assays 
were performed using HCT116/hMC1R, HEK293/hMC4R 
and HEK293/hMC5R cells with ligands 1-8. 1, 2 and 4 were 
found to both strongly and selectively bind to the hMC1R 
receptor (FIG. 3, Table 2), with 1 and 4 showing slightly 
higher affinities for hMC1R as compared to 2 (K; is 0.17 
nM, 0.24 nM and 1.77 nM for 1, 4 and 2, respectively, 









Competitive binding assays were also performed using 
4-targeted triblock polymers, triblock polymer micelles, as 
well as untargeted micelles as a control (FIG. 4A-C). The 
4-targeted micelle exhibits an increased binding avidity to 
the hMC1R receptor compared to the free polymer (K, is 
11.47 nM versus 25.65 nM for the micelle and polymer 
respectively), and a slightly weaker avidity than the native 
ligand (K, is 11.47 nM versus 1.17 nM for the micelle and 
ligand respectively). Not Surprisingly, no binding is 
observed with the untargeted micelles, indicating that the 
triblock polymer does not interact non-specifically with the 
cell surface. DLS and Zeta potential measurements showed 
the size and Surface charge of the 4-targeted micelles to be 
91 nm and 0.93 mV, respectively. 
EXAMPLE 1. 
Preparation of MC1R-Targeted Tri-Block Polymer 
Micelle 
Historically, ligands which are known to interact with the 
hMC1R receptor also demonstrate cross-reactivity with 
other melanocortin receptors, namely hMC4R and hMC5R. 
While MC1R is known to be expressed almost exclusively 
in melanoma cells and melanocytes, hMC4R and hMC5R 
have high expression levels in normal tissues including 
kidney and brain, thus non-specific ligand binding is not 
ideal. To combat this problem and minimize off-target 
effects, several ligands from the literature were examined 
that have been reported to possess nanomolar binding affini 
ties for hMC1R (Table 3). Ligand 1 was reported to have a 
high affinity and selectivity for MC1R (1R/4R selectivity 
ratio of 1200)20, 28 and was consequently chosen as a 
template for the design of the novel ligands 2, 3 and 4. 
Additionally, ligands 5 and 7 were reported to have mod 
erate hMC1R selectivities over hMC4R and hMC5R22: 
thus, each was functionalized with a terminal alkyne for 
attachment to a nanoparticle scaffold. 
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Literature reported dissociation constants for all ligands 
tested are listed in Table 3 for comparison. The most specific 
of these ligands, 1, was determined to have an hMC1R/ 
hMC4R selectivity of 950, which is in good agreement with 
the literature reported selectivity of 1200. Likewise, ligand 
2, based on the same parent amino acid sequence as 1, was 
found to have high 1 R/4R selectivity; however, its 1R/5R 
selectivity was substantially lower. Unfortunately, ligands 3 
and 5-8 were found to be not at all selective for MC1R, with 
ligand 3 showing no affinity for any of the receptors tested. 
Results for ligands 5 and 7 deviate from that which has been 
previously reported; this discrepancy may be due to differ 
ences in the binding assays used to derive the affinity 
constants. The K values are based on europium time 
resolved fluorescence assays; however, previously deter 
mined EC50 values for these ligands were derived via 
'I-labeled competitive binding assays. 
As 1 was determined to be the ligand with the highest 
hMC1R affinity and selectivity, it was chosen for modifica 
tion with a terminal alkyne for attachment of a triblock 
polymer micelle. Compound 4 did not demonstrate a loss of 
affinity of MC1R following alkyne functionalization. This is 
in good agreement with the literature data for MC1R specific 
ligands, which argues that functionalization at the N-termi 
nus of the peptide does not negatively impact binding due to 
the location of this region in a large hydrophobic cavity or 
open extracellular part of the receptor, rather than in a 
confined pocket 20, 28, 29. 
As predicted, 1 and 2 have similar binding profiles given 
the similarity in their structures; however, it was Surprising 
to see a complete loss of affinity in 3. The differences in 
affinity among these three ligands arise from the structural 
differences at the N-terminal end of the peptide, given that 
they all share the same R-HfRW-NH2 parent scaffold. How 
ever, whereas 1 and 2 contain Ph-(CH) CO- and Ac-Hpe 
groups, both of which are non-polar, at the N-terminus, 3 
contains a 4-hydroxyPh-CH=CH-CO—, which is more 
polar due the incorporation of the hydroxyl. Conversely, 
several analogues of 3 possess low nanomolar affinities 
against MC1R with varying selectivities (Table 3). Thus, it 
seems reasonable to conclude that the loss in affinity expe 
rienced by 3 results from the incorporation of the alkene, 
rather than the increased polarity from the addition of the 
hydroxyl group. While the exact reasons behind the affinity 
of 3, or lack thereof, remain unclear, it is plausible that 
incorporation of the alkene in this ligand causes the peptide 
to adopt too rigid a structure, thereby reducing its ability to 
conform to the receptor binding pocket. 
Ligands 5-8 are about twice as large and display binding 
affinities one-to-two orders of magnitude higher with 
hMC1R as compared to ligands 1-4. Ligands 6 and 8 were 
synthesized as analogues of ligands 5 and 7, respectively, to 
be used for potential attachment to nanoparticles. The simi 
larity in binding affinities of 5 versus 6 and 7 versus 8 further 
demonstrates that the H-terminal end of these peptides is a 
Suitable location for the placement of an attachment of a 
scaffold, as it does not seem to impact the binding ability of 
the ligand. 
A targeted triblock polymer micelle was prepared by 
combining 10%. 4-targeted polymer with 90% untargeted 
polymer. As a control, competitive binding assays were 
performed with targeted free polymer and untargeted 
micelles. As previously stated, the 4-targeted micelle exhib 
its an increased binding avidity to the hMC1R receptor as 
compared to the free polymer and a slightly weaker avidity 
than the native ligand. The increase in binding avidity for the 













is noteworthy in that it (1) demonstrates the in vitro stability 
of the micelle; and (2) it indicates that the binding avidity of 
the 4-targeted micelles may be benefiting from multivalent 
interactions. 
While it may be tempting to expect the presence of 
multivalent interactions to have a more profound effect on 
the binding affinity of the micelle system, it is important to 
remember that multivalency is a complex thermodynamic 
issue that is influenced by a number of variables, including 
the enthalpies for each ligand upon individual binding 
events and the entropic consequences experienced by the 
micelle polymer upon binding. Additionally, ligand proxim 
ity and steric repulsions between ligands and polymer chains 
have been shown to be important factors that influence the 
degree, if any, to which multivalency is experienced in 
micellar systems35. It is also important to note that 
improved avidity observed through multivalent interactions 
are most typically seen while using ligands with relatively 
low affinity. In the case of 4, it is unlikely that multivalent 
interactions would greatly enhance binding avidity given the 
high affinity of the targeting ligand for binding the MC1R 
receptor 35, 36. Finally, the experimental set-up also is a 
factor. For example, each polymer is composed of roughly 
100 polymer chains, meaning that at 10% targeting, roughly 
10 targeting groups are present per micelle. While this may 
initially seem like a high number, it is essential to consider 
the accessibility of these ligands to cell Surface, as the 
experimental set-up of the time-resolved fluorescence bind 
ing assay does not necessarily lend itself conducive to 
multivalent interactions in three dimensions. As a conse 
quence of the assay design, cells are adhered to plates in a 
monolayer and are only exposed to the targeted particles on 
one surface. This limited exposure, combined with the 
inflexible nature of the micelle, arguably can explain the 
slight decrease in binding affinity experienced in these 
Supramolecular systems. 
What is Surprising and counter-intuitive is the slight 
decrease in binding affinity experienced between the tar 
geted polymer, targeted micelles and the native ligand. 
However, this decrease in affinity may be the result of the 
conjugation of a large, flexible PEG group to a rather Small 
ligand. In addition to adding to the entropy of the ligand 
system through increased flexibility and size, PEG chains 
are known to have at least moderate interaction with non 
polar hydrophobic groups37. Consequently, it is possible 
that the PEG moiety on the end of the triblock polymer is 
weakly interacting with the hydrophobic amino acids of the 
targeting group, thereby decreasing its affinity for MC1R. 
An hMC1R ligand was identified in literature and modi 
fied by the inventors for attachment to a triblock polymer 
micelle. Functionalization and Subsequent attachment of the 
ligand to a 100 nm polymer micelle resulted in a slight 
decrease in affinity to MC1R. Presumably, this decrease 
results from the thermodynamic hurdles encountered in 
appending a small peptide to a large nanoparticle, as well as 
an inherent handicap in the assay design. As mentioned in 
the introduction, three hurdles must be overcome in the 
design of an effective targeted nanoparticle delivery system: 
(1) it must be insured that there is no loss of ligand affinity 
resulting from the attachment of a small peptide to a large 
nanoparticles, or any Such loss in affinity must be compen 
sated by multivalent binding interactions; (2) nanoparticles 
must be inherently stable; and (3) nanoparticles must be 
Sufficiently small to escape the vasculature and enter the 
tumor. The inventors believe that the invention addresses the 
first two of these concerns. The ligand remains selective 
after attachment and the increased binding affinity observed 
US 9,441,013 B2 
39 
between the free 4-targeted polymer and 4-targeted micelle 
have demonstrated the in vitro stability of the system. 
Additionally, based on DLS data, the inventors are confident 
that the micelles are of sufficient size to escape the vascu 
lature and in vivo studies to evaluate the selectivity and 
stability of this targeted micellar system in mice are cur 
rently underway. 
MC1R-ligand 1 is known to have stronger affinity and 
higher selectivity to hMC1R than NDP-O-MSH. MC1R 
ligand 4 conjugated with the triblock polymer to form a 
stable micelle upon crosslinking or to form uncrosslinked 
micelles of 70-100 nm loaded with Gd-Texaphyrin, a 
T1-weighted MR radiation enhancer shown below, at 0.05 to 
10% weight. FIGS. 5A and B are plots of competitive 
binding of the MC1R-ligand 4 conjugated with the triblock 
polymer, referred to in the Figure as ML21-1, which shows 
that nanomolar binding affinity the micelle retained nano 
molar binding affinity and a significantly higher affinity is 
observed for the crosslinked micelle over uncrosslinked 
micelles. In vitro studies displayed measurable contrast for 
Gd-TX at low concentrations as indicated in FIG. 6. As can 
be seen in FIG. 7, micelles in row 3 show higher T1 values 
than those in row 4, even though both contain 0.01 mg/mL 
Gd-Tx. This indicates that micelles with higher percentages 
of encapsulated Gd-Tx within a single micelle, as tabulated 
in FIG. 8, are experiencing a T2 weighting as a result of the 
tightly packed gadolinium. Micelles with Gd-TX encapsu 
lated at 5%, 0.5% and 0.05% were prepared at 0.1 mg/mL 
Gd-Tx and measurements were made where T1 values 
indicate that micelles with lower Gd-Tx encapsulated pro 
duce lower T1 values as indicated in Table 4, below. 
TABLE 4 








micelle Gd-Tx T1 
(% Gd-Tx w/w) (mg/mL) (mg/mL) (s) 
5 O.2 O.O1 240 
O.S 2 O.O1 2.35 















In vivo studies were carried out where mice were injected 
with micelles at 12 mg/mL Gd-TX concentration. 
T1-weighted images were obtained pre-injection and at 4 
hours, 12 hours, 24 hours and 48 hours after injection, for 
Gd-Tx containing micelles that contained the MC1R-ligand 
for targeting (T) or lacked the ligand (UT) and were either 
crosslinked (XL) of not (UXL), as shown in FIG. 9. No 
contrast was visible at 4 hours and the contrast begins to 
clear at 48 hours. Only mice injected with MC1R-ligand 
comprising crosslinked micelles (T, XL) exhibited appre 
ciable contrast, indicating that only these MC1R-ligand 
comprising crosslinked micelles were sufficiently stable to 
enter and persist in the tumor. FIG. 10 shows the enhance 
ment of the tumor image by the presence of the MC1R 
ligand comprising crosslinked micelles. Further in vivo MRI 
results are shown in FIGS. 18-22. 
The MT-XL micelles are successful at specifically deliv 
ering a theragnostic agent to the site of the tumor. Previous 
systems have fallen short of this goal in that they have 
encountered wide-spread toxicity, especially in the liver, 
kidneys and spleen. The inventors have Successfully dem 
onstrated that MT-XL micelles: (1) are specific for their 
target; (2) are able to deeply permeate the tumor; and (3) 
show a long tumor half-life, making them ideal for therapy. 
While this example focuses mainly on tumor imaging, 
similar constructs can be used to specifically deliver high 
doses of chemotherapeutic agents, such as taxanes, or other 
agents, to MC1R-expressing tumors or other MC1R-ex 
pressing cells or tissues, with low systemic toxicity. 
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Materials and Methods for Example 2 
Cell Culture. A375 human malignant melanoma cells 
were grown in Dulbecco's Modified Eagle's Medium 
(DMEM) containing 10% fetal bovine serum (Life Tech 
nologies, Gaithersburg, Md.), 100 units/mL penicillin and 
100 lug/mL streptomycin in 5% CO at 37°C. The cell line 
was obtained from American Type Culture Collection 
(ATCC), expanded for two passages, and cryopreserved. All 
experiments were performed with cells of passage number 
less than 25. Cells were authenticated a negative for myco 
plasma by testing at the ATCC and were monitored by 
microscopy and confirmed to maintain morphological traits 
over Subsequent passages. 
DNA Microarray analysis of melanoma cell lines. RNA 
extracts of melanoma cell lines were analyzed using the 
Affymetrix U133A array platform (33). Cell lines repre 
sented on the array are: 5 melanocyte lines—FOM101.1, 
FOM103.1, FOM104.1, FOM113.1, FOM99.1; 10 primary 
tumor lines SbC12, WM1366, WM1361A, WM793, 
WM1819, WM278, WM3248, WM35, WM75, WM983A; 
11 metastatic lines WM1321, WM1346, WM1361B, 
WM858, WM1617, WM164, WM1727A, WM239A, 
WM46, WM51, 1205Lu; and 2 lines of unknown stage 
origin/phenotype WM3451 and WM1799. Data generated 
from these arrays have been published previously (33, 34) 
and have been deposited in the NCBIs Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). Data 
are accessible using GEO Series accession GSE4845. 
DNA Microarray Analysis of patient samples. Affymetrix 
expression data for MC1R in patient tissue samples were 
compiled from publicly available datasets. The CEL files for 
four of the normal skin Samples and the skin tumor samples 
were downloaded from the GEO database (http://ww 
w.ncbi.nlm.nih.gov/projects/geo/index.cgi), data series 
GSE7553. Normal tissue data, including additional normal 
skin samples were from the GEO data series GSE7307, 
Human Body Index. The CEL files were processed using the 
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MAS 5.0 algorithm (Affymetrix, Santa Clara, Calif.) and 
screened through a rigorous quality control panel to remove 
samples with a low percentage of probesets called present by 
the MAS 5 algorithm, indicating problems with the ampli 
fication process or poor sample quality; high Scaling factors, 
indicating poor transcript abundance during hybridization; 
and poor 3/5' ratios, indicating RNA degradation either prior 
to or during processing. The remaining samples were nor 
malized to the trimmed average of 500 in the MAS 5 
algorithm before comparison of the expression values across 
tumors and normal samples. 
Immunohistochemistry (IHC) of Melanoma Tissue 
Microarray (TMA). ATMA was constructed at the Moffitt 
Tissue Core containing human tissue samples of formalin 
fixed and paraffin-embedded (FFPE) specimens. The TMA 
contains the following samples 11 normal skin tissue, 11 
normal skin from melanoma, 10 compound nevi, 10 junc 
tional nevi, 10 intradermal nevi. 40 Clark's atypical dys 
plastic nevi, 15 primary cutaneous melanoma in situ, 15 
primary cutaneous melanoma (0.1-0.75 mm), 15 primary 
cutaneous melanoma (0.75-1 mm), 15 primary cutaneous 
melanoma (1-2 mm), 15 primary cutaneous melanoma (2-4 
mm), 15 primary cutaneous melanoma (>4 mm), 10 mela 
noma distant metastasis-M1, 10 melanoma distant metasta 
sis-M2, 10 melanoma distant metastasis-M3, 40 melanoma 
in regional lymph nodes, 15 primary mucosal melanoma. 
The TMA consists of cylindrical punches of the FFPE blocks 
using a Manual Tissue Arrayer (Beecher Instruments, Sun 
Prairie, Wis.). The same method was previously reported for 
construction of a Ewing sarcoma TMA at the Moffitt Tissue 
Core Facility (35), except the melanoma TMA has only one 
sample per case (duplicate samples in Ewing) due to the 
large number of cases. No identifiable human subject infor 
mation was associated with the melanoma TMA. 
Rabbit MC1R polyclonal antibody, 1:200 dilution, 
(GTX70735, GeneTex) was used for staining with diamin 
obenzidine (DAB). The slides were scanned in the Moffitt 
Analytical Microscopy Core Facility (AMC) using an Ape 
rio ScanScope XT digital slide scanner (Aperio, Calif.). The 
digital image of each sample was evaluated by the study 
pathologist (TWM). Scoring ranged from 0 to 9 and was 
derived from the product of staining intensity (0-3+) x the 
percentage of positive tumor (on a scale of 0-3). Scores 24 
are considered moderate to strong positive. 
Generation of stably transfected A375 cells bearing the 
MC1R gene. pCMV6 containing homo sapiens MC1R and 
neomycin as a selection marker was purchased (Origene, 
Rockville, Md.). To identify the optimal concentration for 
selection, a range (100-1000 ug/ml) of G418 (Invitrogen) 
was tested on cells. A375 cells were transfected with 5ug of 
the vector. In response to G418, massive cell death was 
observed after ~5 days. After 2 weeks, resistant colonies 
appeared. Large colonies were selected and transferred to 
individual plates. The clone with the highest expression of 
MC1R was determined using qRT-PCR as previously 
described (36). MC1R specific primer sets were designed 
using Gene Runner Software for Windows version 3.05: 
forward, 5'-AATGTCATTGACGTGATCACCTG-3 (SEQ 
ID NO:12) and reverse, 5'-GCAGTGCGTAGAAGATGGA 
GAT-3' (SEQID NO:13). B-actin was used for normalization 
(36). A clone with the highest expression was selected and 
maintained in medium containing 300 ug/ml of G418. 
Characterization of hMC1R expression on A375 cells by 
Immunocytochemistry (ICC). To verify the cell surface 
expression of hMC1R, two sets of A375 (parental) and 
A375/hMC1R cells were plated at a cell density of 1x10' 














wells and incubated for 16 hours. Cells were then treated 
with 30 g/ml MC1R antibody (Almone Labs) and 5.0 
ug/mL of WGA (Invitrogen) at 4°C. for 10 minutes, washed 
3 times with PBS, fixed with cold methanol:acetone (1:1) 
and air dried for 20 minutes. Plates were washed 3 times 
with warm PBS and incubated with 1:2000 secondary anti 
body (Alexa-Fluor 680 goat anti-mouse IgG, Invitrogen). 
After three washes with PBS, coverslips were mounted with 
mounting medium and DAPI (Vector Laboratories, Inc., 
Burlingame, Calif.). Samples were viewed in the Moffitt 
Analytical Microscopy Core Facility using an automated 
Zeiss Observer Z.1 inverted microscope using 40x/1.3NA 
oil immersion objectives through narrow bandpass DAPI 
and FITC/A488 Chroma filter cubes and Nomarski Differ 
ential Interference Contrast polarizing and analyzing prisms. 
Images were produced using the AxioCam MRm CCD 
camera and Axiovision version 4.6 Software Suite (Carl 
Zeiss Inc., Germany). 
Synthesis, Purification and Characterization Materials. 
N'-Fmoc protected amino acids, HBTU, and HOBt were 
purchased from SynPep (Dublin, Calif.) or from Novabio 
chem (San Diego, Calif.). Rink amide Tentagel S resin was 
acquired from Rapp Polymere (Tubingen, Germany). The 
following side chain protecting groups were used for the 
amino acids: Arg(N-Pbf); His(N"-Trt); Trp(N"-Trt); Lys 
(N-Aloc). 
IR800CW maleimide dye was purchase from Licor (Lin 
coln, Nebr.). Cy5 maleimide dye was purchase from Licor 
(Lincoln, Nebr.). Peptide synthesis solvents, dry solvents, 
and solvents for HPLC (reagent grade), and 4-phenylbutyric 
acid, were acquired from VWR (West Chester, Pa.) or 
Sigma-Aldrich (Milwaukee, Wis.), and were used without 
further purification unless otherwise noted. Compounds 
were manually assembled using 5 to 50 mL plastic syringe 
reactors equipped with a frit, and Domino manual synthe 
sizer obtained from Torvid (Niles, Mich.). The C-18 Sep 
PakTM Vac RC cartridges for solid phase extraction were 
purchased from Waters (Milford, Mass.). 
Peptide Synthesis. Ligands were synthesized on Tentagel 
Rink amide resin (initial loading: 0.2 mmol/g) using 
N'-Fmoc protecting groups and a standard DIC/HOBt or 
HBTU/HOBt activation strategy. The resin was swollen in 
THF for an hour, washed with DMF, and Fmoc protecting 
group removed with 20% piperidine in DMF (2 min-20 
min). The resin was washed with DMF, DCM, 0.2 MHOBt 
in DMF, and finally with DMF and the first amino acid 
coupled using pre-activated 0.3 MHOBt ester in DMF (3 eq. 
of N'-Fmoc amino acid, 3 eq. of HOBt and 6 eq. of DIC). 
An on-resin test using Bromophenol Blue was used for 
qualitative and continuous monitoring of reaction progress. 
To avoid deletion sequences and slower coupling rate in 
longer sequences, the double coupling was performed at all 
steps with 3 eq. of amino acid, 3 eq. of HBTU and 6 eq. of 
DIEA in DMF. Any unreacted NH groups on the resin 
thereafter were capped using an excess of 50% acetic 
anhydride in pyridine for 5 min. When the coupling reaction 
was finished, the resin was washed with DMF, and the same 
procedure was repeated for the next amino acid until all 
residues were coupled. 
Aloc Cleavage. The orthogonal protecting Aloe group of 
C-terminal Lys was cleaved as follows. The resin was 
washed with DCM then flushed with argon for 10 min. A 
cleavage mixture of dimethylbarbituric acid (5 equiv.). 
Pd(TPP) (0.2 equiv.) in DCM (0.5 M solution) was flushed 
with argon and injected into the Syringe. The reaction 
mixture was stirred for 30 min then repeated. The resin was 
washed with DMF, 10% DIEA in DMF, DMF, 2% sodium 
US 9,441,013 B2 
45 
diethyldithiocarbamate trihydride, 10% DIEA in DMF, 
DCM and DMF. The Trt-Mpr was attached to the free amine 
via HBTU coupling as described above. 
Cleavage of ligand from the resin. A cleavage cocktail (10 
mL per 1 g of resin) of TFA (91%), water (3%), triisopro 
pylsilane (3%), and 1.2-ethylenedithiol (3%) was injected 
into the resin and stirred for 4 h at room temperature. The 
crude ligand was isolated from the resin by filtration, the 
filtrate was reduced to low volume by evaporation using a 
stream of nitrogen, and the ligand was precipitated in 
ice-cold diethyl ether, washed several times with ether, 
dried, dissolved in water and lyophilized to give off-white 
solid powders that were stored at -20°C. until purified. The 
crude compound was purified by size-exclusion chromatog 
raphy. 
Labeling Procedure. The purified thiol compound (1 
mmol) was dissolved in 1 mL DMF and reacted with 1 
equiv. of IR800CW or Cy5 maleimide under argon atmo 
sphere. The reaction was monitored by HPLC and additional 
aliquotes (0.1 equiv.) of dye were added until the reaction 
complete. The compound was purified by HPLC. 
Purification and analysis. Purity of the peptides was 
ensured using analytical HPLC (Waters Alliance 2695 sepa 
ration model with a dual wavelength detector Waters 2487) 
with a reverse-phase column (Waters Symmetry, 3.075 mm. 
3.5 um; flow rate=0.3 mL/min). (Conditions: HPLC, linear 
gradient from 10 to 90% B over 30 min, where A is 0.1% 
TFA and B is acetonitrile). Size exclusion chromatography 
was performed on a borosilicate glass column (2.6x250 mm, 
Sigma, St. Louis, Mo.) filled with medium sized Sephadex 
G-25 or G-10. The compounds were eluted with an isocratic 
flow of 1.0 M aqueous acetic acid. Solid-Phase Extraction 
(SPE) was employed where simple isolation of final com 
pound was needed from excess salts and buffers for e.g., 
lanthaligand synthesis. For this purpose, C-18 Sep-PakTM 
cartridges (100 mg or 500 mg) were used and pre-condi 
tioned initially with 5 column volumes (5 times the volume 
of packed column bed) each of acetonitrile, methanol, and 
water, in that order. After loading the compound, the column 
was washed several times with water, and then gradually 
with 5, 10, 20, 30, 50, and 70% of aqueous acetonitrile to 
elute the peptide. Structures were characterized by ESI 
(Finnigan, Thermoquest LCQ ion trap instrument), MALDI 
TOF or FT-ICR mass spectrometry. An appropriate mixture 
of standard peptides was used for internal calibrations. 
Binding assays. A375 melanoma cells engineered to 
express MC1R were used to assess ligand binding in a 
competitive binding assay as described before (32). 
The receptor number of A375/MC1R (engineered cells to 
express MC1R), was determined using Saturation binding 
assay following a previously described method (37), except 
that Eu-DTPA labeled NDP-O-MSH was used as a test 
ligand and 5 uM of NDP-C-MSH was used as a blocking 
ligand. These cells were used as a MC1R high expressing 
line, while the parental (A375) cells were used as a low 
expressing line with 400-93 sites/cell (38). 
In vitro MC1R probe uptake study. To study the uptake of 
the MC1R probe in vitro, two sets of A375 (parental) and 
A375/hMC1R cells were plated at a cell density of 1x10' 
cells/well on glass coverslips placed at the bottom of culture 
wells and incubated for 16 hours. Cells were incubated in 
media containing 15 nM probe and uptake evaluated by 
fluorescence microscopy at different time points from 40 
seconds to 15 minutes. To determine specificity, MC1R 
receptors were blocked by a 10 minute pre-incubation with 
2 uM of NDP-C-MSH prior to addition of MC1R probe and 














Samples were viewed using an Axio Observer Z1 inverted 
fluorescence microscope (Carl Zeiss, Inc, Germany) using 
40x/1.3NA oil immersion objectives through a narrow band 
Cy5 filter. Cy5 fluorescence images were prepared with a 
DIC overlay image using Axiovision 4.6 software (Carl 
Zeiss, Inc., Germany). 
In vivo uptake study: Intravital imaging of the dorsal 
skin-fold window chamber tumor xenograft model. All 
procedures were carried out in compliance with the Guide 
for the Care and Use of Laboratory Animal Resources 
(1996), National Research Council, and approved by the 
Institutional Animal Care and Use Committee, University of 
South Florida. A dorsal skin-fold window chamber was used 
to study the pharmacokinetics of imaging agent uptake 
immediately after i.v. injection of the probe. Starting 3 days 
prior to the Surgery, mice were daily administered 1 ml of 
sterile saline subcutaneously at the planned site of the 
window in order to loosen connective tissue and create a 
receiving “pocket'. SCID mice were prepared immediately 
before Surgery; the Surgical site was shaved, and then a 
combination of oxygen and isoflurane was used for anes 
thesia (animals underwent induction with 3.5% isoflurane 
and were maintained at 1.5-2.0%). The window chamber 
method utilizes a titanium steel or plexiglass “saddle' that is 
sutured to the back of the mouse and holds a flap of dorsal 
skin vertically away from the mouse's body. A small “win 
dow' of skin (approximately 5 mm in diameter) was Surgi 
cally excised from the retained skin flap of the anesthetized 
SCID mouse. Tumor constructs were engineered using the 
tumor droplet method. A375/MC1R or A375 parental mela 
noma cells were suspended in 2.5 mg/ml of type I collagen 
(BD Biosciences #354249) and 1xDMEM at a final con 
centration of 2.5x10° cells/ml. Using a 48-well non-tissue 
culture plate, a 15 Jul drop of the tumor cell Suspension was 
polymerized in the center of the well. After brief polymer 
ization (10-15 minutes) at 37° C., a microvessel outer layer 
was added that completely surrounded the droplet. The 
microvessel outer layer consisted of 3 mg/ml of type I 
collagen, 1xDMEM and, 12,000 to 15,000 GFP expressing 
rat microvessel fragments/ml. After 4-6 days of culture at 37 
C, the constructs were then implanted into the “window 
chamber” by placing them directly onto the exposed sub 
cutaneous fascia. A glass cover was then attached to the 
center of the "saddle' to cover the fascia and implanted 
tumor cells. Post-operatively, tumor growth and micro 
circulation can be visualized in this model for approximately 
a month. 
GFP expressing microVessel fragments were prepared 
from the epidydimal fat of transgenic GFP SpragueIDawley 
rats. A rat was anesthetized, and the abdomen sprayed with 
70% ethanol. Skin was clamped just below penis with a 
hemostat and an incision made with large Scissors starting in 
the center and cutting laterally. A small incision was made 
into the scrotum using Small Scissors exposing the epidy 
dimal fat. The epidydimal fat pads were carefully removed 
using forceps and the animal euthanized by extending the 
incision and performing a thoracotomy while remaining 
under deep anesthesia. MicroVessels were then prepared as 
follows: Epididymal fat pads were removed and digested 
with collagenase (2 mg/ml). Following digestion, large 
tissue debris was removed using a 500 um filter and subse 
quent filtration step done with a 30 um filter to collect the 
microVessel fragments. MicroVessel fragments were then 
added to a solution of type I rat tail collagen at a final 
concentration of 3 mg/ml (BD Bioscience, San Jose, Calif.) 
with 1xDMEM, and kept on ice to keep collagen from 
polymerizing. This preparation was added to the cancer cell 
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droplet and placed under the glass cover of a dorsal skin-fold 
window chamber on a SCID mouse following a 3 to 4 day 
in vitro incubation. As the tumor Xenograft is established, rat 
microVessels become patent with the mouse vasculature 
(39). 5 
Seven days after implantation of microVessels and tumor 
cells, mice were intravenously injected with 100 ul of 5% 
10,000 MW Cascade Blue Dextran (Invitrogen, CA) in 
sterile H2O to verify microvessel patency. Then, 5 nmol/kg 
of the MC1R-Cy5 probe was injected into the tail vein. 
Confocal images of probe uptake into the melanoma tumor 
cells were continuously acquired prior to, during and after 
injection of probe using the Olympus FV1000 (MPE) Mul 
tiphoton Laser Scanning Microscope (Lisa Muma Weitz 
Advanced Microscopy and Cell Imaging facility at USF) 
using a 1.25x and 25x lens and acquisition rate of 3570 
Pixels/minute. The Cy5 conjugated ligand was measured by 
exciting the ligand with an IR laser at 635 nm and the 
emitted light was detected using a 655-755 nm filter. 2O 
Tumor Xenograft studies and fluorescence imaging. 
Female nu/nu mice 6-8 weeks old (Harlan Sprague Dawley, 
Inc., Indianapolis, Ind.) were injected Subcutaneously (s.c.) 
with 1x10" MC1R expressing A375 cells in the right and the 
parental one in the left flank. Tumor volume was determined 25 
with calipers using the formula: Volume=(lengthxwidth)/2. 
Once tumors reached 500-800 mm, 1 nmol/kg-30 nmol/kg 
of MC1R imaging probe in 100 uL sterile saline was injected 
into the tail vein. In vivo fluorescence images were acquired 
using the Optix-MX3 (Advance Research Technologies, Inc. 30 
a subsidiary of SoftScan Healthcare Group, Montreal, 
Canada). Animals were positioned on a heating pad and 
anesthetized using isoflurane (flow 2-2.5 l/min). Fluores 
cence images were acquired using a scan resolution of 1.5 
mm and a 790-nm pulsed laser diode with 40 MHz fre- 35 
quency and 12-ns time window. Images were analyzed using 
Optix-MX3 Optiview Software (version 3.01). Autofluores 
cence background was subtracted by determining the mean 
tumor fluorescence signal prior to injection, then mean 
normalized intensity values were obtained within a ROI on 40 
these images. 
Ex vivo studies. Tumors were excised and center slice of 
each tumor was imaged using both Optix-MX3 (as described 
above) and IVIS 200 imaging system (Caliper LifeSciences, 
MA). For IVIS 200 acquisitions, the standard ICG excitation 45 
and emission filter set was used for imaging. After imaging, 
the slices were fixed in formalin and embedded in paraffin 
for histology. Formalin fixed sections (5 um) were stained 
with hematoxylin and eosin (H&E). Sections were also IHC 
stained with MC1R primary antibody as described above for 50 
TMAS. 
Biodistribution studies. Mice were imaged and euthanized 
at 2-72 hr post-injection. Tumors, kidneys and liver were 
excised, rinsed with PBS, blotted dry, and then imaged ex 
vivo with Optix-MX3 as described above. Images were 55 
analyzed as described above. 
Log D. The log of the octanol-water partition coefficient 
at pH 7.4 (log D7) was determined by miniaturised shake 
flask assay. Briefly, (200 uL to 1 mL) n-octanol (Sigam) was 
added to a solution of the test compound prepared in PBS 60 
(25 mM NaHPO/Na HPO, buffer, pH 7.4, Sigma, HPLC 
grade). Then, three different ratios of octanol to PBS buffer 
were prepared. The mixture was stirred in a vortex mixer at 
room temperature for 1 min and then two layers were 
separated by centrifuge. The concentration of compound in 65 
each layer was determined by HPLC (Poroshell 120 EC-C18 




nm channel. All sample injections were performed 3 times, 
and the results were averaged to yield the final values. 
Statistics. Data are represented as meants.d. All statistical 
analyses were performed with GraphPad Prism version 5.01. 
Unpaired Student's t-test was used to determine the statis 
tical significance of differences between two independent 
groups of variables. For all tests, a ps0.05 was considered 
significant. 
EXAMPLE 2 
Development of a Melanoma Targeted Probe for 
Imaging of Melanocortin Receptor 1 (MC1R) 
Nodal metastases are frequently the initial manifestation 
of metastatic spread in patients with melanoma and accurate 
determination of nodal status is important for both prognos 
tic evaluation and treatment planning. The melanocortin 1 
receptor (MC1R) is overexpressed in most human mela 
noma metastases, thus making it a promising target for 
imaging and therapy of melanomas. In this study, using 
DNA and tissue microarray, MC1R expression was analyzed 
in different normal tissues and melanoma samples, confirm 
ing the expression of MC1R in a large fraction of patients 
with melanoma. The inventors had developed a peptidomi 
metic ligand with high specificity and affinity for MC1R. 
Here, the inventors have conjugated this ligand to a near 
infrared fluorescent dye to generate a MC1R specific optical 
probe (MC1RL-800, 0.4+0.1 nM. K.). The uptake of the 
probe was studied in engineered A375/MC1R cells in vitro 
as well as in vivo by intravital fluorescence imaging, show 
ing internalization of the probe. The in vivo tumor targeting 
of MC1RL-800 was evaluated by intravenous injection of 
probe into nude mice bearing bilateral Subcutaneous tumors 
of A375 cells with low MC1R receptor numbers and engi 
neered A375/MC1R cells. Fluorescence imaging showed 
that the agent has higher uptake values in tumors with high 
expression compared to low (P<0.05), demonstrating the 
effect of expression levels on image contrast-to-noise. In 
addition, the tumor uptake was significantly blocked by 
co-injection with excess NDP-O-MSH peptide (P<0.05), 
indicating specificity of the probe in vivo. The biodistribu 
tion of MC1RL-800 was investigated in xenograft bearing 
mice, showing high kidney uptake as early as 30 min 
post-injection. As kidney is known to express the melano 
cortin receptor family member (MC4R and MC5R), kidney 
uptake of the probe was reduced significantly (P<0.05) by 
co-injection of a ligand the inventors have previously iden 
tified to have higher MC5R affinity compared to MC1R. The 
pharmacokinetics of probe uptake and clearance was also 
characterized using a three-compartment mathematical 
model. The MC1R-specific imaging probe developed in this 
study displays excellent potential for in vivo detection of 
melanoma metastases. 
Malignant melanoma is the most common cause of death 
from cutaneous malignancies and the fastest increasing 
cancer in the U.S. (1,2). Assessment of metastatic spread to 
lymph nodes draining the tumor site is very important not 
only for staging and prognosis but also for adjuvant therapy 
in melanoma (3-5). Sentinel lymph node biopsy (SLNB) is 
the current gold standard for evaluating regional lymph node 
involvement (6). The sentinel lymph node (SLN) receives 
lymph draining directly from the tumor site. In this method, 
a radio colloid is injected intradermally around the tumor 
and SLNs are determined, removed and examined by his 
tological methods for detection of intranodal metastasis (7). 
If cancerous, the patient is then offered a completion lymph 
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adenectomy to remove the remainder of the lymph nodes in 
that anatomic area. This method has limitations, as it is a 
Surgical intervention with all the ensuing complications 
from infection to lymphedema (8), and 80% of patients are 
negative for lymph node metastasis and therefore have 
undergone an unnecessary procedure (9). 
Standard imaging techniques have been used for assess 
ment of regional nodal status, including CT, ultrasound, 
MRI, and F-FDG PET (10, 11). However, each of these 
techniques have limitations as tools for detection of meta 
static melanoma. For example, ultrasound is limited to 
detection of superficial nodes. 'F-FDG PET lacks sufficient 
sensitivity to detect micrometastasis in regional nodes, espe 
cially for the initial assessment of early-stage melanoma 
metastasis where tumor volume is Small or metabolically 
inactive (12-14). In addition, this tracer can not discriminate 
between malignancy and inflammatory lymphadenopathy 
(15, 16). None of these imaging modalities are specific for 
enhancement of melanoma metastases. Therefore, mela 
noma-specific molecular imaging probes are needed for the 
non-invasive detection of metastasis with high sensitivity for 
staging of regional lymph node involvement, and for detec 
tion of distal metastases for diagnosis and to follow therapy 
response. There is also increasing interest in the use of novel 
targeted therapies in malignant melanomas that are resistant 
to most systemic therapies (17). 
Melanoma progression is associated with altered expres 
sion of cell Surface proteins, including adhesion proteins and 
receptors (18-20). It has been estimated that over 80% of 
malignant melanomas express high levels of the MC1R (21). 
MC1R is a member of a family of five G protein-coupled 
receptors (MC1R-MC5R) for melanocortins (22-24), such 
as melanocyte stimulating hormones (MSH). Because of the 
high expression of MC1R in melanoma, it has been inves 
tigated as a target for selective imaging and therapeutic 
agents and a number of selective ligands have been devel 
oped (25-27). One of these ligands, Nle'.D-Phe7-O-MSH 
(NDP-O-MSH) has a high affinity against MCR, except 
MC2R, and has been investigated extensively (28-31). 
In this study, the inventors evaluated the expression of 
MC1R through immunohistochemistry (IHC) and DNA 
microarray analysis in both melanoma patient samples and 
cell lines. While MC1R is not a novel target, this represents 
the most extensive study on its distribution in melanoma to 








affinity selective ligand against MC1R with lower affinity 
for MC4R or MC5R (32). By conjugating a near-infrared 
fluorescent dye to this ligand, we have developed a MC1R 
specific molecular imaging probe (MC1RL-800). The inven 
tors have used this probe to image the expression of MC1R 
in vivo following intravenous injection into nude mice 
bearing bilateral high- and low-MC1R expressing tumors. In 
vivo tumor cell uptake of this probe was studied by intravital 
imaging of a dorsal skin-fold window-chamber mouse Xeno 
graft tumor model. The in vivo biodistribution and pharma 
cokinetics of the probe was also studied. The molecular 
imaging probe designed in this study has potential for the 
detection and staging of melanoma metastases that overex 
press the MC1R, and could be used for the targeted delivery 
of therapy. 
Results 
A. MC1R Expression in Patient Tissue Samples 
It has been estimated that 80% of malignant melanomas 
express high levels of MC1R (21). For further confirmation 
and to characterize mRNA expression in patient tissue 
samples, the inventors analyzed publicly available DNA 
microarray data sets, which showed that MC1R mRNA 
expression was highly and generally expressed in a large 
fraction of melanomas (FIG. 24A, note log scale). In con 
trast, MC1R expression was not elevated in other skin 
cancers, normal skin and organs involved in toxicity and 
drug clearance, i.e., heart, lung, spleen, liver and kidney. 
To determine MC1R protein expression in patient 
samples, immunohistochemistry (IHC) was performed on a 
melanoma tissue microarray containing 267 samples. FIG. 
24C shows representative staining in normal skin relative to 
staining in a primary cutaneous melanoma, distant metasta 
sis and lymph node metastasis. None of the normal skin 
samples (n=19) had staining with a pathology score of >4. 
i.e. homogeneous moderate to high staining (Table 5). 
Benign lesions (n=65) and samples of local invasion to 
regional lymph nodes (n=35) had percentages of >4 staining 
ranging from 15 to 33%. A relationship between primary 
cutaneous melanoma lesion size and pathology score was 
observed, with Smaller lesions ranging from melanoma in 
situ to lesions 1 mm in diameter scoring 18% to 33% 4, and 
lesions from 1 mm to >4 mm in diameter scoring 46 to 79% 
>4. Primary mucosal melanomas (n=11) and melanoma 
from distant metastasis had scores ranging from 40% to 67% 
>4. 
TABLE 5 
IHC Scoring of MC1R Expression in Patient Tissue Samples 
Pathology score 
Tissue type in O 1 2 3 4 6 9 % = 4 
normal skin 19 O 1 S 13 O O O O 
compound nevi 9 O O O 6 O 3 O 33 
junctional nevi 5 O O O 4 O 1 O 2O 
intradermal nevi 7 O O O S O 2 O 29 
Clarks, atypical, dysplastic nevi 33 O 1 5 22 O 5 O 15 
Primary cutaneous melanoma (in situ) 11 O O O 9 O 2 O 18 
Primary cutaneous melanoma (0.1-0.75 mm) 12 O 2 1 5 O 4 O 33 
Primary cutaneous melanoma (0.75-1 mm) 13 O O 3 7 O 3 O 23 
Primary cutaneous melanoma (1-2 mm) 13 O O 3 4 O 6 O 46 
Primary cutaneous melanoma (2-4 mm) 12 O O 1. 3 1 6 1 67 
Primary cutaneous melanoma C-4 mm) 14 O 1 1 1 O 8 3 79 
Primary mucosal melanoma 11 O 1 1 3 O 4 2 55 
Melanoma in regional lymph nodes 3S 1 3 10 12 O 9 O 26 
Melanoma distant metastasis, M1 9 O 1 O 4 O 3 1 44 
Melanoma distant metastasis, M2 9 O O 1 2 O S 1 67 
Melanoma distant metastasis, M3 10 O 1 O S O 4 O 40 
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B. MC1R Expression in Melanoma Cell Lines 
MC1R expression was examined on a previously pub 
lished DNA microarray of a panel of melanoma cell lines 
(33, 34) (FIG. 24B). Moderate to high expression was 
observed in all primary melanocytes and NRAS-positive 
melanoma cells had low to moderate expression. In contrast, 
expression in BRAF-positive melanoma cells was highly 
heterogeneous, with Some lines exhibiting very low expres 
sion (WM 858, 7938, 1799, 35) and some with extremely 
high expression (WM 164, 1727A, 1819, 239A). Notably, 3 
of the 4 high expressing lines were metastatic: WM164, 
WM239A and WM1727A. 
C. Characterization of MC1R Expression in A375/MC1R 
Cells 
A375 malignant melanoma cells were transfected to sta 
bly overexpress MC1R for evaluation of the MC1RL-800 
imaging probe both in vitro and in vivo. The A375 malignant 
melanoma cell line was chosen due to their very low 
endogenous expression of MC1R (38, 40), providing both 
low- and high-expressing cells for the in vitro as well as in 
vivo selectivity studies. qRT-PCR of A375 and A375/MC1R 
cells revealed the mRNA gene expression level in the 
engineered cells to be 457, compared to a gene expression 
level of 4.5 in the parental cells. For further confirmation, 
hMC1R expression on the cell surface of the cells was 
characterized through ICC (FIG. 25A). Both engineered 
A375/hMC1R and parental A375 cells were incubated with 
the nuclear marker DAPI, the plasma membrane marker 
WGA and an MC1R antibody conjugated to a fluorescent 
dye (Alexa 555). The merged images illustrate colocaliza 
tion of MC1R (red) with membrane marker (WGA, green) 
indicating accumulation of the receptor on the cell-surface 
(yellow). Notably, the parental A375 line does appear to 
have a detectable amount of MC1R antibody binding to the 
cells Surface. 
To determine MC1R receptor number on the cell surface, 
saturation binding assays were performed using Eu-NDP 
C-MSH. Increasing amounts of Eu-NDP-C-MSH were 
added to A375/MC1R cells. Non-specific binding was deter 
mined in the presence of 5 uM unlabeled NDP-C-MSH 
(FIG. 25B). Results indicate that the Kd, Bmax and receptor 
number were 1.8 nM, 668,046+67,108 and 75,000 respec 
tively. 
D. Synthesis and Characterization of MC1R Targeted Probes 
The inventors recently described a high affinity and 
selective MC1R ligand: 4-phenylbutyryl-His-DPhe-Arg 
Trp-Gly-Lys(hex-5-ynoyl)-NH. (SEQ ID NO:3). K. values 
for this ligand against MC1R, MC4R and MC5R were 0.24 
nM, 254 nM and 46 nM, respectively (32). Here, the 
inventors further describe the attachment of this ligand to a 
near-infrared (NIR) dye with an excitation at 800 nm (4-phe 
nylbutyryl-His-DPhe-Arg-Trp-Gly-Lys(Mpr-IR800CW)- 
NH. (SEQID NO:14), LiCor IR800CW Maleimide) as well 
as Cy5. 
To evaluate the binding affinity of the MC1RL-800 and 
MC1R-Cy5 probes, competition binding assays were pre 
formed on A375/hMC1R cells with Eu-NDP-a-MSH as the 
competed ligand (FIG. 25C). The MC1RL-800 and MC1R 
Cy5 probes retained high affinity against MC1R, with an K, 
of 0.4+0.1 nM and 0.3+0.05 nM, respectively, compared to 
the K, for unlabeled ligand of 0.24 nM Ki (32). 
E. Cellular and Tumor Uptake Studies 
To study uptake of the MC1R probe onto and into cells, 
MC1RL-800 probe was incubated with live cells and images 
were acquired at different time-points after incubation using 
an inverted microscope. The binding of dye to the surface of 













incubation and intracellular accumulation was observed 
within 5 minutes (FIG. 26A). No attachment of the probe 
was observed when 2 LLM of NDP-C-MSH was used as a 
blocking agent before adding the probe to the cells (FIG. 
26A). 
To study distribution of the probe into tumors and tumor 
cells, intravital imaging of a dorsal skin-fold window cham 
ber xenograft tumor model was employed (see Methods). 
Briefly, the dorsal skin of a mouse is folded up into a saddle 
frame, and one side of the skin is removed in a circular 
region of ~1 cm in diameter and a round cover slip is placed 
over the opening, enabling high-resolution microscopic 
studies (41). For this experiment, A375/MC1R cells were 
mixed with matrigel and GFP expressing rat microvessels 
which were xenografted into the window chamber under the 
glass cover. Following a 5-7 day period of tumor growth, 
microvessel patency was verified by i.v. injection of blue 
Dextran and regions of the tumor with patent GFP vessels 
were chosen for study (see FIG. 31A). Then, 5 nmol/kg of 
the MC1R-Cy5 probe was intravenously injected. Extrava 
sation, tumor cell binding and uptake of the probe was 
observed by continuous confocal microscope acquisitions. 
FIGS. 31 B-1 and 31B-2 show the whole tumor Surrounded 
by GFP microvessels at 24 hr after injection of probe using 
low magnification (1.25 and 4x), while uptake of the probe 
at different time points post-injection are shown in FIG. 26B 
using higher magnification (25x). The probe was observed 
to extravasate, penetrate into the tumor and bind to cells as 
early as 5 min after injection. At five minutes to two hours 
after injection, most of the MC1R probe was observed on the 
surface of the tumor cells, with lesser amounts taken into the 
cells. At 24 hours post-injection, the tumor cells had fully 
internalized the probe. 
F. In vivo Tumor Targeting 
To investigate tumor targeting of the probe in Vivo, 
bilateral subcutaneous xenograft tumors were established 
with A375/MC1R engineered cells in the right flank, and 
A375 parental cells with relatively low MC1R expression in 
the left flank. After tumor growth to approximately 500-800 
mm, MC1RL-800 was injected intravenously and fluores 
cence accumulation was monitored over time. At 2 h post 
injection, the A375 tumors with low MC1R expression had 
significantly lower normalized fluorescence signal com 
pared to A375/MC1R tumors (P<0.05, n=3) (FIG. 27A-1, 
left mouse, and FIG. 32A). Representative A357/MC1R 
tumor slices in the volume in vivo as well as ex vivo are 
shown in FIGS. 32B and 32C, indicating heterogeneity of 
probe labeling within the tumor. The in vivo specificity of 
the probe was confirmed by co-injection of 0.25 ug of 
NDP-a-MSH with 5 nmol/kg of the MC1RL-800 probe. 
After blocking, the probe-related fluorescence signal 
decreased 1.54 fold in the A375/MC1R tumors (P<0.05, 
n=3) and 1.4 fold in A375 tumor (P<0.05, n=3) relative to 
the unblocked tumor at 2 hr after injection (FIG. 27A-1, 
right mouse). Ex vivo images of the corresponding center 
sections of the high- and low-expressing tumors confirmed 
the in vivo results. IHC staining confirmed the high and low 
MC1R expression in the two tumor types, and areas with the 
highest IHC staining corresponded to areas with the highest 
fluorescence signal (FIG. 27B). 
G. Biodistribution and Mathematical Modeling 
For biodistribution studies, mice bearing high expressing 
(A375/MC1R) tumors were injected with probe (n=3), and 
tissue distribution of fluorescence signal determined after 
removing tumors and organs from 30 min to 72 hr post 
administration (FIG. 28A). At 30 minutes post-injection, 
probe was retained at relatively high levels in the MC1R 
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high expressing tumor. At early time points, probe accumu 
lation in the kidneys was significantly higher than in the 
tumors, e.g. at 2 hr after injection, kidney signal was 2 fold 
higher, P-0.001. However, the accumulation was no longer 
significant by 72 hr after injection and the probe was cleared 
from both tumors and kidneys by 96 hr after injection. 
MC1RL-800 did not accumulate in the liver and no signal 
was detected in the other organs, such as spleen, heart, brain, 
etc. 
The pharmacokinetics of probe uptake and clearance was 
also characterized using a three-compartment mathematical 
model, which includes tumor, kidney and mouse Volumes, 
and assumes mass conservation of the ligand. This model 
was used to account for the interference of the tumor ligand 
release in the uptake and clearance dynamics of blood and 
kidneys. The results showed, while this effect is negligible 
in humans, it is significant in mouse models. 
Both ex vivo and in vivo biodistribution studies fit in the 
model (FIG. 28B), Suggesting using in vivo fluorescent 
imaging which provides high sensitivity for biodistribution 
study instead of sacrificing multiples animals at multiple 
time points. In addition, the probe is cleared at the same rate 
from both kidneys and tumor according to the inventors 
model. 
H. Determination of Log D of MC1RL-800 
To measure lipophilicity of the probe, log D (distribution 
co-efficient) was determined. Lipophilicity is a key deter 
minant of the pharmacokinetic behavior of drugs and can 
influence distribution into tissues, absorption and the bind 
ing characteristics of a drug, as well as determination of the 
solubility of a compound (reviewed by (42). The log D of 
MC1RL-800 probe was calculated -2.96, demonstrating 
high solubility of the probe but low permeability across the 
gastrointestinal tract or blood brain barrier. 
I. Reduction of Kidney Uptake 
Significant renal accumulation was observed as early as 
15 min after intravenous injection of the probe. To determine 
whether the amount of the MC1RL-800 probe injected had 
an effect on kidney uptake and retention, different amounts 
of the probe were injected intravenously (i.v.) and the 
pharmacokinetics of uptake and clearance monitored (FIGS. 
30A-D). As expected, the lower dose (1 nmol/kg) provided 
greater discrimination and more rapid renal clearance, com 
pared to the higher dose (5 nmol/kg) (FIGS. 29 A-1 and 
29A-2). Furthermore, with either dose, the measureable 
tumor and kidney half-lives were approximately 10 hr. 
Compared to previous studies, it is possible that this repre 
sents the time for dye to be acid quenched following 
internalization, and this will be characterized more fully in 
the future using Eu-labeled ligands. 
In addition, as the kidneys express MC5R (43. 44) and 
have little or no expression of MC1R (vide supra), the 
inventors hypothesized that renal accumulation is occurring 
via off-target binding of the probe to MC5R. To test this, 1 
nmol/kg of an MC4R/5R-selective ligand, H-Tyr-Val-Nle 
Gly-His-DNal(2)-Arg-DPhe-Asp-Arg-Phe-Gly-NH. (SEQ 
ID NO:10), (32) was injected. This agent has Ki values of 
5.6, 0.77 and 0.71 nM for MC1R, MC4R and MC5R, 
respectively. Co-injection of MC4R/5R compound along 
with 5 nmol/kg of MC1RL-800 significantly reduced renal 
uptake, e.g. 1.56 fold lower at 2 hr after injection, PK0.05, 
compared to control animals (FIG. 29B). Whereas the A375/ 
MC1R tumors had a significantly lower 1.54 fold decrease 
following blocking. Thus, it appears that the renal uptake of 














Early detection of primary melanoma tumors is essential 
because there is no effective treatment for metastatic mela 
noma. MC1R is known to be over-expressed in the majority 
of melanoma patients (21, 45-47), representing one of the 
few specific targets potentially useful for diagnosis and 
therapy of metastatic melanoma. MC1R, has been inten 
sively studied as a target for melanoma therapies; however, 
to the best of the inventors knowledge, this represents the 
first publication in which it has been so extensively evalu 
ated in terms of expression levels in patient samples and cell 
lines. In addition, the inventors have developed MC1R 
specific imaging probes and characterized their tumor cell 
specificity, binding and uptake both in vitro and in vivo. 
It has been previously reported that up to 80% of mela 
noma cells express high levels of MC1R (21); however, 
those data were obtained through the use of radioassays 
using human cell lines, rather than patient tissue samples. It 
is not uncommon for protein expression in cultured cell lines 
to differ from that of primary tumors; in fact, such discrep 
ancies are common throughout literature and undoubtedly 
play a role in the increased sensitivity of cancer lines to 
chemotherapy relative to solid tumors (48). Previous reports 
of MC1R expression in human melanoma and human uveal 
melanoma tissues have been as high as 95% (49, 50); 
however, these studies have taken a “present/not present 
binary approach to data scoring. The inventors have rigor 
ously sought to quantify MC1R expression in patient 
samples with the assistance of a dermatopathologist. The 
data that the inventors have collected from human tissues 
samples suggests that MC1R is moderately to highly 
expressed (with a score of >4) on only 40% to 60% of 
melanoma patient tumors, leading us to believe that earlier 
reports, citing high expression of MC1R in 80-95% of 
melanoma cells (21, 49, 50), may have been an over 
estimate. 
Based on the inventors analysis of publically available 
DNA microarray data from non-affected human tissues, 
MC1R mRNA expression is not elevated in non-melanoma 
skin cancer, normal skin cells, or organs which are typically 
involved in pharmaceutical clearance, such as the heart, 
liver, spleen or kidney. These findings are in good agreement 
with recent literature (49, 50). Additionally, Salazar-Onfray 
et. al (50) conducted an analysis of a broad panel of normal 
tissues through IHC and found that MC1R was detected only 
in low levels in adrenal grand, cerebellum and liver, and very 
weakly in normal appendix, myocardium, kidney and myo 
metrium. Their data indicated that while MC1R is not 
expressed at detectable levels on fresh monocytes, in vitro 
stimulation with several cytokines such as IL-4, GM-CSF, 
and IL-10 can induce a strong expression of MC1R. Herein, 
the inventors report high expression of MC1R mRNA in 
melanocytes, and high protein expression in the basal layer 
of normal skin Samples. Melanocytes are known to be 
present in the basal layer. The inventors’ results indicate that 
MC1R is heterogeneously expressed in normal skin relative 
to the ubiquitous and high expression observed in a large 
fraction of melanomas. The inventors' findings, combined 
with previous reports from the literature, suggest that MC1R 
may be useful as a marker for a large Subset of patients with 
melanoma for specific targeting. 
It has been known that MC1R ligands also show cross 
reactivity with other melanocortin receptors, mainly MC4R 
and MC5R. Since MC4R and MC5R have high expression 
levels in normal tissues including kidney and brain, MC1R 
ligands with non-specific binding to MC4R and MC5R are 
not ideal for targeting of melanoma in patients. Recently, the 
inventors described a high affinity peptidomimetic ligand 
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against MC1R and demonstrated very low interaction 
against MC4R and MC5R, 1000 and 200 times lower affinity 
compared with MC1R, respectively (32). As this ligand had 
the highest hMC1R affinity and selectivity in the inventors 
earlier study, it was chosen for more study here. The use of 5 
Small peptidomimetics as carriers for the delivery of imag 
ing or therapeutic moieties to diseased tissues offers several 
advantages such as high biostability, easy synthesis and 
modification, faster blood clearance, high-affinity and high 
specificity and a low toxicity and immunogenicity (51-55). 10 
In this research, the inventors further developed a molecu 
lar imaging probe by attachment of a near-infrared fluores 
cent dye IRDye800CW to the C-terminus of the MC1R 
specific ligand via lysine-mercaptopropionic acid linker 
(named MC1RL-800). As determined by the europium time- 15 
resolved fluorescence competition binding assay using 
Eu-NDP-O-MSH, the MC1RL-800 probe displays high in 
vitro binding affinity to MC1R in A375/MC1R cells (Ki 
0.4+0.1 nM), a slightly weaker avidity than unmodified 
peptide (0.17 nM). The in vitro microscopic results showed 20 
binding of the probe on the cell membrane as early as 15 
seconds after adding the probe. 
To determine the uptake profile of the probe to the tumor 
cells immediately after injection, in vivo, intravital confocal 
imaging of a dorsal skin-fold window chamber tumor model 25 
was used. The window chamber model has been used for 
high-resolution imaging using wide-field fluorescence, 
transmission or reflectance imaging, as well as epifluores 
cence, confocal and multiphoton/nonlinear microscopy (41). 
The inventors’ results showed internalization of the probes 30 
at 24 h after injection, which makes the ligand a good 
candidate for radionuclide labeling and radiotherapy. 
MC1R expression ranges from several hundred to around 
10,000 receptors per cell in different human cell lines (21). 
Therefore, development of a non-invasive imaging method 35 
for visualizing and quantifying MC1R expression will be 
useful for monitoring alteration in MC1R expression as an 
indicator of treatment response (56). The inventors in vivo 
results indicate that MC1RL-800 imaging probe is able to 
differentiate different levels of MC1R expression in A375 40 
melanoma tumors with low levels of MC1R (400+93 sites/ 
cell, (38) and A375/MC1R tumors with high levels of 
expression (75,000 sites/cell). In addition, co-injection of 
NDP-a-MSH and MC1RL-800 probe significantly 
decreased the probe-related fluorescence signal (P<0.05) in 45 
both A375 and A375/MC1R tumor, showing the specific 
recognition of MC1R by the probe in the tumors. 
Here, the inventors used whole animal imaging and ex 
vivo imaging of tumors and organs to study MC1RL-800 
probe biodistribution and both were in agreement and fit in 50 
the inventors’ mathematical model. Therefore, near infrared 
fluorescent imaging provides high sensitivity for detection, 
visualization, and quantification of fluorescence distributed 
throughout the body of living mice and consequently, there 
is no need to sacrifice multiple animals at multiple time 55 
points for this type of study. 
The in vivo biodistribution of MC1RL-800 indicates high 
tumor and kidney uptake as early as 15 min after injection. 
While the inventors show higher accumulation of the probe 
in kidneys compared to MC1R high expressing tumor at 60 
early time points, the probe was completely cleared from 
both kidneys and tumor at the same rate by 72 hr after 
injection based on the inventors’ experimental as well as 
simulation data. Co-injection of MC4R/5R-selective ligand 
is shown to significantly decrease the nonspecific accumu- 65 
lation of the probe in the kidneys. MC4R/5R-selective 
ligand has high affinity against MC5R which is expressed in 
56 
the kidneys (43). The results here confirmed high specificity 
of this compound against MC5R. Thus, it appears that the 
renal uptake of MC1RL-800 is due to off-target binding and 
can be pharmacologically blocked. In addition, the inven 
tors’ study showed that the lower dose of 1 nmol/kg provides 
greater discrimination and faster renal clearance compared 
to the higher dose at 5 nmol/Kg, re-demonstrating its high 
affinity to MC1R compared to MC5R. Therefore, kidney 
accumulation of the probe can be reduced either by co 
injection of MC4R/5R-selective ligand or by using lower 
doses of the MC1RL-800 probe. Although, kidney accumu 
lation should not be a serious problem in use of the probe for 
detection of regional lymph node metastases, since it will be 
administered peritumorally and clear through the lymphatics 
where macrophages will likely ingest the probe decreasing 
systemic circulation. Also, since the probe clears within days 
after administration, toxicity to the kidneys should be mini 
mal when delivered systemically for detection of distal 
metaStaSeS. 
In summary, to the best of the inventors knowledge, this 
represents the first account in which MC1R has been vali 
dated as a potential target in both melanoma cell lines 
(through DNA microarray) and patient samples (through 
DNA microarray and IHC). The inventors’ results have 
indicated that, while MC1R is highly expressed in 40%-67% 
of melanomas, previous reports Suggesting high expression 
in 80% of melanomas may have been an over-estimate. In 
addition, the specific MC1R fluorescent imaging probe with 
high affinity to the MC1R was successfully synthesized and 
characterized. The uptake study of the probe was carried out 
in vitro as well as in vivo. The inventors’ study demonstrates 
that the probe can differentiate high- from low-MC1R 
expressing tumors. Therefore, MC1RL-800 is a promising 
molecular probe for imaging of MC1R-positive melanoma 
and MC1R expression. Despite the promising tumor-target 
ing properties of the probe, its biodistribution profile could 
still be improved. Lower kidney uptake could be obtained by 
decreasing affinity for MC5R by modifying the physico 
chemical properties or peptidomimetic structure of the 
ligand. 
Since the boundaries of lesions often cannot be reliably 
determined in patients with melanoma, repeated Surgical 
excisions are frequently required to achieve tumor-free 
margins (57). Invisible NIR fluorescent light with high 
resolution and sensitivity is used for real-time intraoperative 
image-guidance during Surgery (58). The targeted agents of 
the invention (e.g., fluorescent targeted agents) can also offer 
an opportunity for image guided Surgery for assessment of 
tumor margins in melanoma patients. 
In conclusion, the imaging probe developed in this study 
is useful for translation as a clinical PET tracer for nonin 
vasive identification of regional lymph node metastasis 
when injected locally at the primary lesion site as well as 
detection of distal metastases in malignant melanomas. In 
addition, it could have particular benefit for the evaluation of 
therapeutic efficacy. In the future, this ligand could also be 
used in clinic as a MC1R targeted delivery vehicle for 
radionuclides, toxins, and chemotherapeutic molecules. 
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Materials and Methods for Example 3 
Online Methods 
Synthesis of Gd-Tx. Information on the synthesis of 
Gd-Tx, including mass spectral data, can be found in the 
Supporting Information. 
Crystallization of Gd-Tx and determination of structure. 
Crystals suitable for X-ray diffraction were obtained by 
dissolving Gd-TX (2 mg, 2.26 umol) in 1 mL methanol. 
Sodium nitrate (0.2 mg, 4 equiv.) was added and the solution 
was heated to reflux at 60°C. for 24 hours. At this point, 0.25 
mL chloroform was added and the solution was placed in a 
vial and diethyl ether was allowed to slowly diffuse into the 
solution at 5° C. For full crystallographic data, please see 
Supporting Information. Further details of the structure may 
also be obtained from the Cambridge Crystallographic Data 
Centre by quoting CCDC number 859294. 
Synthesis of targeted triblock polymers. IVECTTM tri 
block polymers with a terminal azide were obtained from 
Intezyne Technologies (Tampa, Fla.) and either NDP-O- 
MSH-lys-hexyne 2 or 1' (Scheme 1) were used as the 
MC1R-selective ligand. Standard click chemistry was con 
ducted as previously published." 
Formulation and Stabilization of Gd-TX Micelles. For 
targeted formulations, 5-10% of the targeted polymer and 
90-95% of the untargeted polymer were used, respectively. 
Gd-Tx (0.05-5% w/w), was dissolved in dimethylsulfoxide 
(DMSO, 380 uL). The triblock polymer (750 mg) was 
dissolved in water (150 mL) at a concentration of 5 mg/mL 
and stirred with slight heating until fully dissolved. After 
cooling to room temperature, the polymer Solution was 
placed in a sheer mixer and the Gd-Tx solution was added. 
The resulting Solution was then passed through a microflu 
idizer (Microfluidics M-1 10Y) at 23,000 PSI, filtered 
through a 0.22 Lum Steriflip-GP Filter Unit (Millipore) and 
lyophilized. 
For stabilized formulations, micelles were subject to an 
Fe(III)-mediated crosslinking reaction. FeCls was pre 
pared at concentration of 1.35 g/mL in 20 mM Tris-Cl (pH 
7.4). The targeted and untargeted micelles were then dis 
solved in the Fe(III)-tris solution at a concentration of 20 
mg/mL and the Solution was adjusted to pH 8 through the 
dropwise addition of 0.1-1 M aqueous NaOH. The cross 
linking reaction was stirred for 12 hours. The contents of the 
reaction vessel were then lyophilized. 
Cell Culture. HCT116 cells overexpressing hMC1R were 
engineered in our lab. HCT 116 cells were transfected with 
the pCMV6-Entry Vector (Origene: RC 203218) using the 
Fugene 6 transfection reagent (Roche: 1814-443). Trans 
fected cells were grown in a selection media containing 0.4 
mg/ml geneticin (Life Technologies; 11811-031) and tested 
for the hMC1R cell surface expression by saturation ligand 
binding assay. Cells were maintained under standard con 
ditions (37° C. and 5% CO) and were grown in Dulbecco's 
modified Eagle medium (DMEM) supplemented with 10% 
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FBS and 5% penicillin/streptomycin. For HCT116/hMC1R 
cells, geneticin (G418S, 0.8%) was added to the media to 
ensure proper selection. hMC1R expression was verified 
through immunohistochemistry (IHC, see Supplemental 
Information). 
Europium Binding Assays. Europium binding assays were 
conducted as previously published. ' 
In vivo murine tumor models. All animal experiments 
were approved by institution review board guidelines on the 
care and use of animals in research. HCT116/hMC1R 
expressing tumor models were studied in female SCID/beige 
mice obtained from Harlan Laboratories at 6-8 weeks of age. 
HCT116/hMC1R cells were injected at concentrations of 
3x10°-10x10 cells per 0.1 mL of phosphate-buffered saline. 
Tumor Volume measurements were made bi-weekly and 
calculated by multiplying the length by the width squared 
and dividing by two. Final Volume measurements were 
determined through ROI analysis on the MRI. 
MRI Imaging and Analysis.All imaging was completed 
on a 7 Tesla, 30 cm horizontal bore Agilent magnetic 
resonance imaging spectrometer ASR310 (Agilent Life Sci 
ences Technologies, Santa Clara, Calif. Detailed information 
on the MRI imaging and analysis, including imaging pro 
cessing, can be found in the Supporting Information. Briefly, 
SCOUT images were acquired for slice selection for both in 
vitro and in vivo imaging. For in vitro phantom T1 studies, 
multiple TR SEMS (spin echo) imaging was performed to 
calculate T1 values. For in vivo imaging and quantification 
of tumor enhancement due to uptake of the micelles, T1 
weighted spin echo multi slice (SEMS) images were 
acquired, and intensity histograms for right (R) and left (L) 
whole tumors, and R and L whole kidney and liver were 
prepared using the MATLAB program (Mathworks, Natick, 
Mass.) for each time point. This was done by drawing an 
ROI across all applicable slices. The mean intensity value 
for each time point was normalized to the mean intensity of 
the thigh muscle. A percent change value was then calcu 
lated by comparing each time point after injection to the 
normalized pre-injection intensity mean. The % change 
values for all tumors in a given group (n 3 for all groups) 
were averaged to obtain the “mean tumor % change' at time 
points from 1 to 48 h. Percent change values were also 
averaged for R and L kidney to obtain the “mean kidney 9% 
change' values. 
Supporting Information for Example 3 
Synthesis of Gd-TX 6. 
All chemicals were obtained from commercial sources 
(Fisher Scientific, Acros Chemicals, Sigma-Aldrich or 
Strem Chemicals) and used as Supplied unless otherwise 
noted. All solvents were of reagent grade quality. Fisher 
silica gel (230-400 mesh, Grade 60 A) and Sorbent Tech 
nologies alumina (neutral, standard activity I, 50-200 um) 
were used for column chromatography. Thin layer chroma 
tography (TLC) analyses were either performed on silica gel 
(aluminum backed, 200 um or glass backed, 250 um) or 
alumina neutral TLC plates (polyester backed, 200 um), 
both obtained from Sorbent Technologies. Low- and high 
resolution ESI mass spectra (MS) were obtained at the Mass 
Spectrometry Facility of the Department of Chemistry and 
Biochemistry at The University of Texas at Austin using a 
Thermo Finnigan LTQ instrument and a Qq FTICR (7 Tesla) 
instrument, respectively. HPLC spectra were taken on a 
Shimadzu High Performance Liquid Chromatograph (Frac 
tion Collector Module FRC-10A, Auto Sampler SIL-20A, 
System Controller CBM-20A, UV/Vis Photodiode Array 
Detector SPD-M20A, Prominence). The tripyrrane dialde 













vided by Pharmacyclics Inc. and synthesized as previously 
described. The precursor 1,2-dimethoxy-4,5-dinitroben 
Zene 4 was synthesized as previously described. 
The gadolinium complex used in this study (Gd-TX 6) was 
prepared as shown in Scheme 51. Briefly, compound 4 (1 g, 
4.38 mmol) was dissolved in 10 mL methanol and placed in 
a hydrogenation flask. The solution was purged with nitro 
gen for 5 minutes and palladium on activated carbon (10%, 
0.1 g) was added. The mixture was degassed and allowed to 
react with hydrogen gas at 100 psi with agitation for 18 
hours, filtered under Schlenk conditions through a minimal 
pad of Celite, and added instantly to a solution of TP-45 
(2.11g, 4.38 mmol) in 15 mL methanol under nitrogen at 70° 
C. At this point, aqueous hydrochloric acid was added (2 
mL, 0.5 M) and the deep red reaction mixture was stirred for 
4 hours. Next, gadolinium acetate tetrahydrate (2.67 g. 6.57 
mmol. 1.5 equiv) was added together with 3 ml triethylam 
ine and the solution was stirred at 70° C. for 16 hours, during 
which time the Solution gradually changed color from deep 
red to deep green. The solvent was removed in vacuo and the 
residue was then Subjected to column chromatography 
(silica gel). To remove apolar impurities, the column was 
eluted first with a mixture of 95% CHC1 and 5% MeOH. 
The product slowly starts to elute when a mixture of 60% 
CH2Cl and 40% MeOH is used as the eluent. The deep 
green fraction isolated using this eluent mixture was col 
lected and the solvent was removed in vacuo to give 6 
(Gd-TX) as a deep green crystalline material (1.63 g, 42%). 
UV/Vis (MeOH, 25° C): 470 (Soret-type band); 739 
(Q-type band); Low Resolution MS (ESI in MeOH): 797.25 
(M*-2OAc+OMe), 825.42 (M'-OAc). High Resolution MS 
(ESI in MeOH): calculated for Csh-N-OGd'=825.2611; 
found: 825.2621(CHNOGd', M-OAc). 
MRI Imaging and Analysis. All imaging was completed 
on a 7 Tesla, 30 cm horizontal bore Agilent magnetic 
resonance imaging spectrometer ASR310 (Agilent Life Sci 
ences Technologies, Santa Clara, Calif.). In vitro imaging of 
Gd-Tx micelle phantoms was completed using a SCOUT 
image for slice selection, and a multiple TR SEMS (spin 
echo) image was performed in order to calculate the T 
values. The TR calculation sequence consisted of TR values 
of 20, 10.99, 6.03, 3.31, 1.82, 1.00, 0.55, 0.30, 0.17, 0.09 and 
0.05 s, the TE was 8.62 ms, the data matrix was 128x128, 
4 averages, 2 dummy scans, FOV was 80 mmx40 mm or 40 
mmx90 mm and the slice thickness was 1-2 mm (depending 
on the phantom). The T values were calculated using the 
Vnmr J software (Agilent Life Sciences Technologies, Santa 
Clara, Calif.), and values were verified using MATLAB 
(Mathworks, Natick, Mass.). 
Once the tumors in the animals reached an average of 
~500 mm, the animals were pair-matched by tumor size and 
sorted into four groups which would receive the following 
micelles: TGXL; UT-XLT-UXL, or UT-UXL. Each animal 
was imaged the day before micelle injection for “pre” 
images. The following morning, each animal was individu 
ally administered 12 umol/kg Gd-TX (as Gd-Tx micelles) 
dissolved in 200 uL saline, via tail vein injection, and the 
time of injection was noted. Follow-up MRI images were 
taken at 1 hr., 4 hr, 12 hr. 24 and 48 h after injection of the 
micelles. 
All animals were sedated using isoflurane and remained 
under anesthesia for the duration of the imaging. Animals 
were kept at body temperature (-37° C) using a warm air 
blower; the temperature of the air was adjusted to maintain 
the body temperature and was monitored using a fiber optic 
rectal probe. SCOUT images were taken to determine ani 
mal position within the magnet and setup the slices for the 
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T. weighted spin echo multi slice (SEMS) images. The 
SEMS images were taken as coronal-90 images (read direc 
tion along the X-axis, phase-encode along the Z-axis), with 
data matrix of 128x128 and a FOV of 40 mm (read)x90 mm 
(phase); 15 one-mm thick slices were taken with a 0.5 mm 
gap between slices; the TR was 180 ms, and TE was 8.62 
ms; there were 8 averages taken for each image, resulting in 
a total scan time of about 3 minutes per SEMS image. 
Images were processed using MATLAB (Mathworks, 
Natick, Mass.) to draw regions of interest (ROI) in the 
tumors, kidney, liver and thigh muscle over multiple slices 
for each mouse at each time point. All intensities for each 
area of interest were averaged to determine a mean intensity. 
The mean intensity of each area was then normalized to the 
mean intensity of the thigh to generate a normalized inten 
sity (NI): 
humor 
N = thigh 
A percent change value was then calculated by comparing 
each normalized time point after injection to the normalized 
pre-injection intensity mean: 
% Change = x 100 
pre 
Since the right and left tumors are histologically equiva 
lent (Figure S.4), the % change values for all tumors were 
averaged to obtain an "average tumor '% change' at time 
points 1-24 h. Percent change values were also averaged for 
R and L kidney to obtain an "average kidney '% change' at 
time points 1-24 h. 
X-ray experimental 
CHOH HO 6. 
Crystals grew as dark green prisms by slow diffusion of 
diethyl ether into a solution of 6 dissolved in methanol/ 
chloroform (4:1) and Sodium nitrate (4 equiv.). The data 
crystal had approximate dimensions: 0.23x0.07x0.07 mm. 
The data were collected on a Nonius Kappa CCD diffrac 
tometer using a graphite monochromator with MoKa radia 
tion (0.71073 A). A total of 384 frames of data were 
collected using w-scans with a scan range of 1.2° and a 
counting time of 144 seconds per frame. The data were 
collected at 153 K using an Oxford Cryostream low tem 
perature device. Details of crystal data, data collection and 
structure refinement are listed in Table 7. Data reduction 
were performed using DENZO-SMN. The structure was 
solved by direct methods using SIR97 and refined by 
full-matrix least-squares on F with anisotropic displace 
ment parameters for the non-H atoms using SHELXL-97. 
The hydrogen atoms were calculated in ideal positions with 
isotropic displacement parameters set to 1.2xUeq of the 
attached atom (1.5xUeq for methyl hydrogen atoms). 
The function, X w(IFI-IF'), was minimized, where 
w=1/(s(F))+(0.0313*P)+(3.8824*P) and P=(IF?-- 
2|Fl')/3. R(F) refined to 0.103, with R(F) equal to 0.0537 
and a goodness of fit S=1.17. Definitions used for calculat 
ing R(F), R(F) and the goodness of fit, S, are given 
below.* The data were checked for secondary extinction but 
no correction was necessary. Neutral atom scattering factors 
and values used to calculate the linear absorption coefficient 
are from the International Tables for X-ray Crystallography 














Tables of positional and thermal parameters, bond lengths 
and angles, torsion angles and figures are included in the 
tables below. 
* R(F)={Sw(IF-FI)/Sw(IFI)''' where w is the 
weight given each reflection. R(F)=S(F-IFI)/SIFI} for 
reflections with F>4(s(F)). S-Sw(F°-Fl')/(n-p) 
}'', where n is the number of reflections and p is the 
number of refined parameters. 
TABLE 7 
Crystal data and structure refinement for 6. 
Empirical formula C37H48GdN7O12 
Formula weight 940.07 
Temperature 123(2) K 
Wavelength 0.71069 A 
Crystal system Monoclinic 
Space group P21 c 
Unit cell dimensions a = 15.3250(10) A a = 90°. 
b = 11.5950(8) A b = 99.592(2). 
c = 21.5387(15) A g = 90°. 
Volume 3773.8(4) A 
Z. 4 
Density (calculated) 1.655 Mg/m 
Absorption coefficient 1.832 mm 
F(000) 1916 
O.23 x 0.07 x 0.07 mm 
2.00 to 25.00. 
-18 <= h K= 18, -13 <= k <= 12, 
Crystal size 
Theta range for data collection 
index ranges 
-25 <= i <= 25 
Reflections collected 11918 
independent reflections 6623 R(int) = 0.0816) 
Completeness to theta = 25.00° 99.9% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.869 
Refinement method Full-matrix least-squares on F? 
Data restraints parameters 6623,1,523 
Goodness-of-fit on F2 1.171 
Final R indices I > 2sigma(I) 
R indices (all data) 
Largest diff. peak and hole 
R1 = 0.0537, wR2 = 0.0838 
R1 = 0.1176, wR2 = 0.1031 
1.759 and -0.791 e - A 
*Rw(F) = {Sw(IFo-Flc')/Sw(IFol)''' where w is the weight given each reflection. 
(F) S(IFol-FCSIFol for reflections with Fox 4(s(Fo)). S=Sw(IFol-Fo)/(n 
-p) 12, where n is the number of reflections and p is the number of refined parameters. 
TABLE 8 
Atomic coordinates (x10') and equivalent isotropic displacement 
parameters (A’ x 10) for 6. U(eq) is defined as 
one third of the trace of the orthogonalized UP tensor. 
X y Z. U(eq) 
Gd1 2938(1) 2064(1) 5736(1) 23(1) 
N1 2083 (3) 3925(4) 5489(2) 17(1) 
N2 3053(3) 2448(5) 4665(2) 24(1) 
N3 3286(3) 289(5) 5126(2) 22(1) 
N4 2637(3) 119(4) 6196(2) 19(1) 
N5 1931(3) 2166(5) 6471(2) 22(1) 
O1 4487 (3) 6406(4) 3226(2) 45(1) 
O2 4064(3) -3804(4) 5297(2) 29(1) 
O3 3469(3) –3945(4) 6334(2) 26(1) 
O4 1365(3) 5187(4) 9116(2) 36(1) 
O5 3875(3) 3725(4) 6020(2) 40(1) 
C1 1631(4) 4533(6) 5874(3) 23(2) 
C2 1404(4) 5691 (5) 5629(3) 22(2) 
C3 1739(4) 5767(5) 5087(3) 21(2) 
C4 2168(4) 4675(6) 5001(3) 22(2) 
C5 2587(4) 4440(5) 4486(3) 20(2) 
C6 2986(4) 3440(6) 4317(3) 23(2) 
C7 3341(4) 3225(6) 3735(3) 25(2) 
C8 3587(4) 2099(6) 3745(3) 26(2) 
C9 3414(4) 1636(6) 4331(3) 26(2) 
C10 3525(4) 491 (6) 4579(3) 27(2) 
C11 3361 (4) –784(6) 5424(3) 21(2) 
C12 3739(4) -1768(6) 5191 (3) 27(2) 
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TABLE 13 
Hydrogen bonds for GIA and l. 
D-H... A d(D-HI) d(H. . . A) d(D. . . A) <(DHA) 5 
O1 H1 . . . O3Bii1 O.84 2.04 2.851(7) 162 
O4. H4 . . . O2Bi2 O.84 2.08 2.887(7) 160 
O1C H1OC . . . O4iii.3 O.80 2.OO 2.757(6) 157 
OS- H1WA. . . O1H4 O.81 1.97 2.758(6) 162 
OS H1WB . . . O3#1 O.81 2.10 2.878(6) 161 
10 
Symmetry transformations used to generate equivalent 
atOms: 
#1 X.y--1.Z #2 X.-y+1/2.Z+1/2 #3 X.-y+1/2.Z-1/2 #4-X+1.- 
y+1-Z+1 15 
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Development and In vivo Quantitative Magnetic 
Resonance Imaging of Polymer Micelles Targeted 
to the Melanoma-Specific Marker MC1R 40 
Recent emphasis has been placed on the development of 
rationally-designed polymer-based micelle carriers for ther 
agnostics. In this study, micelles were decorated with a 
specific ligand for the melanocortin 1 receptor (MC1R), 45 
which has been evaluated as a cell-surface marker for 
melanoma. The inventors describe the synthesis and char 
acterization of a new gadolinium texaphyrin (Gd-TX) chelate 
that was encapsulated in an IVECTTM micellar system, 
stabilized by crosslinking with Fe(III) and targeted to 50 
MC1R. The inventors have demonstrated that these stabi 
lized Gd-Tx micelles are able to actively target MC1R 
expressing Xenograft tumors in vitro and in vivo more 
effectively than control systems, including untargeted and/or 
uncrosslinked Gd-Tx micelles. Taken in concert, the find- 55 
ings reported herein provide Support for the conclusion that 
appropriately designed micelles are able to deliver payloads 
to tumors expressing MC1R. Gd-Tx is a known redox active 
agent; therefore, this approach may see eventual use in the 
development of theragnostic agents. 60 
Rationally-designed, polymer-based micelle carriers rep 
resent a promising approach to the delivery of therapeutic 
and/or diagnostic payloads. They offer many potential 
advantages as delivery agents and could serve to: (1) 
enhance the solubility of lipophilic drugs; (2) increase 65 
circulation times; and (3) lower the toxicity of the payload 
in question. Micelles with diameters between 20 and 200 nm 
76 
are particularly attractive since particles of this size can 
escape renal clearance. This generally translates into longer 
circulation times and can lead to improved accumulation in 
tumor tissues as the result of an enhanced permeability and 
retention (EPR) effect.' It has also been suggested that 
selective accumulation in tumors relative to normal tissues 
can be enhanced through the use of tumor-specific cell 
Surface targeting groups, and that binding events may be 
used to trigger release mechanisms. Such strategies are 
appealing since they could serve not only to enhance uptake 
in tumor relative to normal tissues, but also to reduce the 
toxicity in peripheral organs." 
Despite the advantages offered by micellar delivery sys 
tems, to date no micellar system has been described that 
achieves the full promise of targeting in vivo. Of additional 
concern is the fate of micelle delivery systems in biological 
media. Though extensively studied in vitro, most published 
delivery systems lack adequate information on micelle 
integrity in vivo. Moreover, previously described micelle 
delivery systems have suffered from an inherent instability 
in Vivo, generally undergoing collapse in the presence of 
serum lipids and proteins. Micelles can be stabilized for in 
Vivo use through crosslinking of individual acyl chains. To 
date numerous crosslinking reactions have been attempted, 
employing strategies that range from the use of disulfides 
6 and other redox-sensitive bonds' to temperature- and 
pH-sensitive functional groups.' Here, the inventors 
describe a novel crosslinking procedure that relies on the pH 
sensitivity of metal-oxygen coordination bonds.' " This 
particular form of crosslinking is known to increase blood 
circulation times and result in a stable micelle delivery 
system that is able to selectively dissociate and release its 
contents in the acidic tumor microenvironments." 
There are a number of micelle-based delivery systems for 
drugs such as doxorubicin and paclitaxel currently in Phase 
I and Phase II clinical trials." These systems do provide for 
increased circulation times and larger area-under-the curve 
pharmacokinetics relative to the corresponding free drug. 
Some systems now in preclinical study are also “passively 
targeted.' ' ' ' meaning they lack any specific surface 
ligands and rely solely on EPR to deliver their payload. 
16 A significant disadvantage with passive targeting of 
micelle delivery systems is an increased probability for 
nonspecific delivery and accumulation in clearance organs, 
such as liver and kidney, relative to tumor. 7 Additionally, 
the significance of EPR in human cancers remains largely 
unproven and there is increasing evidence that EPR alone 
may not be enough to ensure the selective delivery of a 
payload.'" 
Most attempts at micelle targeting have come from the use 
of ligands such as O?3 (RGD), EGFR, or folate.' ' 
Unfortunately, most of these targeted systems suffer from a 
high peripheral toxicity. ' ' ' ' have only seen limited 
testing in vivo (e.g., in animal models lacking tumor Xeno 
'' ''), or have not yet quantitatively demonstrated 
selective tumor accumulation relative to peripheral organs." 
11, 18, 23, 24. It is also noteworthy, that various other targeted 
systems have been reported to provide little improvement in 
tumor uptake as compared to their untargeted controls.' ' 
20 Thus, there remains a need for more specific biological 
targeting agents, including those that rely on localization 
strategies that are not EPR dependent. This may be of 
particular relevance in clinical systems, where it has recently 
been proposed that human cancers have only a modest EPR, 
as compared to murine xenografts." 
One attractive target is the melanocortin 1 receptor 
(MC1R). Over 80% of malignant melanomas express high 
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levels of this receptor. Not surprisingly, the MC1R has 
been investigated as a target for delivery of imaging and 
therapeutic agents. Indeed, a number of MC1R ligands have 
been developed for this purpose.’’ ‘’ The best known of 
these, Nile, DPhe7-O-MSH(NDP-O-MSH), is considered 
the “gold standard for in vitro assays due to its ease of 
synthesis, low cost and high MC1R affinity.’ ' However, 
NDP-O-MSH is not selective for MC1R and displays strong 
nanomolar binding affinities to other melanocortin receptor 
isoforms, e.g., MC4R and MC5R.'" Such off-target bind 
ing is undesirable given the presence of these receptors in 
the kidney, brain and CNS. Koikov et al. has reported 
the development of a ligand, 4-phenylbutyryl-His-DPhe 
Arg-Trp-NH. (SEQ ID NO:6), with high selectivity and 
specificity for MC1R. We have recently altered this ligand 
with an alkyne (4-phenylbutyryl-His-DPhe-Arg-Trp-Gly 
Lys(hex-5-ynoyl)-NH. (SEQ ID NO:3): 1)" for click 
attachment to a micelle-forming triblock polymer. More 
over, we have demonstrated in vitro that micelles decorated 
with compound 1 retain the high binding affinity (2.9 nM K.) 
of the free ligand and display improved target selectivity. In 
this prior work, the K, of targeted crosslinked (XL) micelles 
for MC1R was found be to four times lower than the 
corresponding targeted uncrosslinked (UXL) micelles while 
not binding to either of the undesired targets, MC4R or 
MC5R." In this report we show how these micelles can be 
used to deliver a contrast-enhancing agent to MC1R-ex 
pressing tumor Xenografts. 
Texaphyrins are a series of expanded porphyrins that have 
attracted interest in the area of cancer research.' ' 
Gadolinium complexes of texaphyrin (Gd-Tx) have been 
specifically evaluated in numerous clinical trials, including 
those for metastatic cancer to the brain, non-Small cell lung 
cancer (NSCLC) and non-Hodgkin’s lymphoma. Due to 
its high electron-affinity, Gd-Tx is able to capture elec 
trons from reducing metabolites and transfer them to endog 
enous oxygen, thereby triggering cell death via oxidative 
stress without modification of cellular DNA.' 'Texaphy 
rins have been tested as radiation sensitizers in both animal 
and human trials." Additionally, the incorporation of 
gadolinium into the texaphyrin macrocycle allows the tissue 
distribution of Gd-TX to be studied non-invasively via 
standard magnetic resonance imaging (MRI) methods.’ “ 
The combined imaging and therapeutic features of Gd-TX 
makes it attractive as a theragnostic agent. One way to 
realize this promise would be to enhance tumor localization 
through use of a targeted micelle. Here, we show that this 
can indeed be achieved through use of crosslinked systems 
conjugated to 1. 
To develop micelles containing Gd-Tx., the inventors have 
taken advantage of a triblock polymer micelle system with 












enhanced stability (IVECTTM) that was initially developed 
by Intezyne Technologies Inc. (Tampa, Fla.).' ' This 
triblock polymer is composed of a hydrophobic encapsula 
tion block, a responsive stabilizer block, and a hydrophilic 
masking block that contains an azide for functionalization 
via click chemistry. The main advantage of IVECTTM 
micelles over traditional micelles is the incorporation of the 
stabilization block, which allows the micelles to be cross 
linked via a pH-sensitive Fe(III) metal coordination reac 
tion.' ' ' They are also biodegradable and designed to 
release their payload in the acidic microenvironment of 
tumors." As detailed below, this approach has allowed for 
the generation of a stabilized IVECTTM micelle system that 
incorporates Gd-Tx and which both penetrates into xeno 
grafted tumors with high selectively and clears from circu 
lation without being retained in the kidney or liver. Tumor 
penetration, as inferred from MRI studies, was not observed 
with either untargeted or uncrosslinked micelles. On this 
basis, the inventors propose that the present approach pro 
vides for tumor-specific targeting that is Superior to that 
provided by EPR alone. 
Results 
A. Gadolinium-Texaphyrin (Gd-Tx) Structure 
The Gd-TX complex used in this study was prepared using 
a synthetic protocol similar to those published previously 
47 (cf. FIG. 39). A single crystal X-ray diffraction analysis of 
the Gd-Tx complex confirmed the expected planar structure 
for the core macrocycle and revealed several ancillary ligand 
and solvent interactions (FIG. 34). 
B. Physical Properties of the Gd-Tx Micelles 
The targeted Gd-TX micelles were prepared using a novel 
optimized encapsulation strategy (FIG. 34). The average 
particle size was determined using standard dynamic light 
scattering (DLS) methods. The Surface charge and gado 
linium percent loading by weight were determined by Zeta 
potential and elemental analyses, respectively (Table 6). 
These studies provided support for the notion that there are 
no differences in micelle size for the crosslinked (XL) and 
uncrosslinked (UXL) pairs, or for the targeted (T) and 
untargeted (UT) pairs. However, significant differences in 
micelle size were seen depending on the extent of Gd-weight 
loading. For example, micelles with 5% Gd-Tx (wt:wt) were 
significantly larger (169+40 nm) than those containing 0.5% 
(87+40 nm) (ps0.01: vs. 5%) or 0.05% (84+24 nm) Gd-Tx 
(ps0.01: vs. 5%). However, the size of the latter two micelle 
systems, both of which are characterized by relatively low 
Gd-Tx loading levels, were not significantly different. 
Attempts to create formulations with Gd-Tx weight loading 
percentages above 10% proved unsuccessful. Particle 
charges ranged from -0.33 to -29 mV as deduced from Zeta 
potential analyses. 
TABLE 6 
Encap. Encap. Charge Size 
Targeting (calculated) (actual) (mV) (nm) 
UXL UT 5.4 5.3 -26.61 208.20 
UXL T 5.4 5.2 -29.23 11360 
XL UT 5.3 S.1 -11.12 174.70 
XL T 5.2 S.O - 13.73 179.40 
UXL UT O.S4 O.S1 -17.70 88.90 
UXL T O.S3 OSO -1774 88.80 
XL UT O.S2 O.S2 -10.73 87.50 
XL T O.S1 O.S1 -949 82.50 
UXL UT O.OS4 O.049 -20.33 104.8O 
UXL T O.OS3 O.OS -17.28 49.40 
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TABLE 6-continued 
% Gd-Tx % Gd-Tx 
Encap. Encap. Charge 
Sample # Stability* Targeting * (calculated) (actual) (mV) 
11 XL UT O.OS2 O.OS2 -2.62 







*Micelles are stabilized with Fe(III) crosslinking (XL) reaction. UXL denotes uncrosslinked micelles, 
**Micelles are targeted (T) with an MC1R-specific ligand. UT denotes untargeted micelles, 
C. Gd-Tx Micelle Stability 
Uncrosslinked Gd-TX (20 mg/mL in PBS) micelles at 5% 
weight loading were dialyzed for 6 hours against PBS (pH 
7.4). Elemental analyses (ICP-OES, Galbraith Labs) of the 
Gd-Tx micelles pre- and post-dialysis indicated that the 
uncrosslinked micelles retained 60% of the encapsulated 
Gd-Tx after dialysis. 
D. Competitive Binding Assays 
Time-resolved lanthanide fluorescence competitive bind 
ing assays ' were performed in an effort to optimize 
ligand loading for maximal avidity. In these assays, increas 
ing concentrations of micelles were measured for their 
ability to competitively displace Eu-labeled NDP-C-MSH 2. 
The remaining Eu was then measured using time resolved 
fluorescence (TRF, see Methods). As gadolinium(III) cations 
can potentially interfere with the lanthanide-based TRF 
binding assays, unloaded triblock polymer micelles (i.e., 
free of Gd-TX) targeted with 2.5% to 30% ligand 2 by weight 
loading (see FIG. 34) were used. Micelles stabilized with 
Fe(III) crosslinking had the highest binding avidity at 5% 
ligand loading, as reflected in the lowest K, (1.49+0.12 nM 
K. n=4). It was also observed that XL micelles had signifi 
cantly higher binding avidities at all ligand loading levels 
(p<0.001). In vitro assays were also conducted with ligand 
1-targeted XL and UXL micelles at 10% ligand loading, as 
well as 1-targeted monomers (see FIG. 34)." The K, of the 
1-targeted XL micelles (2.9+0.42 nM; n=4) was 4 times 
lower than the corresponding UXL micelles (12+2.6 nM; 
n=4)." Control assays with untargeted micelles (XL and 
UXL) and untargeted polymer revealed no detectable inter 
action with the receptor. 
E. In vitro MR Imaging 
To determine the MRI relaxivity of Gd-Tx labeled 
micelles, phantoms were constructed in which each sample 
(T-XL, T-UXL, UT-XL, UT-UXL micelles) was prepared at 
the same Gd-Tx concentration (0.01 mg/mL) (FIG. 36). T 
values were determined by progressive saturation relaxation 
measurements using an Agilent 7T Small animal MRI spec 
trometer using a spin echo sequence, SEMS (see Methods) 
and T values for each cohort of samples were averaged. 
There was no apparent T effect attributable to the different 
micelle formulations, with coefficients of variation (CVs) 
ranging from 0.02 to 0.1 for each row of T, measurements. 
Individual T values for each well are provided in the 
Supplemental Information (Supplemental FIG. 44). The 
phantom studies served to confirm the expectation that the 
observed T values are positively correlated with Gd-Tx 
weight loading, with 0.05% encapsulated Gd-Tx providing 
the lowest mean T value (1.6 s). 
F. In Vivo MR Imaging 
SCID mice with subcutaneous MC1R-expressing tumors 
were injected with 0.5% and 5% w/w Gd-Tx micelles 
(T-XL, T-UXL, UT-XL, UT-UXL) via tail vein at a dose of 
12 umol Gd-TX/kg. Targeted micelles (T-UXL and T-XL) 
were formulated with 5% (w/w) of 2-targeted polymer. 











nal T-weighted spin echo multi slice (SEMS) images were 
acquired of each animal prior to and 1, 4, 12, 24 and 48 h 
after injection of the micelles. Following imaging, MC1R 
expression was confirmed in each tumor by immunohisto 
chemistry staining (FIGS. 43A-B). FIG. 37A shows repre 
sentative images of the center slices of the tumors of animals 
injected with the different 0.5% Gd-Tx loaded micelles 
recorded at different time-points. FIG. 37B shows the pre 
injection and 24 h post-injection image of the T-XL formu 
lation loaded with 5% Gd-Tx (w/w). 
To quantify enhancement due to tumor uptake of the 
micelles, intensity histograms for right (R) and left (L) 
whole tumors, kidneys and livers were prepared using a 
MATLAB program (Mathworks, Natick, Mass.) by drawing 
a region of interest (ROI) across all applicable slices for each 
time point. A mean intensity value was then calculated and 
normalized to thigh muscle (see Methods Section and Sup 
porting Information for more details). FIGS. 38A-D show 
the tumor uptake and clearance data for each 0.5% Gd-Tx 
micelle group in tumor (FIG. 38A), kidneys (FIG. 38C) and 
liver (FIG. 38D). The T-XL micelle group is the only one to 
show significant contrast enhancement in the tumors (4b). 
with a peak accumulation occurring at 24 h (FIG. 48D). The 
5% Gd-Tx loaded micelles did not show significant tumor 
enhancement at any time-point for any targeting or cross 
linking formulation (FIG. 37B). The increased enhancement 
in the tumors of animals injected with the 0.5% Gd-TXT-XL 
micelles can be visualized in the post-injection MR images 
(FIG. 37A, top row) relative to tumors in all other animals 
injected with the control formulation (UT-XL, T-UXL, UT 
UXL). Again, no other micelle group displayed visible 
tumor uptake. The contrast enhancement for the T-XL 
micelles peaked in the kidneys at 4 hand steadily decreased 
thereafter, whereas enhancement in the liver peaked at 1 h. 
To test whether the enhancement observed in the 0.5% 
Gd-Tx, T-XL tumors was statistically different from the 
other groups, a 1-way ANOVA analysis (Dunnett's Multiple 
Comparison Test) was carried out. While no significant 
difference was observed among the groups at 1 h, the T-XL 
group was statistically different from all other groups at 4h 
to 48 h (p<0.001 for 4-24 h; p-0.05 at 48 h). Additional 
analyses using the Student's t-test revealed that there are no 
statistical differences among the control groups (UT-XL, 
T-UXL or UT-UXL) at any time point. 
In vitro europium time-resolved fluorescence competition 
binding assays conducted with both 1- and 2-targeted 
micelles provide support for the central hypothesis under 
lying this study, namely that crosslinking provides stability 
to the micelle system and that the composition of the micelle 
can be modified to allow for targeting. NDP-O-MSH 2 was 
chosen as a modelligand for competition due to its relatively 
high affinity for MC1R (1.9 nM), and for the ease of 
synthesis that it provides.’ ” In the percent targeting 
optimization assays with an alkyne-functionalized NDP-O- 
MSH (2, FIG. 35), there was a clear difference between the 
binding affinities of the crosslinked (XL) and uncrosslinked 
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(UXL) micelles. This finding is ascribed to the Fe(III) 
crosslinking, which serves to stabilize the micelles in bio 
logical media. In the absence of crosslinking, the micelles 
dissociate, in whole or in part, to free monomers, leading to 
a loss of structural integrity and the premature release of the 
payload (the encapsulated contrast agent in the present 
instance). A second advantage of crosslinking is that it leads 
to an operational increase in binding avidity, a result that 
may reflect a benefit of multivalent interactions. The 1-tar 
geted (T) micelles of this study also exhibited a stronger 
avidity to the MC1R receptor when crosslinked (T-XL) as 
compared to their uncrosslinked counterpart (T-UXL), a 
finding we take as further support for the contention that i) 
crosslinking Stabilizes micelles and ii) multiple ligands on 
the micelle surface provide for enhanced binding. 
In vitro phantom experiments demonstrated that micelles 
with a lower percentage of Gd-Tx loading (w/w) produced 
shorter T1 values (FIG. 36). Moreover, in vivo experiments 
served to confirm that those with 5% Gd-Tx loading (w/w) 
provided no measurable contrast enhancement (relative to 
background) in tumor Xenografts. At first blush, these obser 
Vations appear counter-intuitive since higher contrast 
enhancement might be expected at higher gadolinium con 
centrations. However, gadolinium overloading, wherein 
encapsulated gadolinium is less accessible to water at higher 
concentrations due to “overcrowding within the micelle, 
would give rise to a lower level of enhancement. The lack of 
differentiation in the T values of the crosslinked and 
uncrosslinked micelles at lower loading levels is thought to 
result from overcrowding. However, overcrowding does not 
provide an explanation for the lack of differentiation 
between the crosslinked and uncrosslinked micelles at equal 
concentrations. We believe this result is best explained by a 
different effect, namely localization of the Gd-Tx complex 
within the stabilized (hydrophilic) block of the micelle, 
rather than within the core. This portion of the polymer is 
composed of poly(aspartic acid), to which Gd-TX is known 
to coordinate." and is expected to mask the differences is 
micelle stabilization. 
Based on the results of the phantom experiment and the 
lack of significant in vivo tumor contrast enhancement in the 
case of the 5% (w/w) Gd-Tx micelles, the micelles with 
0.5% Gd-Tx (w/w) micelle loading were chosen for the in 
Vivo experiments. In accord with the design expectations, 
these in vivo experiments revealed improved MRI contrast 
enhancements upon administration of the Gd-TX containing 
T-XL micelles, with maximal enhancement observed at 24 h. 
As can be seen by an inspection of FIGS. 37A-B and 38A-D, 
this enhancement was not seen with the other micelle 
systems, Supporting the contention that the T-XL micelles 
provide good systems for effecting tumor localization and 
imaging. 
The unique ability of the T-XL micelles to penetrate the 
tumor appears to result from a combination of the MC1R 
specific targeting group and the enhanced stability provided 
by the Fe(III) crosslinking. If targeting alone were enough to 
produce effective tumor enhancement, we would also 
observe a substantial uptake in the case of the T-UXL 
micelles. Likewise, if crosslinking and EPR alone were 
enough to affect accumulation, we would observe an 
increased build-up in the UT-XL group. Finally, it is impor 
tant to note that the enhancement observed in the T-XL 
group was not the result of free Gd-Tx (which is known to 
accumulate in tumors selectively' ' ' ). If this were the 
case, we would have observed enhanced uptake in all four 
micelle groups (i.e., UT-UXL, T-UXL and UT-UXL, in 













in vivo data are consistent with the conclusion that the 
Gd-Tx containing T-XL micelles allow for functionally 
acceptable binding avidity, stability, tumor penetration and 
uptake. Presumably, the crosslinking reaction stabilizes the 
micelles after administration and during initial time points 
while they circulate throughout the bloodstream, while the 
targeting group allows the system to bind to, and be retained 
within, the tumor cells. 
The present inventors have reported the development of a 
ligand specific to MC1R and have shown that the conjuga 
tion of this ligand to the IVECTTM micelle system does not 
result in a significant decrease in binding avidity." In this 
Example, the inventors describe the synthesis, incorporation 
and characterization of a new gadolinium texaphyrin (Gd 
Tx) that is characterized by a high inherent T. relaxivity. The 
inventors also detail its encapsulation within the IVECTTM 
system and the production of crosslinked micelles by reac 
tion with Fe(III). Moreover, we have demonstrated that the 
targeted Gd-Tx micelles are selectively retained in target 
expressing Xenograft tumors in vivo. To the best of our 
knowledge, this is the first example of a targeted micelle that 
is capable of carrying a payload and which outperforms 
systems based on EPR in terms of tumor penetration, uptake 
and retention. 
Advantages of the current system include the following: 
(1) the target, MC1R, is highly expressed in melanoma cells 
and not in healthy tissues, except for melanocytes; (2) high 
short term stability, and (3) an ability to accumulate in 
tumors, rather than various clearance organs. These attri 
butes are reflected in the in vivo images that reveal uptake 
deep within the tumor with peak accumulation at 24 h. In 
contrast, peak kidney and liver accumulations were seen at 
1–4 h. These differences are thought to reflect the benefits of 
targeting. However, biodegradation of the stabilized 
micelles may contribute to the effect; to the extent it occurs 
on short time scales (on the order of hours), it would allow 
for release of payload (Gd-Tx) within the tumor while 
concurrently clearing from circulation. While further inves 
tigations will be required to detail the full pharmokinetic 
profile of these new micelles, it is important to appreciate 
that from an operational perspective they constitute the first 
examples of systems that are capable of delivering a payload 
in a tumor selective fashion. 
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